


11-10-05

AP 27W

Please type a plus sign (+) inside this box □ +

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/015,394
		Filing Date	December 11, 2001
		First Named Inventor	Kevin P. Baker
		Group/Art Unit	1647
		Examiner Name	Bunner, Bridget E.
Total Number of Pages in This Submission	65	Attorney Docket Number	39780-2830 P1C41

**ENCLOSURES (check all that apply)**

- Fee Transmittal Form  
 Fee Attached  
 Amendment / Response  
 After Final  
 Version With Markings Showing Changes  
 Affidavits/declaration(s)  
 Extension of Time Request  
 Information Disclosure Statement  
 Certified Copy of Priority Document(s)  
 Response to Missing Parts/ Incomplete Application  
 Response to Missing Parts under 37 CFR 1.52 or 1.53  
 Copy of Notice

- Copy of an Assignment  
 Drawing(s)  
 Licensing-related Papers  
 Petition Routing Slip (PTO/SB/69) and Accompanying Petition  
 Petition to Convert to a Provisional Application  
 Power of Attorney, by Assignee to Exclusion of Inventor Under 37 C.F.R. §3.71 With Revocation of Prior Powers  
 Terminal Disclaimer  
 Small Entity Statement  
 Request for Refund

- After Allowance Communication to Group  
 Appeal Communication to Board of Appeals and Interferences  
 Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  
 Request for Oral Hearing  
 Status Letter  
 ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW):  
 EVIDENCE APPENDIX 1-5; AND RETURN POSTCARD

## Remarks

**AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES DUE IN CONNECTION WITH THIS PAPER, REFERENCING ATTORNEY'S DOCKET NO. 39780-2830P1C41.**

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual name	HELLER EHRLMAN LLP 275 Middlefield Road, Menlo Park, California 94025		
Signature			
Date	NOVEMBER 8, 2005	Customer Number:	35489

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: MAIL STOP APPEAL BRIEF - PATENTS, Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on this date: NOVEMBER 8, 2005


Express Mail Label EV 582 622 762 US

Typed or printed name	ELENA TORRES 		
Signature	Date	NOVEMBER 8, 2005	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop \_\_\_, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**BEST AVAILABLE COPY**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# FEES TRANSMITTAL for FY 2005

Effective 12/08/2004. Patent fees are subject to annual revision.

I claim small entity status. See 37 CFR 1.27

**TOTAL AMOUNT OF PAYMENT**

(\$ 500.00)

*Complete if Known*

Application Number	10/015,394
Filing Date	December 11, 2001
First Named Inventor	Kevin P. Baker
Examiner Name	Bunner, Bridget E.
Art Unit	1647
Attorney Docket No.	39780-2830P1C41

**METHOD OF PAYMENT** (check one)
 Check     Credit card     Money Order     Other     None
 Deposit Account:

Deposit Account Number

08-1641 (Docket No. 39780-2830P1C41)

Deposit Account Name

Heller Ehrman LLP

## The Commissioner is authorized to: (check all that apply)

- Charge fee(s) indicated below     Credit any overpayments
- Charge any additional fee(s) during the pendency of this application
- Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

**FEE CALCULATION** (continued)**3. ADDITIONAL FEES**

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	500.00
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460		1460		Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

**SUBTOTAL (1)**  **( \$ )****2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	Extra Claims	Fee from below	Fee Paid
	-20** =	<input style="width: 50px; height: 15px; border: 1px solid black;" type="text"/>	<input style="width: 50px; height: 15px; border: 1px solid black;" type="text"/>
Independent Claims	-3** =	<input style="width: 50px; height: 15px; border: 1px solid black;" type="text"/>	<input style="width: 50px; height: 15px; border: 1px solid black;" type="text"/> 0

Multiple Dependent  =  0

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	**Reissue independent claims over original patent
1205	50	2205	25	**Reissue claims in excess of 20 and over original patent


**SUBTOTAL (2)**  **( \$ )**


\*\*or number previously paid, if greater; For Reissues, see above

Other fee (specify) \_\_\_\_\_

\* Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)**  **( \$ )500.00****SUBMITTED BY***Complete (if applicable)*

Name (Print/Type)	Barrie D. Greene	Registration No. (Attorney/Agent)	46,740	Telephone	650-324-7000
Signature		Date	November 8, 2005	Customer No. 35489	



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kevin P. BAKER, *et al.*

Application Serial No. 10/015,394

Filed: December 11, 2001

For: ANTI-PRO1760 ANTIBODIES

) Examiner: Bunner, Bridget E.  
)  
) Art Unit: 1647  
)  
) Confirmation No: 9887  
)  
) Attorney's Docket No. 39780-2830 P1C41  
)  
) Customer No. 35489  
)  
)

---

EXPRESS MAIL LABEL NO.: EV 582 622 762 US

DATE MAILED: November 8, 2005

**ON APPEAL TO THE BOARD OF PATENT APPEALS AND INTERFERENCES**  
**APPELLANTS' BRIEF**

**MAIL STOP APPEAL BRIEF - PATENTS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

On April 8, 2005, the Examiner made a Final Rejection to pending Claims 28-35 and 38-40. A Notice of Appeal was filed on September 8, 2005.

Appellants hereby appeal to the Board of Patent Appeals and Interferences from the last decision of the Examiner.

The following constitutes Appellants' Brief on Appeal.

AC# 081641

11/14/2005 WABDELRI 00000045 10015394

01 FC:1402 500.00 DA

500.00 DA  
01 FC:1402

10015394

## **1. REAL PARTY IN INTEREST**

The real party in interest is Genentech, Inc., South San Francisco, California, by an assignment of the patent application U.S. Serial No. 09/946,374 recorded January 8, 2002, at Reel 012288 and Frame 0504.

## **2. RELATED APPEALS AND INTERFERENCES**

The claims pending in the current application are directed to antibodies that bind a polypeptide referred to herein as "PRO1760". A related patent applications, U.S. Serial No. 10/013,913, filed December 10, 2001 (containing claims directed to PRO1760 polypeptides), is also under final rejection from the same Examiner and based upon the same outstanding rejection, and appeal of this final rejection is being pursued independently and concurrently herewith.

## **3. STATUS OF CLAIMS**

Claims 28-32 are in this application.

Claims 1-27 and 33 are canceled.

Claims 28-32 stand rejected and Appellants appeal the rejection of these claims.

A copy of the rejected claims involved in the present Appeal is provided in the Claims Appendix.

## **4. STATUS OF AMENDMENTS**

An amendment to the claims was submitted in the Response to Final Office Action filed June 3, 2005. In the Advisory Action mailed October 17, 2005, the Examiner advised that this amendment would be entered for the purpose of this appeal. Accordingly, the claims shown in the Claims Appendix incorporate the amendment of June 3, 2005.

## **5. SUMMARY OF CLAIMED SUBJECT MATTER**

The invention claimed in the present application concerns an isolated antibody that specifically binds to the polypeptide of SEQ ID NO:376 (Claim 28). The invention further provides monoclonal antibodies (Claim 29), humanized antibodies (Claim 30), antibody

fragments (Claim 31), and labeled antibodies (Claim 32) that specifically bind to the polypeptide of SEQ ID NO:376.

Support for the preparation and uses of antibodies is found throughout the specification, including, for example, pages 372-380. The preparation of antibodies is described in Example 132, while Example 133 describes the use of the antibodies for purifying the polypeptides to which they bind. Isolated antibodies are defined in the specification at page 311, lines 30-39. Support for monoclonal antibodies is found in the specification at, for example, page 373, line 6, to page 374, line 25, and Example 132. Support for humanized antibodies is found in the specification at, for example, page 374, line 27, to page 375, line 27. Support for antibody fragments is found in the specification at, for example, page 310, line 31, to page 311, line 29, and page 376, line 19, to page 377, line 7. Support for labeled antibodies is found in the specification at, for example, page 312, lines 1-4, and page 380, lines 5-13.

The polypeptide of SEQ ID NO:376 is designated PRO1760, and its amino acid sequence is shown in Figure 220, while the encoding nucleic acid sequence (SEQ ID NO:375) is shown in Figure 219. The isolation of cDNA clones encoding PRO1760 of SEQ ID NO:277 is described in Example 113. Examples 128-131 describe the expression of PRO polypeptides in various host cells, including *E. coli*, mammalian cells, yeast and Baculovirus-infected insect cells. Finally, Example 149, in the specification at page 511, line 34, to page 512, line 10, sets forth a adipocyte glucose/FFA uptake assay which shows that PRO1760 is an inhibitor of glucose/FFA uptake in adipocyte cells (see page 512, lines 9-10).

The specification discloses that antibodies to PRO polypeptides may be used, for example, in purification of PRO (page 380, lines 15-21 and Example 133), in diagnostic assays for PRO expression (page 363, line 31, to page 364, line 3, and page 380, lines 2-13), as antagonists to PRO (page 371, lines 27-30), and as elements of pharmaceutical compositions for the treatment of various disorders (page 379, lines 1-37).

## **6. GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL**

- I. Whether Claims 28-32 satisfy the utility requirement of 35 U.S.C. §101.
- II. Whether Claims 28-32 satisfy the enablement requirement of 35 U.S.C. §112, first paragraph.

## 7. ARGUMENT

### Summary of the Arguments

#### Issue I: Utility

Patentable utility of the claimed antibodies that bind PRO1760 is based upon the results of the adipocyte glucose/FFA uptake assay for the PRO1760 polypeptide. The specification discloses that the adipocyte glucose/FFA uptake assay is designed to determine whether a polypeptide is capable of modulating, either positively or negatively, the uptake of glucose or free fatty acids in adipocyte cells. By making such determinations, the assay identifies polypeptides that are expected to be useful for treating disorders wherein stimulation or inhibition of glucose uptake by adipocytes is expected to be therapeutically effective. Examples of these types of disorders include obesity, diabetes, and hyper- or hypo-insulinemia.

The glucose/FFA uptake assay as described in Example 149 of the instant application was also well known in the art at the time of the effective filing date of the instant application. As demonstrated by the references of record, similar assays were commonly used to identify potential anti-diabetic agents, as well as to study the regulatory mechanisms of important molecules involved in fat cell metabolism.

According to the Examiner, "Applicant asserts the PRO1760 polypeptide inhibits glucose uptake in adipocyte cells. If one skilled in the art were to administer the PRO1760 polypeptide of the instant application to a patient with obesity, diabetes, and hyper- or hypo-insulinemia, the PRO1760 polypeptide would exacerbate the condition." (Page 5 of the Office Action mailed April 8, 2005).

The fact that PRO1760 inhibits glucose uptake does not make it useless in such treatment. One of skill in the art would readily understand that a protein which inhibits glucose uptake into adipocytes is a useful therapeutic target, since blocking the function of this protein would decrease the inhibition, and thus increase glucose uptake into adipocytes. One of skill in the art would further understand that antagonists to the PRO1760 polypeptide include antibodies, such as the claimed antibodies which specifically bind the PRO1760 polypeptide. PRO1760, as an inhibitor of adipocyte glucose uptake, also has utility as a pharmacological tool for investigation of leptin regulation, and associated disorders such as obesity, in the same way as agents already known and used in the art such as 2-DG, phloretin, and cytocholasin B.

The Examiner has asserted that these uses are each only "simply a starting point for further research and investigation into potential practical uses of the polypeptides." (Page 2 of the Advisory Action mailed October 17, 2005). Appellants submit that no further research or investigation is required to show that PRO1760 is an inhibitor of glucose uptake, and that its function can be inhibited by molecules such as the claimed antibodies, the preparation of which is disclosed the specification. In addition, the use of PRO1760 in the study of glucose transport and leptin regulation is for the purpose of characterizing not the PRO1760 polypeptide itself, but adipocyte glucose transport and the disorders with which it is associated, such as obesity, diabetes, and hyper- and hypo-insulinemia. There is no authority for the proposition that inventions useful in the research setting cannot have patentable utility.

The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration. Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner has made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant. Therefore, the legal standard for patentable utility is not absolute certainty. Clear evidence supports the glucose uptake inhibition activity of PRO1760. The Examiner's statements regarding minor assay protocol variations do not suffice to make it more likely than not that one of skill in the art would doubt the truth of this asserted utility of PRO1760 as an inhibitor of glucose uptake.

Accordingly, Appellants submit that when the proper legal standard is applied, one should reach the conclusion that the present application discloses at least one patentable utility for the PRO1760 polypeptide and the claimed antibodies that bind it.

## Issue II: Enablement

Claims 28-32 stand rejected under 35 U.S.C. §112, first paragraph, allegedly "since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention." (Page 17 of the Office Action mailed April 8, 2005).

Appellants submit that, as discussed above, the PRO1760 polypeptide and the claimed antibodies that bind it have utility in the treatment of disorders wherein stimulation or inhibition

of glucose uptake by adipocytes is expected to be therapeutically effective, such as obesity, diabetes, and hyper- or hypo-insulinemia. Based on such a utility, one of skill in the art would know exactly how to use the claimed antibodies, without any undue experimentation.

These arguments are all discussed in further detail below under the appropriate headings.

### **ISSUE I: Claims 28-32 satisfy the utility requirement of 35 USC §101**

Claims 28-32 stand rejected under 35 U.S.C. §101 because allegedly "the claimed invention is not supported by either a credible, specific and substantial asserted utility or a well-established utility." (Page 3 of the Office Action mailed April 8, 2005).

Appellants submit, for the reasons set forth below, that the specification discloses at least one credible, substantial and specific asserted utility for the claimed PRO1760 polypeptides.

#### **A. The Legal Standard for Utility**

According to 35 U.S.C. § 101:

Whoever invents or discovers any new and *useful* process, machine, manufacture, or composition of matter, or any new and *useful* improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. (Emphasis added).

In interpreting the utility requirement, in *Brenner v. Manson*,<sup>1</sup> the Supreme Court held that the *quid pro quo* contemplated by the U.S. Constitution between the public interest and the interest of the inventors required that a patent applicant disclose a "substantial utility" for his or her invention, i.e. a utility "where specific benefit exists in currently available form."<sup>2</sup> The Court concluded that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion. A patent system must be related to the world of commerce rather than the realm of philosophy."<sup>3</sup>

Later, in *Nelson v. Bowler*,<sup>4</sup> the C.C.P.A. acknowledged that tests evidencing pharmacological activity of a compound may establish practical utility, even though they may not

---

<sup>1</sup> *Brenner v. Manson*, 383 U.S. 519, 148 U.S.P.Q. (BNA) 689 (1966).

<sup>2</sup> *Id.* at 534, 148 U.S.P.Q. (BNA) at 695.

<sup>3</sup> *Id.* at 536, 148 U.S.P.Q. (BNA) at 696.

<sup>4</sup> *Nelson v. Bowler*, 626 F.2d 853, 206 U.S.P.Q. (BNA) 881 (C.C.P.A. 1980).

establish a specific therapeutic use. The court held that "since it is crucial to provide researchers with an incentive to disclose pharmaceutical activities in as many compounds as possible, we conclude adequate proof of any such activity constitutes a showing of practical utility."<sup>5</sup>

In *Cross v. Iizuka*,<sup>6</sup> the C.A.F.C. reaffirmed *Nelson*, and added that *in vitro* results might be sufficient to support practical utility, explaining that "*in vitro* testing, in general, is relatively less complex, less time consuming, and less expensive than *in vivo* testing. Moreover, *in vitro* results with the particular pharmacological activity are generally predictive of *in vivo* test results, i.e. there is a reasonable correlation there between."<sup>7</sup> The court perceived "No insurmountable difficulty" in finding that, under appropriate circumstances, "*in vitro* testing, may establish a practical utility."<sup>8</sup>

Furthermore, M.P.E.P. §2107.03 (III) states that:

"If reasonably correlated to the particular therapeutic or pharmacological utility, data generated using *in vitro* assays, or from testing in an animal model or a combination thereof almost invariably will be sufficient to establish therapeutic or pharmacological utility for a compound, composition or process."

Thus, the legal standard accepts that *in vitro* or animal model data is acceptable utility as long as the data is "reasonably correlated" to the pharmacological utility described.

The case law has also clearly established that Appellants' statements of utility are usually sufficient, unless such statement of utility is unbelievable on its face.<sup>9</sup> The PTO has the initial burden to prove that Appellants' claims of usefulness are not believable on their face.<sup>10</sup> In general, an Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. §101, "unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope."<sup>11,12</sup>

---

<sup>5</sup> *Id.* at 856, 206 U.S.P.Q. (BNA) at 883.

<sup>6</sup> *Cross v. Iizuka*, 753 F.2d 1047, 224 U.S.P.Q. (BNA) 739 (Fed. Cir. 1985).

<sup>7</sup> *Id.* at 1050, 224 U.S.P.Q. (BNA) at 747.

<sup>8</sup> *Id.*

<sup>9</sup> *In re Gazave*, 379 F.2d 973, 154 U.S.P.Q. (BNA) 92 (C.C.P.A. 1967).

<sup>10</sup> *Ibid.*

<sup>11</sup> *In re Langer*, 503 F.2d 1380, 1391, 183 U.S.P.Q. (BNA) 288, 297 (C.C.P.A. 1974).

Compliance with 35 U.S.C. §101 is a question of fact.<sup>13</sup> The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration.<sup>14</sup> Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant. The issue will then be decided on the totality of evidence.

The well established case law is clearly reflected in the Utility Examination Guidelines (“Utility Guidelines”)<sup>15</sup>, which acknowledge that an invention complies with the utility requirement of 35 U.S.C. §101, if it has at least one asserted “specific, substantial, and credible utility” or a “well-established utility.” Under the Utility Guidelines, a utility is “specific” when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic without also identifying the conditions that are to be diagnosed.

In explaining the “substantial utility” standard, M.P.E.P. §2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient, at least with regard to defining a ‘substantial’ utility.”<sup>16</sup> Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement,<sup>17</sup> gives the following instruction to patent examiners:

---

<sup>12</sup> See also *In re Jolles*, 628 F.2d 1322, 206 U.S.P.Q. 885 (C.C.P.A. 1980); *In re Irons*, 340 F.2d 974, 144 U.S.P.Q. 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 U.S.P.Q. 209, 212-13 (C.C.P.A. 1977).

<sup>13</sup> *Raytheon v. Roper*, 724 F.2d 951, 956, 220 U.S.P.Q. (BNA) 592, 596 (Fed. Cir. 1983) cert. denied, 469 US 835 (1984).

<sup>14</sup> *In re Oetiker*, 977 F.2d 1443, 1445, 24 U.S.P.Q.2d (BNA) 1443, 1444 (Fed. Cir. 1992).

<sup>15</sup> 66 Fed. Reg. 1092 (2001).

<sup>16</sup> M.P.E.P. §2107.01.

<sup>17</sup> M.P.E.P. §2107 II(B)(1).

"If the applicant has asserted that the claimed invention is useful for any particular practical purpose . . . and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility."

**B. The Data and Documentary Evidence Supporting a Patentable Utility**

Appellants respectfully submit that Appellants rely on the results of the adipocyte glucose/FFA uptake assay for patentable utility of the PRO1760 polypeptides, and that the adipocyte glucose/FFA uptake assay data for the PRO1760 polypeptide is clearly disclosed in the instant specification under Example 149.

The adipocyte glucose/FFA uptake assay is designed to determine whether a polypeptide is capable of modulating, either positively or negatively, the uptake of glucose or free fatty acids in adipocyte cells. By making such determinations, the assay identifies polypeptides that are expected to be useful for treating disorders wherein stimulation or inhibition of glucose uptake by adipocytes is expected to be therapeutically effective. Examples of these types of disorders include obesity, diabetes, and hyper- or hypo-insulinemia.

The adipocyte glucose/FFA assay is performed as follows: primary rat adipocyte cells are plated on a 96 well plate and incubated overnight with media supplemented with PRO1760 polypeptide. After the initial overnight incubation, samples of the media are taken at hour 4 and hour 16 and residual glycerol, glucose and FFA are measured. After the hour 16 sample is taken, insulin is added to the media and the adipocytes are allowed to incubate for an additional 4 hours. After this final 4 hour incubation, another sample is taken and residual glycerol, glucose and FFA is measured again. As a control, identical incubations and samplings are performed on cells that have been incubated overnight in media initially supplemented with insulin rather than PRO1760 polypeptide. Results are scored as positive in the assay if the uptake is greater than 1.5 times (stimulatory) or less than 0.5 time (inhibitory) the uptake of the insulin control. As PRO1760 resulted in less than 0.5 the uptake of the insulin control, PRO1760 tested positive as an inhibitor of glucose/FFA uptake in adipocyte cells.

The glucose/FFA uptake assay as described in Example 149 of the instant application was also well known in the art at the time of the effective filing date of the instant application. Similar assays were commonly used to identify potential anti-diabetic agents and study the regulatory mechanisms of important molecules involved in fat cell metabolism.

For example, at the time of the effective filing date of the instant application, it was well known in the art that increasing glucose uptake by adipocyte cells is a hallmark of a number of therapeutically effective agents, such as troglitazone and pioglitazone. (Tafuri, *Endocrinology*, 137(11): 4706-4712 (1996); Sandouk, *et al.*, *Endocrinology*, 133(1):352-359 (1993); made of record in Appellants' Response filed January 10, 2005). Both troglitazone and pioglitazone are members of the thiazolidinedione class of compounds and have been used to effectively treat noninsulin-dependent diabetes mellitus (NIDDM), the most common form of diabetes. Both compounds function, at least in part, by increasing the number of cellular glucose transporters in order to facilitate increased glucose uptake.

Further, at the time of the effective filing date of the instant application, vanadium salts were considered as a possible treatment for diabetes, and several clinical trials had already been performed. (See page 26617, right column, Goldwaser *et al.*, *J. Biol Chem.*, 274(37):26617-26624 (1999); made of record in Appellants' Response filed January 10, 2005). Using a rat adipocyte culture system similar to the system disclosed in the instant application, Goldwaser *et al.* showed that vanadium ligand 1-Glu ( $\gamma$ )HXM potentiates the capacity of free vanadium ions to activate glucose uptake and glucose metabolism in rat adipocytes *in vitro* by 4-5 fold, and to lower blood glucose levels in hyperglycemic rats *in vivo* by 5-7 fold. This is further evidence that at the effective filing date of the present application one skilled in the art would have reasonably expected that molecules activating glucose uptake would find utility in the treatment of diabetes and related diseases.

In addition, the investigators in Mueller *et al.*, who were interested in determining the influence of glucose uptake on leptin secretion, employed essentially the same assay to measure changes in glucose uptake after insulin exposure. (Mueller *et al.*, *Endocrinology*, 139(2): 551-558 (1998); made of record in Appellants' Response filed January 10, 2005). Figure 1A shows the glucose concentrations in medium from 0-96 hours from isolated rat adipocytes in primary culture with various insulin concentrations. As indicated by the decrease in glucose in the medium in the Figure, Mueller *et al.* suggest that insulin produced a concentration-dependent increase in glucose uptake by the cultured adipocytes. Based on these experimental results, the authors stated that insulin increased leptin secretion over 96 hours, and that the increase in leptin was more closely related to the amount of glucose taken up by the adipocytes than to the insulin

concentration, suggesting a role for glucose transport and/or metabolism in regulating leptin secretion. (See Abstract).

Using the same assay system, Mueller *et al.* further studied the effect on leptin secretion of two well-known anti-diabetic agents, metformin and vanadium, which were known to enhance glucose uptake. (Muller *et al.*, *Obesity Research*, 8(7): 530-539 (2000); made of record in Appellants' Response filed January 10, 2005). The experimental data indicated that both metformin and vanadium increased glucose uptake and inhibited leptin secretion from cultured adipocytes.

Accordingly, Appellants respectfully submit that at the effective filing date of the instant application, one of skill in the art would have reasonably accepted that various compounds, such as PRO1760, that are capable of modulating glucose uptake have a substantial, practical, real life utility. The above-mentioned studies have clearly established that the glucose/FFA uptake assay as described in the instant application is a reliable assay system to identify therapeutic agents for treating diseases and conditions such as obesity, diabetes, and hyper- or hypo-insulinemia. Therefore, Appellants respectfully submit that a variety of real-life utilities, such as treatments for glucose uptake related diseases, including obesity and diabetes, are envisioned for PRO1760 based on the glucose/FFA uptake assay results disclosed herein.

**C. A prima facie case of lack of utility has not been established**

The Examiner has asserted that "Applicant asserts the PRO1760 polypeptide inhibits glucose uptake in adipocyte cells. If one skilled in the art were to administer the PRO1760 polypeptide of the instant application to a patient with obesity, diabetes, and hyper- or hypo-insulinemia, the PRO1760 polypeptide would exacerbate the condition." The Examiner concludes that "the data do not support the implicit conclusion of the specification that PRO1760 would be useful for the therapeutic treatment of disorders where the inhibition of glucose uptake by adipocytes would be beneficial including, for example, obesity, diabetes or hyper- or hypo-insulinemia." (Page 5 of the Office Action mailed April 8, 2005).

The Examiner states that "one skilled in the art would want to enhance glucose uptake into adipocyte cells" in order to treat disorders such as diabetes. (Page 5 of the Office Action mailed April 8, 2005). Appellants respectfully point out that the fact that PRO1760 inhibits glucose uptake does not make it useless in such treatment. One of skill in the art would readily

understand that a protein which inhibits glucose uptake into adipocytes is a potential therapeutic target, since blocking the function of this protein would decrease the inhibition, and thus increase glucose uptake into adipocytes. One of skill in the art would further understand that antagonists to the PRO1760 polypeptide include antibodies, such as the claimed antibodies which specifically bind the PRO1760 polypeptide. (See the specification at, for example, page 310, lines 2-4). Accordingly, the claimed antibodies are useful in the therapeutic treatment of disorders wherein stimulation of glucose uptake by adipocytes is expected to be therapeutically effective, such as obesity, diabetes, and hyper- or hypo-insulinemia.

Appellants also point out that Mueller *et al.* (1998) disclose that inhibitors of adipocyte glucose uptake, including 2-DG, phloretin, and cytocholasin B, inhibit leptin gene expression and leptin secretion from adipocytes. It was known in the art at the time of filing that leptin is involved in the regulation of food intake, energy expenditure, and body fat stores, and that leptin decreases after fasting or caloric restriction and increases a number of hours after refeeding. (Mueller *et al.* (1998), p. 551, col. 1). One of skill in the art would therefore have understood that agents capable of modulating leptin regulation would be useful in investigations regarding the treatment of obesity. Similarly, PRO1760, as an inhibitor of adipocyte glucose uptake, would be useful as a pharmacological tool for investigation of leptin regulation, in the same way as agents already known and used in the art such as 2-DG, phloretin, and cytocholasin B.

The Examiner asserts that "[t]he specification of the instant application does not teach that PRO1760 is involved in leptin regulation." (Page 2 of the Advisory Action mailed October 17, 2005). As discussed above, Mueller *et al.* (1998) demonstrated that insulin-induced increases in leptin secretion were more closely related to the amount of glucose taken up by the adipocytes than to the insulin concentration, suggesting a role for glucose transport and/or metabolism in regulating leptin secretion. Mueller *et al.* further demonstrated that both metformin and vanadium increased glucose uptake and inhibited leptin secretion from cultured adipocytes. (Muller *et al.*; 2000). Thus it was known in the art at the time of filing that molecules which regulated glucose uptake by adipocytes also, as a consequence, regulated leptin secretion. The specification clearly discloses that PRO1760 is an inhibitor of glucose uptake into adipocyte cells; thus one of ordinary skill in the art would understand that as a necessary consequence of regulating adipocyte glucose uptake, PRO1760 would also affect leptin secretion. Thus

PRO1760 would be useful as a pharmacological tool for investigation of leptin regulation and the disorders with which it is associated, such as obesity.

*I     The utility for PRO1760 is based upon a specific, demonstrated activity and requires no further research or investigation*

The Examiner has asserted that "the proposed use of the PRO1760 polypeptides as potential therapeutic targets is simply a starting point for further research and investigation into potential practical uses of the polypeptides and antibodies." (Page 2 of the Advisory Action mailed October 17, 2005). Appellants respectfully disagree.

One of skill in the art would understand, as the Examiner acknowledges, that increasing glucose transport would be beneficial to the treatment of diabetes. PRO1760 was demonstrated to be an inhibitor of glucose uptake, as shown in Example 149. Inhibiting the function of PRO1760 would therefore increase glucose uptake. The specification has also described antagonists of PRO1760 function, for example, the claimed antibodies specific for PRO1760. See the specification at, for example, page 254, lines 11-12, and page 371, lines 27-30. Methods of making antibodies to PRO1760 are disclosed at, for example 132 and pages 371-374 of the specification, and methods of testing such antibodies for antagonist activity are disclosed at, for example, pages 369-372 of the specification. No further research or investigation is required to show that PRO1760 is an inhibitor of glucose uptake, and that its function can be inhibited by molecules such as inhibitory antibodies. Accordingly, one of ordinary skill in the art would understand that inhibitors of PRO1760, such as the claimed antibodies, could be used in the treatment of disorders for which increased glucose uptake by adipocytes would be beneficial, such as diabetes, obesity, and hyper- and hypo-insulinemia, and would understand exactly how to make and use these antibodies, without any undue experimentation.

Appellants note that while an asserted utility must be described with specificity, the patent applicant need not demonstrate utility to a certainty. In *Stiftung v. Renishaw PLC*,<sup>18</sup> the United States Court of Appeals for the Federal Circuit explained, "An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications." The Court has further explained that "the fact that an invention has only

---

<sup>18</sup> *Stiftung v. Renishaw PLC*, 945 F.2d 1173, 1180, 20 U.S.P.Q.2d 1094 (Fed. Cir. 1991).

limited utility and is only operable in certain applications is not grounds for finding lack of utility.”<sup>19</sup>

The specificity requirement is not, therefore, an onerous one. The specificity requirement is met unless the asserted utility amounts to a “nebulous expression” such as “biological activity” or “biological properties” that does not convey meaningful information about the utility of what is being claimed.<sup>20</sup> Such is clearly not the case here. The asserted utility for PRO1760 is not based upon vague “biological properties,” but a specific activity, inhibition of glucose uptake by adipocytes. This activity has already been demonstrated, as shown in Example 149 of the specification. Accordingly, PRO1760, and the claimed antibodies that bind it, have a specific utility in the treatment of disorders for which increased glucose uptake by adipocytes would be beneficial, such as diabetes, obesity, and hyper- and hypo-insulinemia.

2. *The uses of PRO1760 in the study of diabetes, obesity, and hyper- and hypo-insulinemia are practical uses beyond mere study of the invention itself*

The Examiner has further asserted that “the proposed use of the claimed PRO1760 polypeptides as a potential therapeutic tool to investigate leptin regulation is simply a starting point for further research and investigation into potential practical uses of the polypeptides and antibodies.” (Page 2 of the Advisory Action mailed October 17, 2005).

Appellants respectfully submit that the asserted uses for PRO1760 in the investigation of leptin regulation is for the purpose of further characterizing not PRO1760 itself, but the processes and diseases associated with glucose transport by adipocytes. PRO1760, as an inhibitor of adipocyte glucose uptake, is useful as a pharmacological tool for investigation of leptin regulation and obesity, in the same way as agents already known and used in the art such as 2-DG, phloretin, and cytocholasin B. The rejection of the claims at issue is tantamount to an assertion that the use of an invention as tool for research is not a “substantial” use. Because the rejection assumes a substantial overstatement of the law, and is incorrect in fact, it must be withdrawn.

---

<sup>19</sup> *Envirotech Corp. v. Al George, Inc.*, 730 F.2d 753, 762, 221 U.S.P.Q. 473, 480 (Fed. Cir. 1984).

<sup>20</sup> *Cross v. Iizuka*, 753 F.2d 1040, 1048 (Fed. Cir. 1985).

There is no authority for the proposition that use as a tool for research is not a substantial utility. Indeed, the Patent Office itself has recognized that just because an invention is used in a research setting does not mean that it lacks utility:

Many research tools such as gas chromatographs, screening assays, and nucleotide sequencing techniques have a clear, specific and unquestionable utility (e.g., they are useful in analyzing compounds). An assessment that focuses on whether an invention is useful only in a research setting thus does not address whether the specific invention is in fact “useful” in a patent sense. Instead, Office personnel must distinguish between inventions that have a specifically identified substantial utility and inventions whose asserted utility requires further research to identify or reasonably confirm.<sup>21</sup>

The PTO’s actual practice has been consistent with that approach. It has routinely issued patents for inventions whose only use is to facilitate research, such as DNA ligases, acknowledged by the PTO’s Training Materials to be useful.

The subset of research uses that are not “substantial” utilities is limited. It consists only of those uses in which the claimed invention is to be an **object** of further study, thus merely inviting further research on the invention itself. This follows from *Brenner*, in which the U.S. Supreme Court held that a process for making a compound does not confer a substantial benefit where the only known use of the compound was to be the object of further research to determine its use.<sup>22</sup>

Beneficial uses beyond studying the claimed invention itself have been demonstrated for PRO1760, in particular, the study of disorders associated with altered glucose uptake by adipocytes, such as diabetes, obesity, and hyper- and hypo-insulinemia. Accordingly, the PRO1760 polypeptide, and the claimed antibodies that bind it, have a specific and substantial utility.

---

<sup>21</sup> M.P.E.P §2107.01 I(C)

<sup>22</sup> *Brenner v. Manson*, 383 U.S. 519, 148 U.S.P.Q. (BNA) 689 (1966).

3. *The results of the adipocyte glucose/FFA uptake assay would be accepted as credible by the skilled artisan and would be understood to assert a specific and substantial utility*

The Examiner has asserted that the various references submitted by Appellants allegedly teach different methodologies for the measurement of glucose uptake in adipocyte cells as compared to the glucose assay of the instant specification. The Examiner further asserted that none of the references utilize the stimulatory and inhibitory scale disclosed in the specification. The Examiner asserted that the instant specification "does not report any specific cell numbers or statistical differences and there is no indication in the specification as to statistically how much the PRO1760 inhibited glucose uptake as compared to control." (Page 6 of the Office Action mailed April 8, 2005).

Appellants respectfully point out that the Examiner has not provided any evidence that the minor variations in assay protocols disclosed by the various references would be expected to alter the assay results. In fact, the main features of the protocol described in the specification are well within the parameters established in the literature. For example, all the cited references utilized adipocytes (Appellants note that the 3T3-F442A cells disclosed in Sandouk *et al.* were differentiated into adipocytes before running the glucose uptake assay). In particular, Mueller *et al.* 1998 use rat adipocytes, as disclosed in the specification. The incubation periods of the adipocytes prior to measuring glucose uptake range from 15 minutes as disclosed in Sandouk *et al.*, to 24, 48, 72, or 96 hours as disclosed in Mueller *et al* 2000. Thus the 4 and 16 hour incubations used in the specification are well within the range established as valid within the literature. Appellants note that such details as the incubation with metformin or vanadium as disclosed in Mueller *et al.* 2000 are not relevant, as the purpose of the Mueller experiments was specifically to test the effects of metformin or vanadium on glucose transport.

Appellants note that because most of the experiments described in the cited literature were concerned with stimulation of glucose uptake, they do not describe their data in terms of a stimulatory and inhibitory scale. However, the expression of data as a percentage of the control, instead of in specific numbers, is hardly unusual, and a similar scale is used, for example, in Figs. 1-4 of Sandouk *et al.* Further, the specification clearly discloses that the inhibition of glucose

transport by PRO1760 was decreased by at least 50% as compared to the control (see the specification at page 512, lines 3-6).

Appellants reiterate that, as discussed above, the Examiner must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the Examiner made a proper *prima facie* showing of lack of utility, does the burden of rebuttal shift to the applicant. The issue will then be decided on the totality of evidence. Therefore, the legal standard for patentable utility is not absolute certainty. Appellants submit that clear evidence supports the glucose uptake inhibition activity of PRO1760. The Examiner's statements regarding minor assay protocol variations do not suffice to make it more likely than not that one of skill in the art would doubt the truth of this asserted utility of PRO1760 as an inhibitor of glucose uptake.

Accordingly, Appellants respectfully submit that at the effective filing date of the instant application, one of skill in the art would have reasonably accepted that various compounds, such as PRO1760, that are capable of modulating glucose uptake have a substantial, practical, real life utility. The above-mentioned studies have clearly established that the glucose/FFA uptake assay as described in the instant application is a reliable assay system to identify therapeutic agents beneficial in the treatment of diseases and conditions such as obesity, diabetes, hyper- or hypo-insulinemia, or pharmacological tools for the study of these diseases and conditions. Therefore, Appellants respectfully submit that a variety of real-life utilities, such as study and treatment of glucose uptake related diseases, including obesity and diabetes, are envisioned for the PRO1760 polypeptide and the claimed antibodies that bind it based on the glucose/FFA uptake assay results disclosed herein.

For the reasons given above, Appellants respectfully submit that the present specification clearly describes, details and provides a patentable utility for the claimed invention. Accordingly, Appellants respectfully request reconsideration and reversal of the rejection of Claims 28-32 under 35 U.S.C. §101.

**ISSUE II: Claims 28-32 satisfy the enablement requirement of 35 USC §112, first paragraph.**

Claims 28-32 stand rejected under 35 U.S.C. §112, first paragraph, allegedly "since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention." (Page 17 of the Office Action mailed April 8, 2005).

In this regard, Appellants refer to the arguments and information presented above in response to the outstanding rejection under 35 U.S.C. § 101, wherein those arguments are incorporated by reference herein. Appellants respectfully submit that as described above, the PRO1760 polypeptide and the antibodies that bind it have utility in the treatment of disorders for which modulation of glucose uptake by adipocytes would be beneficial, such as obesity, diabetes, and hyper- or hypo-insulinemia, and based on such a utility, one of skill in the art would know exactly how to use the claimed antibodies without undue experimentation.

Accordingly, Appellants respectfully request reconsideration and reversal of the enablement rejection of Claims 28-32 under 35 U.S.C. §112, first paragraph.

## **CONCLUSION**

For the reasons given above, Appellants submit that the adipocyte glucose/FFA uptake assay disclosed in Example 149 of the specification provides at least one asserted specific and substantial patentable utility for the PRO1760 polypeptide and the claimed antibodies that bind it, , and that one of ordinary skill in the art would accept this asserted utility as credible and would understand how to make and use the claimed antibodies. Therefore, claims 28-32 meet the requirements of 35 U.S.C. §101 and 35 U.S.C. §112, first paragraph.

Accordingly, reversal of all the rejections of Claims 28-32 is respectfully requested.

Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (referencing Attorney's Docket No. 39780-2830 P1C41).

Respectfully submitted,

Date: November 8, 2005

By: Barrie D. Greene  
Barrie D. Greene (Reg. No. 46,740)

**HELLER EHRMAN LLP**  
275 Middlefield Road  
Menlo Park, California 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638



## 8. CLAIMS APPENDIX

### Claims on Appeal

28. An isolated antibody that specifically binds to the polypeptide of SEQ ID NO:376.
29. The antibody of Claim 28 which is a monoclonal antibody.
30. The antibody of Claim 28 which is a humanized antibody.
31. The antibody of Claim 28 which is an antibody fragment.
32. The antibody of Claim 28 which is labeled.

## **9. EVIDENCE APPENDIX**

1. Tafuri, S.R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Levels in 3T3-L1 Adipocytes," *Endocrinology*, 137:4706-4712 (1996).
2. Sandouk, T., et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability", *Endocrinology* 133:352-359 (1993).
3. Goldwaser, I., et al., "L-Glutamic Acid  $\gamma$ -Monohydroxamate: A potentiator of vanadium-evoked glucose metabolism *in vitro* and *in vivo*", *J. Biol. Chem.* 274:26617-26624 (1999).
4. Mueller, W. M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat Adipocytes", *Endocrinology* 139:551-558 (1998).
5. Mueller, W. M., et al., "Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat Adipocytes", *Obesity Research* 8:530-539 (2000).

Items 1-5 were made of record by Appellants in their IDS filed January 10, 2005, and were initialed as considered by the Examiner on April 5, 2005.

## **10. RELATED PROCEEDINGS APPENDIX**

None.

SV 2164037 v1  
11/4/05 9:51 AM (39780.2830)

# Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut1 Protein Levels in 3T3-L1 Adipocytes

SHERRIE R. TAFURI

Department of Cell Biology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co.,  
Ann Arbor, Michigan 48105

## ABSTRACT

Troglitazone is a member of the thiazolidinedione class of compounds, which act as insulin-sensitizing agents when administered to human patients and animal models displaying noninsulin-dependent diabetes mellitus. In Zucker rats, the antidiabetic activity is associated with increased glucose uptake in adipose tissue. To understand the direct effects troglitazone has on adipocyte metabolism, 3T3-L1 preadipocytes and adipocytes were treated with the compound. The addition of troglitazone enhanced the rate and percent differentiation of fibroblasts to adipocytes. Northern analysis indicated that during differentiation, expression of the adipocyte-specific transcription factor, CCAAT enhancer binding protein- $\alpha$ , increased more rapidly in

troglitazone-treated cells, but did not change in fully differentiated adipocytes. To assess the metabolic consequences of troglitazone treatment, both basal and insulin-stimulated glucose uptake were monitored in treated cells. Troglitazone treatment increased basal glucose transport 1.5- to 2.0-fold, whereas insulin-stimulated uptake was unaffected. Enhanced basal transport was caused by an increased synthesis of both Glut1 glucose transporter messenger RNA and protein. These results suggest the possibility that *in vivo*, the troglitazone-dependent increase in glucose disposal may be attributable in part to modifications in the expression of Glut1 in insulin-responsive tissues. (*Endocrinology* 137: 4706-4712, 1996)

NONINSULIN-DEPENDENT diabetes mellitus (NIDDM), the most common form of diabetes, is estimated to affect more than 4 million people in the United States (1). This disease commonly develops during middle age and is characterized by hyperglycemia, hyperinsulinemia, and insulin resistance. At present, treatment consists of behavioral modifications in conjunction with the administration of insulin and oral hypoglycemic agents (sulfonylureas and biguanide compounds). However, these treatments often fail to ameliorate one of the main underlying causes of the disease, insulin resistance. The thiazolidinediones, a new class of compounds, differ markedly from other antidiabetic agents in that they decrease hyperglycemia and hyperinsulinemia by increasing insulin sensitivity in target tissues. These compounds increase peripheral glucose uptake while decreasing insulin secretion and gluconeogenesis in a wide variety of type II animal models (2-4). Troglitazone, a member of this compound class, improves glucose tolerance and insulin sensitivity in both diabetic (5, 6) and glucose-intolerant (7) patients. Little is known about the biochemical mechanism of action of these compounds.

Adipose tissue is highly responsive to insulin. Its primary role is to store energy when nutrients are plentiful and to release energy during fasting and starvation. Adipose tissue also plays a pivotal role in metabolic homeostasis. Adipose tissue is responsible for 50-70% of lactate production in the adult and consequently contributes to the regulation of glycogen synthesis and gluconeogenesis (8). Moreover, the recent discovery of the ob gene product indicates that adipose

tissue secretes hormones capable of regulating feeding patterns, satiety, and adiposity (9). Because of the importance of adipose tissue in metabolic regulation and insulin resistance, it may play an important role in the mechanism of action of thiazolidinediones.

To understand if and how the thiazolidinediones affect adipose cell metabolism, a study was designed to determine how troglitazone affects glucose utilization in 3T3-L1 adipocytes. This system was chosen because it is easily manipulated and is not complicated by the problems associated with the metabolic feedback loops present *in vivo*. Additionally, previous experiments with pioglitazone, another member of the thiazolidinedione family, in 3T3-F442A adipose cells suggested that these compounds increase differentiation (10, 11) and glucose uptake (12) in adipocytes. In the studies discussed here, troglitazone increased differentiation in 3T3-L1 cells when administered at the initiation of the differentiation protocol. Furthermore, troglitazone enhanced glucose uptake in these cells by altering the total number of basal glucose transporters within the cell.

## Materials and Methods

### Materials

3T3-L1 cells were obtained from the American Type Tissue Culture Collection (Rockville, MD). High glucose DMEM culture medium and bovine serum were purchased from Life Technologies (Gaithersburg, MD). Insulin, dexamethasone, and isomethylbutylxanthine were purchased from Sigma Chemical Co. (St. Louis, MO). Troglitazone and pioglitazone were synthesized by Parke-Davis (Ann Arbor, MI) and Sankyo (Tokyo, Japan), respectively.

### Cell culture

3T3-L1 fibroblasts were grown and passaged in DMEM containing 10% FBS. For adipocyte differentiation, 2 day postconfluent cells were placed in 10% FBS-DMEM, 1  $\mu$ g/ml insulin, 0.25  $\mu$ M dexamethasone,

Received May 1, 1996.

Address all correspondence and requests for reprints to: Sherrie R. Tafuri, Ph.D., Department of Cell Biology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48105. E-mail: Tafuris@aa.wl.com.

and 0.5 mM isomethylbutylxanthine. Forty-eight hours later, the medium was changed to 10% FBS-DMEM containing 1  $\mu$ g/ml insulin, and after an additional 48 h, the medium was replaced with 10% FBS-DMEM. Thereafter, the medium was changed every 2 days. Troglitazone was dissolved in dimethylsulfoxide as a 1000-fold stock solution and administered at the initiation of differentiation and with every medium change unless otherwise indicated.

#### Glucose uptake

Basal glucose uptake was measured using a modified version of the hexose transport procedure described by de Herreros and Birnbaum (13). Briefly, cells were washed with PBS and placed in glucose-free DMEM containing 1% BSA for 30 min at 37°C. At this time, 1  $\mu$ Ci/ml [ $^{14}$ C]2-deoxyglucose and 1 mM glucose were added, and the cells were incubated for 30 min at 22°C. Subsequently, the cells were washed with PBS and 10 mM glucose at 4°C and lysed with 0.5 N NaOH. The lysates were neutralized with acetic acid and counted. To measure insulin-stimulated glucose uptake, cells were serum starved for 3 h before initiation of the assay. Stimulation with insulin ( $1 \times 10^{-6}$  M) was initiated 15 min before the addition of labeled glucose.

#### RNA preparation, Northern blot analysis, and ribonuclease (RNase) protection assays

The guanidinium lysis method (Ultraspec RNA isolation system, Bioteck, Houston, TX) was used to prepare RNA samples. For Northern analysis, 15–30  $\mu$ g RNA/sample were resolved on an 0.8–1% agarose formaldehyde gel and transferred to nitrocellulose. The blots were hybridized in 1 M NaCl, 1% SDS, and 10% dextran sulfate for 16–20 h at 42°C. Washes were conducted in 0.1  $\times$  SSC (standard saline citrate)-0.1% SDS at 50°C. The indicated complementary DNAs were labeled with [ $\alpha$ - $^{32}$ P]deoxy-CTP using the random prime method and used as probes. RNase protection assays were performed using the RNase A nuclease assay according to manufacturer's instructions (Ambion, Houston, TX). [ $\alpha$ - $^{32}$ P]UTP-labeled single stranded RNA probes were generated using T3/T7 *in vitro* transcription procedures. All results were quantitated using a Molecular Dynamics PhosphorImager (Sunnyvale, CA).

#### Western blot analysis

Cell lysates were prepared in HNTG buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 10% glycerol, and 1 mM EDTA). The Bio-Rad protein analysis system (Bio-Rad Laboratories, Richmond, CA) was used to determine protein content. Western blots were performed using standard protocols. Antibody interactions were detected using the chemiluminescent assay (ECL, Amersham, Arlington Heights, IL). The Glut1 antibody was produced using a glutathione S-transferase fusion protein encoding the last 39 amino acids of the Glut1 glucose transporter. The antibody was immunoaffinity purified and shown not to cross-react with purified Glut4 glucose transporter protein. The Glut4-specific antibody was kindly provided by Dr. Michael Mueckler.

#### Results

##### Troglitazone enhances adipocyte differentiation in 3T3-L1 cells

The differentiation of 3T3-L1 preadipocytes into adipocytes is a complex process that is affected by cell passage number and a variety of environmental conditions. Under ideal conditions, 95–100% of confluent preadipocytes can be converted into fat droplet-containing adipocytes in 5–7 days, with fat droplets first appearing on day 4. However, as the preadipocytes are passaged, the efficiency of differentiation diminishes in a clonal manner, such that a confluent plate will contain islands of adipocytes within undifferentiated fibroblasts. This loss of phenotype is also associated with a decrease in the rate of differentiation, causing the initial appearance of fat droplets to occur around day 5 or 6. Initial experiments were conducted using cells with an adipocyte

conversion frequency of approximately 50%. To study the effects of troglitazone on differentiation, 0.5–5  $\mu$ M compound was added with 167 nM insulin, 0.25  $\mu$ M dexamethasone, and 0.5 mM isomethylbutylxanthine (hormone cocktail) at the initiation of differentiation and reapplied with each medium change. Eight-day troglitazone treatment without hormone cocktail showed minimal differentiation (Fig. 1, A and B). Less than 1% of the cells became adipocytes; however, the number of adipocytes in the drug-treated sample was greater than that in the untreated sample. In the presence of hormone cocktail, troglitazone significantly enhanced the percentage of adipocyte differentiation (Fig. 1, C and D). Nearly 100% of treated cells contained fat droplets compared to 50% of the untreated group. Additionally, the rate of differentiation was enhanced as fat droplets began to accumulate in the treated group 1 day before the control group.

Adipocyte differentiation has been shown to be dependent upon the activation of several transcription factors, which, in turn, initiate the expression of a repertoire of adipocyte genes. One such factor, CCAAT enhancer binding protein- $\alpha$  (C/EBP $\alpha$ ), has been shown to be necessary and sufficient for adipocyte conversion in both preadipocyte and fibroblast cell lines (14–17). Moreover, mice lacking C/EBP $\alpha$  expression fail to accumulate both white and brown fat, suggesting that C/EBP $\alpha$  is required for terminal adipocyte differentiation (18). C/EBP $\alpha$  mRNA is not expressed in preadipocytes, is induced 2–3 days after the initiation of differentiation, and is maintained at a high level in the adipocyte (19). As troglitazone increases adipocyte differentiation, total RNA was isolated from differentiating cells treated with hormone cocktail containing 0 or 5  $\mu$ M troglitazone and probed with labeled C/EBP $\alpha$  complementary DNA to determine whether troglitazone enhances C/EBP $\alpha$  expression. The control cells used in this experiment differentiated 95–100% without the




FIG. 1. Troglitazone enhances the differentiation of 3T3-L1 preadipocytes to adipocytes. Confluent preadipocytes were maintained in culture for 8 days without compound (A) or with 5  $\mu$ M troglitazone (B), as described in Materials and Methods. Identical cells were treated with differentiation cocktail (167 nM insulin, 0.25  $\mu$ M dexamethasone, and 0.5 mM isomethylbutylxanthine) with (D) or without (C) 5  $\mu$ M troglitazone.

addition of drug; therefore, the ratio of adipocytes/preadipocytes in the drug-treated and untreated samples was identical. As shown in Fig. 2, troglitazone increased the rate of C/EBP $\alpha$  mRNA accumulation during differentiation, but did not affect the levels of C/EBP $\alpha$  message after differentiation was complete. At 48 h, treated cells contained 2.5 times the level of C/EBP $\alpha$  mRNA found in control cells. Conversely, the levels on day 6 were nearly identical in both samples. Multiple experiments demonstrated that the onset of C/EBP $\alpha$  expression varied with the passage number of the cells; however, in all cases troglitazone enhanced the rate of C/EBP $\alpha$  expression. This suggests that troglitazone influences factors that regulate when C/EBP $\alpha$  mRNA production is induced, but not those that modulate the total amount of C/EBP $\alpha$  mRNA expressed.

#### Troglitazone increases basal glucose uptake in differentiated adipocytes

To determine whether troglitazone has a direct effect on glucose metabolism in the adipocytes, the 3T3-L1 tissue culture system was used to mimic adipocyte function in a controlled environment. Initial experiments were performed using 3T3-L1 cells, which showed a 35% conversion frequency without troglitazone. Cells were differentiated under standard conditions with or without troglitazone for 8 days, as described in *Materials and Methods*. On day 9, basal glucose uptake was assessed by monitoring the accumulation of [<sup>14</sup>C]deoxyglucose within the adipocytes. As shown in Fig. 3, 0.5  $\mu$ M troglitazone treatment enhanced basal glucose uptake 9.6-fold in these cells. No effect was observed if cells were




FIG. 2. Troglitazone affects the rate of C/EBP $\alpha$  message accumulation during differentiation, but not the overall level of message in the adipocyte. Northern analysis of total RNA collected every 24 h during adipocyte differentiation with and without 5  $\mu$ M troglitazone using a <sup>32</sup>P-labeled, random primed, C/EBP $\alpha$  probe. RNA loading was evaluated by quantitation of 18S RNA. Multiple experiments demonstrated that the onset of C/EBP $\alpha$  expression varied with the passage number of the cells; however, in all cases, troglitazone enhanced the rate of C/EBP $\alpha$  expression.




FIG. 3. Troglitazone treatment in combination with insulin increases basal glucose uptake in adipocytes. Adipocytes were differentiated using 100 nM insulin in combination with 0.25  $\mu$ M dexamethasone and 0.5 mM isomethylbutylxanthine. After 8 days, the cell [<sup>14</sup>C]deoxyglucose uptake was monitored, as described in *Materials and Methods*. The values were obtained from duplicate samples. When assayed, the control cells exhibited 10% differentiation, whereas the troglitazone-treated cells showed 80% differentiation.

treated without the addition of the hormone cocktail (data not shown). This suggests that troglitazone increases the activity or number of functional glucose transporters per cell, or both.

Noninsulin-dependent (basal) glucose uptake is a result of transport through the membrane-associated Glut1 glucose transporter, whereas insulin-stimulated glucose uptake results from the combined activities of Glut1 and the hormone-sensitive glucose transporter, Glut4, which are associated with both the plasma membrane and microsomal compartments. Comparison studies have shown that the levels of these two glucose transporter proteins differ between preadipocytes and adipocytes (13, 20, 21) (see Fig. 7). Total cellular levels of Glut1 decline slightly with differentiation. Conversely, the amount of Glut4 transporter in the adipocyte increases from undetectable in the preadipocyte to a value 2-fold greater than that of Glut1. Comparison of the adipocyte morphology between the cultures in the glucose uptake experiment in the previous experiment indicated that the troglitazone-treated samples had a higher adipocyte/preadipocyte ratio than the control samples (data not shown). Therefore, because the number and type of glucose transporters change during adipocyte differentiation, the adipocyte/preadipocyte ratio must be equivalent between samples to accurately determine how troglitazone affects glucose transport. To do this, we repeated the previous experiment using 3T3-L1 cells that differentiated more than 95% under standard differentiation conditions without troglitazone and whose morphology and final C/EBP $\alpha$  mRNA levels (Fig. 2) were not significantly enhanced by troglitazone treatment. In addition, we compared the basal glucose uptake to insulin-stimulated glucose uptake, which distinguishes between Glut1 and Glut4 transporter activities. As shown in Fig. 4,




FIG. 4. Troglitazone increases basal glucose uptake in adipocytes. Adipocytes were differentiated under standard conditions in the presence or absence of 0.5  $\mu\text{M}$  troglitazone. The percentage of adipocyte differentiation in all samples was more than 95%. [ $^{14}\text{C}$ ]Deoxyglucose uptake was monitored 8 days after differentiation. For insulin-stimulated uptake, the cells were incubated for 30 min in  $1 \times 10^{-6}$  M insulin after a 3-h preincubation in serum-free DMEM. All values were obtained from duplicate samples.

basal glucose uptake increased 1.7-fold in response to 0.5  $\mu\text{M}$  troglitazone. Similar results (1.4-fold) were found for Glut4-dependent insulin-stimulated glucose uptake. As basal glucose uptake is a function of Glut1 transporters, and insulin-stimulated uptake results from the combination of Glut1 and Glut4 transporter activities, the fact that troglitazone enhances both basal and insulin-stimulated glucose uptake equivalently suggests that the compound only alters Glut1 transporter activity.

To further separate the effects of troglitazone on glucose uptake from those on adipocyte differentiation, adipocytes differentiated in the absence of troglitazone were treated with 0.5 or 5  $\mu\text{M}$  troglitazone for 48 h before the glucose uptake assay. As shown in Fig. 5, 0.5 and 5  $\mu\text{M}$  troglitazone treatment produced 2- and 2.7-fold increases in basal glucose transport activity. As there was no change in morphology in the cells during treatment, these data show that troglitazone can enhance basal glucose uptake activity without affecting cell differentiation.

To determine whether the enhancement of glucose transporter activity is due to an increase in transporter number or an increase in transporter function, Western analysis was performed on whole cell lysates (from cells differentiated in the presence or absence of troglitazone) using either Glut1- or Glut4-specific antibodies (Fig. 6). Again, the adipocyte/preadipocyte ratio required to eliminate the effects of differentiation on transporter levels was identical in treated and untreated samples. As previously described (13, 20, 21), Glut1 transporter levels decreased slightly with adipocyte differentiation, whereas Glut4 levels increased dramatically. Troglitazone caused a 2.3-fold increase in Glut1 protein without altering Glut4 levels. Thus, troglitazone enhances glu-





FIG. 5. Troglitazone enhances basal glucose uptake in fully differentiated adipocytes. Fully differentiated adipocytes were treated with 0, 0.5, or 5  $\mu\text{M}$  troglitazone. Basal glucose uptake was assessed 48 h after treatment. All values were obtained from duplicate samples. The percentage of adipocyte differentiation in all samples was more than 95%.

cose uptake by increasing the number of basal glucose transporters per cell. Additionally, a Glut1 RNase protection assay was performed on RNA isolated from cells differentiated in the presence or absence of 5  $\mu\text{M}$  troglitazone (Fig. 7). The Glut1/actin ratio was approximately 1.5–2 fold higher in the RNA samples isolated from troglitazone-treated cells. This directly correlates with the 2-fold increase in glucose transport and shows that troglitazone increases the number of Glut1 transporters in adipocytes.

As differentiation also affects Glut1 mRNA stability, and a previous report (12) indicated that thiazolidinediones increased mRNA stability, a Glut1 RNase protection assay was performed on RNAs isolated from adipocytes treated with 5  $\mu\text{g}/\text{ml}$  actinomycin D. Figure 8 shows that when the control cells and troglitazone cells displayed the same adipocyte/preadipocyte ratio, the rate of Glut1 mRNA decay was the same for both treated and untreated cells. Identical results were obtained from cells treated with pioglitazone, another antidiabetic thiazolidinedione (data not shown). Albeit indirectly, these data also suggest that the increase in Glut1 mRNA is due to an increase in Glut1 transcription.

## Discussion


Troglitazone treatment of 3T3-L1 cells increases both the rate and percentage of adipocyte differentiation. This phenomenon is linked to the increased rate of C/EBP $\alpha$  accumulation in differentiating cells. Because this accumulation of C/EBP $\alpha$  message occurs within 24 h of drug treatment, it implies that troglitazone interacts with proteins that are present in the preadipocyte or are rapidly induced by the differentiating hormone cocktail. Recent work on adipocyte differentiation suggests that the proteins involved are members of the peroxisome proliferator-activated receptor (PPAR) family (22, 23). These nuclear receptors are activated by endogenous fatty acid or PG ligands (24–26) and in combination with C/EBP family members are believed to induce



**FIG. 6.** Troglitazone increases the synthesis of the Glut1 transporter protein in adipocytes. Western analysis was performed using a Glut1- or Glut4-specific antibody of protein samples collected from adipocytes treated with or without 5 µM troglitazone. The percentage of adipocyte differentiation in all samples was more than 95%. Thirty micrograms of protein were loaded per lane, as determined using Bio-Rad analysis. Histograms represent data acquired from two independent experiments.

adipocyte differentiation (27–29). Lehmann and colleagues (30) have shown that another thiazolidinedione, BRL 49653, is a ligand for PPAR $\gamma$ , the adipocyte-specific PPAR family member. This suggests that by interacting with the PPARs, troglitazone initiates the cascade of transcriptional events that enhances the rate of adipogenesis.

To determine whether the increased glucose uptake in adipocytes *in vivo* is a direct effect of troglitazone or a consequence of secondary effects brought about by insulin sensitization, the effects of troglitazone were assessed in the isolated 3T3-L1 tissue culture system. Apart from the enhanced glucose uptake associated with adipocyte differentiation, troglitazone directly increased glucose uptake 2-fold in these cells. This effect was shown to be a direct result of an increased synthesis of Glut1 transporter mRNA and protein. This disagrees with previously reported results (12), which have shown that pioglitazone, another thiazolidinedione with antidiabetic activity, enhances glucose uptake in 3T3-442A adipocytes by increasing both Glut1 and Glut4 transporter mRNA and protein via mRNA stabilization. However, this study failed to distinguish between the increases in glucose uptake associated with the enhancement of adipocyte differentiation and those resulting from the direct effects of the thiazolidinedione on the adipocyte. By



**FIG. 7.** The levels of Glut1 mRNA were increased in response to 5 µM troglitazone. A RNase protection assay was performed on RNAs collected at the indicated times from cells treated with or without 5 µM troglitazone. Ten micrograms of RNA per sample were hybridized to mouse Glut1 and  $\beta$ -actin probes and processed as described in Materials and Methods. Message levels were quantitated using a Molecular Dynamics PhosphorImager, and the values are represented as the Glut1/actin ratio.

controlling for the ratio of adipocytes/preadipocytes in the experiments presented here, the indirect effects of differentiation by the compound on Glut4 were eliminated, demonstrating that troglitazone enhances glucose uptake by increasing Glut1 mRNA and protein levels. Additionally, identical experiments with pioglitazone yielded similar results (data not shown).

These results provoke at least two questions. First, can a 2-fold increase in adipocyte glucose uptake account for the decreased hyperglycemia *in vivo* or must other tissues also be affected? Secondly, are the transcriptional responses involved in differentiation the same as those used in the expression of Glut1; do both require the activation of PPARs by the thiazolidinediones?

Glucose transporter number has been shown to directly affect glucose transport and blood glucose levels in animal models. Several transgenic mice have been engineered that overexpress the glucose transporters in a tissue-specific fashion (30–34). In general, overexpression of either Glut1 or Glut4 enhanced glucose transport in the targeted tissue. Enhanced transport directly correlated with decreased plasma glucose levels in both fasted and fed animals, demonstrating that enhanced transporter expression has profound effects on glucose disposal *in vivo*. Surprisingly, however, increased Glut1 expression in skeletal muscle, and hence increased muscle basal transport, resulted in resistance of Glut4 to insulin stimulation and various other stimuli, including contraction and hypoxia (32). Additionally, Glut4 overproduction in fat cells did not protect animals from the impaired glucose tolerance induced by a high fat diet (34). Thus, although enhanced transporter synthesis can ameliorate hy-




FIG. 8. Troglitazone does not alter the stability of Glut1 mRNA. RNase protection assay of Glut1 message was performed on RNA collected after actinomycin D (5  $\mu$ g/ml) treatment of adipocytes differentiated in the presence or absence of 5  $\mu$ M troglitazone. Ten micrograms of RNA were used per sample, and message levels were quantitated using a Molecular Dynamics PhosphorImager.

perglycemia, it does not appear to directly influence insulin resistance. This would imply that enhanced Glut1 synthesis in adipocytes would only represent a portion of troglitazone's antidiabetic activity. This is supported by data indicating that troglitazone influences the metabolic activities of skeletal muscle, liver, and pancreas (35–38).

The precise role of PPARs in the antidiabetic activities of the thiazolidinediones has yet to be fully explored. Clearly, the PPARs are intimately involved in lipid metabolism in a number of tissues, including adipose and liver, and are responsible for the lipid-lowering effects of the fibrates (39). Interestingly, the lipid-lowering effects associated with thiazolidinedione treatment are similar to those of other PPAR-activating, lipid-lowering compounds (40). Moreover, as elevated lipid levels have been linked to peripheral insulin resistance, the alteration of lipid metabolism may ameliorate insulin resistance (41). However, *in vitro*, thiazolidinediones bind specifically to the PPAR $\gamma$  isoform, which is mainly present in adipose tissue (22, 23). Thiazolidinediones have been shown to influence metabolism in liver, pancreas, and skeletal muscle. If all of these antidiabetic responses are to be attributed to PPAR activation, all insulin-responsive tissues must contain sufficient levels of this isoform. Alternatively, it is possible that the ligand binding specificity *in vivo* differs from that *in vitro*, and/or that the compounds stimulate the formation of ligands that activate the PPAR isoforms present in these other tissues. Future studies addressing these issues will undoubtedly reveal the role of the PPARs in the antidiabetic activity of the thiazolidinediones. However, it is clear

that the regulation of Glut1 transporter synthesis could contribute to the antidiabetic activity of troglitazone.

### Acknowledgments

I thank Dr. Joseph Menetski, Dr. Roman Herrera, Dr. Alan Saltiel, Dr. Heidi Camp, and Amy Whitton for their assistance with manuscript preparation. I also thank Parul Matani for her help in purifying the Glut1 antibody.

### References

- Harris MI 1995 Summary. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) Diabetes in America, ed 2. NIDDK, NIH publication 95-1468. NIH, Bethesda, p 13
- Fujiwara T, Yoshioka A, Yoshioka T 1980 Characterization of a new oral anti-diabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549–1558
- Stevenson R, Hutson N, Krupp MN, Volkman R, Holland G, Eggler JF, Clark D, McPherson RK, Hall KL, Danbury BH, Gibbs M, Kreutter D 1990 Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic Ob/Ob mice. Diabetes 39:1218–1226
- Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW 1994 A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43:1203–1210
- Akanuma Y, Kosaka K, Kuzuya T, Shigeta Y, Kaneko T 1993 Clinical evaluation of a new oral hypoglycemic agent CS-045 in NIDDM. Diabetologia [Suppl 1] 36:A182
- Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi N, Masakado M, Sako Y, Nawata H 1994 Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabetic Med 11:685–691
- Nolan JJ, Ludvik B, Beerdse P, Joyce M, Olefsky J 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188–93
- Digriolamo M, Newby FD, Lovejoy J 1992 Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J 6:2405–2412
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J 1994 Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432
- Kletzien RF, Clarke SD, Ulrich RG 1991 Enhancement of adipocyte differentiation by an insulin sensitizing agent. Mol Pharmacol 41:393–398
- Sandouk T, Reda D, Hofmann C 1993 Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 264:C1600–C1608
- Sandouk T, Reda D, Hofmann C 1993 The antidiabetic agent pioglitazone increases the expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 133:352–359
- de Herreros AG, Birnbaum MJ 1989 The acquisition of increased insulin-responsive hexose transport in 3T3-L1 adipocytes correlates with expression of a novel transporter gene. J Biol Chem 264:19994–19999
- Umek RM, Friedman AD, McKnight SL 1991 CCAAT-enhancer binding protein: a component of a differentiation switch. Science 251:288–292
- Lin FT, Lane MD 1992 Antisense CCAAT/enhancer-binding protein RNA suppresses coordinate gene expression and triglyceride accumulation during differentiation of 3T3-L1 preadipocytes. Genes Dev 6:533–544
- Lin FT, Lane MD 1994 CCAAT/enhancer binding protein  $\alpha$  is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci 91:8787–8791
- Freytag S, Geddes T 1992 Reciprocal regulation of adipogenesis by Myc and C/EBP $\alpha$ . Science 256:379–382
- Wang N-D, Finegold MJ, Bradley A, Ou CN, Abdelsayed SV, Wilde MD, Taylor LR, Wilson DR, Darlington GJ 1995 Impaired homeostasis in C/EBP $\alpha$  knockout mice. Science 269:1108–1112
- Cao Z, Umek RM, McKnight SL 1991 Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5:1538–1552
- Weiland M, Schurmann A, Schmidt WE, Joost HG 1990 Development of the hormone-sensitive glucose transport activity in differentiating 3T3-L1 murine fibroblasts. Biochem J 270:331–336
- Ziehm D, Schurmann A, Weiland M, Joost HG 1992 Biphasic alteration of glucose transport in 3T3-L1 cells during differentiation to the adipocyte-like phenotype. Horm Metab Res 25:71–76
- Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPAR $\gamma$ : tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234
- Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA 1994 Peroxisome proliferator-activated receptor (PPAR) $\gamma$ : adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135:798–800
- Forman BM, Tontonoz P, Chen J, Brun R, Spiegelman BM 1995 15-

- Deoxy-<sup>12,14</sup>-prostaglandin J<sub>2</sub> is a ligand for the adipocyte determination factor PPAR $\gamma$ . *Cell* 83:803–812
25. Kliewer SA, Lenhard JM, Wilson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J<sub>2</sub> metabolite binds peroxisome proliferator-activated receptor  $\gamma$  and promoter adipocyte differentiation. *Cell* 83:813–819
26. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA 1995 Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J Biol Chem* 270:23975–23983
27. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR $\gamma$ , a lipid-activated transcription factor. *Cell* 79:1147–1156
28. Brun RP, Tontonoz P, Forman BM, Ellis R, Chen J, Evans R, Spiegelman BM 1996 Differential activation of adipogenesis by multiple PPAR isoforms. *Genes Dev* 10:974–984
29. Wu Z, Xie Y, Bucher NLR, Farmer SR 1995 Conditional ectopic expression of C/EBP $\beta$  in NIH-3T3 cells induces PPAR $\gamma$  and stimulates adipogenesis. *Genes Dev* 9:2350–2363
30. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ). *J Biol Chem* 270:12953–12956
31. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB 1993 Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing Glut4 selectively in adipose tissue. *J Biol Chem* 268:22243–22246
32. Gulve EA, Ren J-M, Marshall BA, Gao J, Hansen PA, Holloszy JO, Mueckler M 1994 Glucose transport activity in skeletal muscles from transgenic mice overexpressing Glut1. *J Biol Chem* 269:18366–18370
33. Hansen PA, Gulve EA, Marshall BA, Gao J, Pessin JE, Holloszy JO, Mueckler M 1995 Skeletal muscle glucose transport and metabolism are enhanced in transgenic mice overexpressing the Glut4 glucose transporter. *J Biol Chem* 270:1679–1684
34. Gnudi L, Tozzo E, Shepherd PR, Bliss JL, Kahn BB 1995 High level overexpression of glucose transporter-4 driven by an adipose-specific promoter is maintained in transgenic mice on a high fat diet, but does not prevent impaired glucose tolerance. *Endocrinology* 136:995–1002
35. Furuta H, Sowa R, Tabata H, Hirayama J, Negoro T, Sanke T, Nanjo K 1994 Effect of new antidiabetic drug CS-045 on peripheral insulin resistance. *J Jpn Diabetes Soc* 37:343–348
36. Horikoshi H, Okuno A, Fujiwara T, Shiota M, Sugano T 1993 Peripheral effects of a new antidiabetic agent, CS-045: acute stimulation of insulin-induced glucose uptake in perfused rat hindlimb. *Diabetes* 42:59A
37. Inoue Y, Tanigawa K, Nakamura S, Tamura K, Kato Y, Nakase A 1993 Effect of CS-045, a new oral antidiabetic agent, on B-cell function in rats after 90% pancreatectomy. *Diabetologia* 36:A182
38. Lee MK, Miles PDG, Khoursheed M, Gao KM, Moosa AR, Olefsky JM 1994 Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. *Diabetes* 43:1435–1439
39. Auwerx J 1992 Regulation of gene expression fatty acids and fibrin acid derivatives: an integrative role for peroxisome proliferator activated receptors. *Horm Res* 38:269–177
40. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N, Kobayashi K, Masakado M, Sako Y, Nawata H 1994 Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. *Diabetic Med* 11:685–691
41. McGarry JD 1992 What if Minkowski had been ageusic? An alternative angle on diabetes. *Science* 258:776–770

# The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3-F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability\*

TAGRID SANDOUK, DOMENIC REDA†, AND CECILIA HOFMANN

Department of Molecular and Cellular Biochemistry (T.S., C.H.) and Department of Surgery, Loyola University Stritch School of Medicine, Maywood, Illinois 60153; and Research Service (C.H.) Hines VA Hospital (D.R., C.H.), Hines, Illinois 60141

## ABSTRACT

Whereas adipocytes normally play an important role as a major site for systemic energy homeostasis, adipocyte function is markedly altered in disorders such as diabetes. In this study, we investigated the effect of pioglitazone, a novel antidiabetic agent known to lower plasma glucose in animal models of diabetes mellitus, on expression of glucose transporters GLUT1 and GLUT4 in 3T3-F442A cells. Treatment of confluent 3T3-F442A preadipocyte cultures for 7 days with pioglitazone ( $1 \mu\text{M}$ ) and insulin ( $1 \mu\text{g}/\text{ml}$ ) resulted in nearly 100% differentiation of cells to lipid-accumulating adipocytes, and such adipocytes showed a markedly increased capacity for glucose uptake. Analysis of messenger RNA transcripts encoding GLUT1 and GLUT4 glucose transporters over the 7-day differentiation period indicated time-dependent in-

creases in abundance of each type that were maximal at more than 5-fold with the combined presence of insulin and pioglitazone. In accord, GLUT1 and GLUT4 protein levels also increased to maximal levels of 10-fold and 7-fold, respectively, over those in undifferentiated preadipocytes. Increased messenger RNA half-lives from 2.2 to greater than 24 h for GLUT1 and from 1.2 to greater than 24 h for GLUT4 correlated with this induced adipocyte differentiation. Taken together, these findings indicated that pioglitazone markedly enhanced expression of cellular glucose transporters, and the mechanism for this action was mainly stabilization of transporter messenger RNA transcripts. Such increased expression of glucose transporters in adipocytes establishes the cells in a state active for glucose uptake, thus ultimately facilitating storage and metabolism as well. (*Endocrinology* 133: 352–359, 1993)

**A**DIPOSE tissues play a key role in systemic energy homeostasis. Adipocytes possess hormonally regulated transport and metabolic systems allowing energy storage as triglycerides when nutrients abound or energy release during nutritional dearth. In accord with this role, a recent report indicated that adipose may be responsible for up to 30% of whole body glucose metabolism (1). Altered adipocyte function has been associated with abnormal physiological states including obesities and obesity-linked diabetes (2–4). In non-insulin-dependent diabetes mellitus, elevated blood glucose levels result from insufficient glucose uptake in adipose and muscle, a consequence of insulin resistance (5, 6).

The hyperglycemia of noninsulin-dependent diabetes mellitus can be corrected clinically by treatment of patients with oral hypoglycemic agents. Whereas presently used sulfonylurea agents appear to act principally as secretagogues to increase the availability of insulin to enhance glucose disposal (7, 8), an alternate treatment strategy could employ agents acting as insulin sensitizers, thus overcoming target tissue insulin resistance. New antidiabetic compounds belonging to the thiazolidinedione class of drugs appear to lower blood glucose in animal models of diabetes by improv-

ing insulin sensitivity in peripheral tissues (9). Treatment of insulin-resistant fatty rats or mice with the thiazolidinedione pioglitazone resulted in lowered blood glucose, triglyceride, and insulin levels (10, 11).

We and others have previously reported that thiazolidinedione agents enhanced insulin sensitivity for glucose uptake and metabolism in adipose tissues of diabetic animals (10–13). It has also been found that such agents have potent adipogenic effects on preadipocyte cell cultures (14–16). We therefore sought to more fully investigate the mechanism underlying the effect of pioglitazone to promote adipocyte differentiation with the aim of gaining insight into how such an effect could contribute to regulation of cellular glucose uptake. Findings in our present report indicate that pioglitazone treatment of 3T3-F442A preadipocytes markedly enhances expression of glucose transporters GLUT1 and GLUT4, and the mechanism for this action is a stabilization of transporter messenger RNA (mRNA) transcripts.

## Materials and Methods

### Cells and tissue culture

3T3-F442A fibroblasts were grown as monolayer cultures at 37°C in an atmosphere of 10% CO<sub>2</sub>-90% air essentially as described previously (17). Subcultured cells were grown to confluence (usually 7 days) in Dulbecco's Modified Eagle's Medium (DMEM) containing glucose (4.5 g/L), bovine serum (10%), streptomycin (50 µg/ml), penicillin (50 U/ml), Fungizone (0.25 µg/ml), and glutamine (2 mM). Confluent cell cultures were then converted to adipocytes by culture for 7 days in

Received November 4, 1992.

Address all correspondence and requests for reprints to: Cecilia Hofmann, Ph.D., Research Service 151, Hines VA Hospital, Hines, Illinois 60141.

\* This study was supported by the VA Medical Research Service and The Upjohn Company.

DMEM in the presence of 10% fetal calf serum and insulin (1 µg/ml) and/or pioglitazone (1 µM). Cell differentiation was assessed by evaluating cell morphology under phase contrast microscopy; cells were considered to be adipocytes if numerous lipid droplets were observed in the cytoplasm. The cell line was used during the 10th to 20th passage after clone isolation.

#### *Measurement of 2-deoxy-D-[<sup>14</sup>C]glucose uptake*

For assay, 3T3-F442A cell monolayers (~10<sup>6</sup> cells/17 mm well) were rinsed with PBS and incubated with 0.5 ml assay medium (DMEM, no glucose, 5 mM NaHCO<sub>3</sub>, 20 mM N-[2-hydroxyethyl]-N'-piperazine-[2-ethanesulfonic acid], 0.1% BSA, pH 7.4) for 15 min at 22°C. Then 0.5 µCi D-[U-<sup>14</sup>C]glucose (stock = 57 mCi/mmol, Amersham Corp., Arlington Heights, IL) was added for an additional 15 min. After this incubation, medium was aspirated, and cells were rinsed with ice-cold PBS containing 10 mM glucose. Cells were then solubilized with 0.5 ml 0.5 N NaOH, transferred to vials, neutralized with 52 µl glacial acetic acid, and counted for radioactivity using 5 ml Ready Value scintillation fluid (Beckman, Inc., Palo Alto, CA).

#### *Northern blot analysis of RNA for determination of GLUT1 and GLUT4 mRNA transcript abundance*

Total RNA was extracted from 3T3-F442A cell monolayers essentially according to the method of Chomczynski and Sacchi (18). RNA was then size-fractionated on 1% agarose gels and transferred to nylon membranes according to the method of Fournier *et al.* (19). RNA transcripts were cross-linked to the membrane with a UV Stratalinker (Stratagene, La Jolla, CA).

Hybridization was performed using anti-sense RNA Riboprobes prepared according to the protocol of the reagent supplier (Promega Corp., Madison, WI). For GLUT1, pSPGT-1 (20) was kindly provided by Dr. Graeme Bell (Chicago, IL), and the entire 1591 base pair coding region of rat brain glucose transporter was excised using BglII and subcloned into the BamHI site of pGEM-4Z. EcoRI was used for linearization, and T7 RNA polymerase was used for GLUT1 Riboprobe transcription. A GLUT4 construct pSM1D2 in the pBluescript KS<sup>+</sup> (21) was generously provided by Dr. Morris Birnbaum (Boston, MA). For GLUT4 Riboprobe preparation, this construct was linearized with Hind III, and T7 RNA polymerase was used for Riboprobe preparation.

High stringency hybridizations with Riboprobes were performed by 65°C overnight incubation of membranes in glass tubes in a Hybaid Oven (National Labnet Co., Woodbridge, NJ) using procedures we have detailed previously (11). After rinses, labeled membranes were exposed at -70°C to Hyperfilm-MP (Amersham Corp., Arlington Heights, IL) with an intensifying screen. Autoradiographic bands on film were quantitated by two-dimensional densitometry using an AMBIS Optical Imaging System (San Diego, CA). RNA samples were quantitated for correction of minor loading differences by densitometry of ethidium bromide-stained 28S ribosomal bands (22) on photographic negatives (type 55 P/N film, Polaroid, Cambridge, MA).

#### *Measurement of GLUT1 and GLUT4 mRNA stability*

Confluent 3T3-F442A cells were induced to differentiate with insulin, pioglitazone, or both as described above. On day 7 of treatment, the transcription inhibiting agent Actinomycin D (Act D) was added (5 µg/ml) to treated cell cultures as well as undifferentiated control cultures, essentially as reported earlier (23-26). Total RNA was extracted from these cells at selected time points after Act D addition (0, 1, 2, 4, 6, and 24 h), and abundance of remaining GLUT1 and GLUT4 mRNA transcripts was assessed by Northern blot analyses as described above. Glucose transporter mRNA abundance data were fitted to a single exponential decay curve by nonlinear least square regression analysis. The estimated first-order rate constant was used to calculate the mRNA half-life. Since it was suggested that Act D may have nonspecific effects with long-term (24 h) treatments (24), glucose transporter mRNA half-life calculations were based on changes in mRNA abundance over only the first 6 h of Act D treatment.

#### *Western blot analysis of glucose transporter proteins*

Total particulate membrane proteins were prepared as previously described (27). Briefly, cells were washed with PBS and scraped into homogenization buffer [20 mM Tris-HCl, 255 mM sucrose, 1 mM EDTA, 1 mM phenylmethyl sulfonylfluoride, 10 U/ml Trasylol] and were homogenized with 10 pulses by a Tekmar Tissuemizer (Tekmar Inc., Cincinnati, OH). A total membrane fraction was prepared by centrifugation of the homogenate at 200,000 × g at 4°C. Protein concentrations were determined by the Bradford assay (28) using BSA as a standard. Initial Western blot analyses revealed diffuse bands of GLUT1 and GLUT4 proteins, possibly due to heterogenous glycosylation of the transport proteins. Therefore, samples were routinely treated with peptide N-glycosidase F (1 U/100 µg protein) in a buffer containing 20 mM sodium phosphate, pH 7.5, 10 mM EDTA, 1.7% Triton X-100, and 1 mM phenylmethyl sulfonylfluoride for 48–72 h at 37°C to remove sugar residues (23). Treated protein samples were then mixed with one fourth volume of 4X electrophoretic sample buffer [200 mM Tris-HCl at pH 6.8, 400 mM dithiothreitol, 8% sodium dodecyl sulfate, 40% glycerol, 0.4% bromophenol blue] and stored at -20°C. Samples were thawed and loaded in parallel onto two discontinuous 12% polyacrylamide gels, and size-fractionated according to the method of Laemmli (29) using a Mini-Protean II Dual Slab Cell (Bio-Rad, Richmond, CA). The amount of protein loaded (10 µg/lane for GLUT1 and 60 µg/lane for GLUT4) was determined empirically to be within the linear response range for the system used. Proteins separated on each gel were electrophoretically transferred to Immobilon PVDF membranes (Millipore Corp., Bedford, MA) using a Mini-Transblot electrophoretic transfer cell (Bio-Rad). One membrane was stained for total protein (0.1% Coomassie R-250, 40% methanol, 10% acetic acid). The second membrane was immunostained for GLUT1 or GLUT4 using a double antibody system and the Immuno-Blot Assay Kit (Bio-Rad). The supplier's instructions were followed except 5% BSA was used for membrane blocking. The primary antibodies (RaGLUTRANS for GLUT1 and RaIRGT for GLUT4, East Acres Biologicals, Southbridge, MA) were diluted 1:3000 and 1:2000, respectively, and the alkaline phosphatase-conjugated second antibody (GAR-AP, Bio-Rad) was diluted 1:3000 for use. Resulting signals were quantitated with the reflective mode of a Model 620 Video Densitometer (Bio-Rad). Sample loading corrections were made based on densitometry data from the Coomassie-stained membrane.

#### *Data analysis*

Statistical analysis was performed using SAS version 6 (SAS Institute, Inc., Cary, NC). All hypothesis tests were two-sided and were considered significant if the *P* value was less than or equal to 0.05.

## **Results**

#### *Induction of preadipocyte differentiation and glucose transport by insulin and pioglitazone*

Treatment of confluent 3T3-F442A cells for 7 days with insulin (1 µg/ml), pioglitazone (1 µM), or both agents in the presence of 10% fetal calf serum resulted in conversion of cells into lipid-accumulating adipocytes. Whereas some cells differentiated into adipocytes by either treatment alone (insulin, 60%; pioglitazone, 80%), nearly complete differentiation (95%) was achieved with both agents together. Such cellular differentiation was associated with markedly increased capacity for glucose transport. Treatment of 3T3-F442A cells for 7 days with insulin or pioglitazone resulted in basal glucose transport levels that were 22- and 30-fold increased compared to untreated fibroblasts (Table 1). Together, both agents appeared to act additively for a maximal enhancement of 61-fold at day 7. Age-matched, undifferentiated cells maintained in growth medium showed no

**TABLE 1.** P and I-induced increases in glucose transport activity in differentiating 3T3-F442a Cells

Cell treatment	Glucose uptake (dpm/cell $\pm$ SEM)
Control, day 0	0.0030 $\pm$ 0.00007
Control, day 7	0.0013 $\pm$ 0.00031
Insulin	0.0670 $\pm$ 0.0076
Pioglitazone	0.0887 $\pm$ 0.015
Insulin + pioglitazone	0.1830 $\pm$ 0.037


Confluent monolayer cultures of preadipocytes in DMEM (day 0) were induced to differentiate by treatment with insulin and/or pioglitazone. Preadipocyte cells maintained for 7 days in DMEM without added insulin and/or pioglitazone also served as controls. After treatment for 7 days, glucose transport activity was measured by uptake of 2-deoxy-D-[<sup>14</sup>C]glucose as described in *Materials and Methods*. Since the radiolabeled glucose has a specific activity of 300 mCi/mmol, there are 1.5 f/dpm. Thus, maximal basal transport was approximately 0.3 fmol/cell for cells differentiated in medium containing insulin and pioglitazone.

increase in glucose transport over the 7-day interval, and actually declined about 60%, likely an indication of quiescence.

#### *Insulin- and pioglitazone-enhanced expression of glucose transporters in 3T3-F442A cells*

To assess whether such increased glucose transport activity could be explained by amplified expression of glucose transporters in adipocytes, we analyzed the levels of GLUT1 and GLUT4 mRNA abundance. When assessed by Northern blotting, the abundance of mRNA transcripts encoding GLUT1 and GLUT4 glucose transporters increased in a time-dependent manner (Figs. 1, 2). Whereas 7-day treatment with either insulin (1  $\mu$ g/ml) or pioglitazone (1  $\mu$ M) increased GLUT1 mRNA abundance by 2.3- and 1.5-fold, respectively, above the level in undifferentiated cells (day 0), insulin and pioglitazone together acted synergistically to increase this message by almost 6-fold (Fig. 1). GLUT1 mRNA levels did not change in age-matched undifferentiated cells maintained in growth medium over the same interval. In contrast to the observed synergistic treatment effects on GLUT1 mRNA levels, GLUT4 mRNA abundance was increased to similar levels above undifferentiated cells (day 0) reaching 3.8-, 4.6-, and 5.2-fold elevation by respective treatments for 7 days with insulin, pioglitazone, or both (Fig. 2). Whereas these values for GLUT4 mRNA abundance reflected an overall increase at day 7, a small decline was observed at this time point in some experiments with combined treatment by insulin and pioglitazone (Fig. 2, lower). Such results indicate that some down-regulation may occur in the final differentiated state.

These changes in GLUT1 and GLUT4 glucose transporter mRNA levels were accompanied by changes in levels of the encoded transporter proteins as determined by Western blotting. Whereas either insulin or pioglitazone treatment appeared to increase GLUT1 protein levels on day 7 of differentiation by 2.3- and 3.5-fold respectively, the agents together seemed to act synergistically to increase protein levels by almost 10-fold above those of age-matched undifferentiated cells (Fig. 3). In contrast to the observed synergistic




**FIG. 1.** Effect of insulin and pioglitazone treatment on GLUT1 mRNA abundance. *Upper*, Time-dependent increases in abundance of GLUT1 mRNA during differentiation of 3T3-F442A cells induced by insulin (INS), pioglitazone (PIO), or both. Cells were seeded, grown to confluence, and differentiated as described in *Materials and Methods*. Untreated age-matched fibroblasts maintained in DMEM containing only 10% calf serum were used as control (CS). Total RNA was isolated at indicated time points, and samples (10  $\mu$ g/lane) were electrophoretically size-fractionated on agarose gels. Northern blots were hybridized to Riboprobes specific for rat GLUT1 mRNA. Autoradiographic bands were quantitated by densitometry and normalized for minor loading differences as described in *Materials and Methods*. Data represent mean values for  $n = 5-6$  determinations. A three factor analysis of variance (ANOVA; insulin, pioglitazone, time) with interactions showed a significant effect on GLUT1 mRNA abundance from combined treatment with I and P ( $P < 0.001$ ). *Lower*, Representative Northern blot showing GLUT1 mRNA abundance in control (CS) and treated (INS, PIO, I + P) cells on day 7 of differentiation.

effect on GLUT1 protein, GLUT4 protein levels increased by about 2.2-, 6.6-, and 4-fold by insulin, pioglitazone, or both, respectively (Fig. 4).

#### *Increased stability of glucose transporter messages*

We next investigated possible effects of insulin and pioglitazone on the stability of GLUT1 and GLUT4 mRNAs. Fibroblast 3T3-F442A cells were induced to differentiate by treatment with insulin (1  $\mu$ g/ml), pioglitazone (1  $\mu$ M), or both for 7 days. The transcription inhibiting agent, Act D (5  $\mu$ g/ml), was added to differentiated cells on day 7 or to undifferentiated control cells just before such cells reached conflu-



GLUT4 mRNA




FIG. 2. Effect of insulin and pioglitazone treatment on GLUT4 mRNA abundance. *Upper*, Time-dependent increases in GLUT4 mRNA abundance in 3T3-F442A cells during differentiation. Cells were grown to confluence, and differentiated in the presence of insulin (INS), pioglitazone (PIO), or both (INS + PIO) as described in *Materials and Methods*. Untreated, age-matched fibroblasts maintained in DMEM containing only 10% calf serum were used as control (CS). Total RNA was isolated, Northern blots were prepared as described for Fig. 1, and membranes were hybridized with Riboprobe transcripts specific for rat GLUT4. Quantitation of resultant autoradiographs was done as described in *Materials and Methods*. Data represent mean values for  $n = 5$ –6 determinations. A three factor ANOVA (insulin, pioglitazone, time) with interactions showed significant effects on GLUT4 mRNA abundance by INS ( $P = 0.001$ ) or PIO ( $P < 0.0001$ ). *Lower*, Representative Northern blot showing GLUT4 mRNA abundance in control (CS) and treated (INS, PIO, I + P) cells on day 7 of differentiation.

ence, and total RNA was extracted from cells at indicated times after addition of the transcription inhibitor (0, 1, 2, 4, 6, and 24 h). Even after 24-h treatment with Act D, cell membranes remained intact and appeared refractile, and there was no visible sloughing of cells from the plates. The abundance of remaining mRNA transcripts for each of the glucose transporter genes was assessed on Northern blots. Differentiation of 3T3-F442A cells increased the GLUT1 mRNA half-life from about 2.2 h in control undifferentiated cells to about 5.7, 3.6, and greater than 24 h in adipocytes differentiated by treatment with insulin, pioglitazone, or both, respectively (Fig. 5, Table 2). The stabilization of GLUT1 mRNA appeared to account for corresponding increases in GLUT1 mRNA abundance. Similarly, GLUT4


FIG. 3. Effect of insulin and pioglitazone treatments on GLUT1 protein abundance. *Upper*, Increased GLUT1 protein abundance on differentiation of 3T3-F442A cells. Confluent 3T3-F442A cells were differentiated with I (INS), P (PIO), or both (INS + PIO) as described in *Materials and Methods*. On day 7, cellular membranes were isolated from undifferentiated (CS) or differentiated (INS-, PIO-, or INS + PIO-treated) cells, and protein (10  $\mu$ g/lane) was electrophoresed and immunoblotted for GLUT1 detection using the rabbit anti-GLUT1 primary antibody (see *Materials and Methods*). Resulting colorimetrically stained bands were quantitated by densitometry and normalized for minor loading differences. Data are expressed as percent of control and represent mean values  $\pm$  SEM for  $n = 8$  determinations. With background subtraction, the mean basal value was  $0.20 \pm 0.06$  arbitrary density units. Two factor ANOVA showed significant effects on GLUT1 protein by INS ( $P = 0.014$ ), PIO ( $P = 0.015$ ), and INS + PIO ( $P < 0.0001$ ). *Lower*, Representative immunoblot showing expression of GLUT1 protein in selected samples from control (CS) and treated (INS, PIO, I + P) cells on day 7 of differentiation. Molecular weight markers are indicated in lane M; the GLUT1 band ran as  $M_r = 41,000$ .

mRNA half-life increased from about 1.2 h in undifferentiated control cells to about 14.2, 10.3, and greater than 24 h in cells differentiated with insulin, pioglitazone, or both, respectively (Fig. 5, Table 2). Again, GLUT4 mRNA stabilization appeared to account for observed increases in mRNA abundance.

As shown in Fig. 6, we were able to quantitate differential expression of transporter messages in cells undergoing different treatments by differentially exposing the Northern blots to film. This allowed calculation of message half-lives even when transcripts were present only at relatively low levels.


## Discussion

Pioglitazone, 5-[4-(2-(5-ethyl-pyridyl)ethoxy]-2,4-thiazolidinedione, is an antidiabetic agent that has been shown to



**FIG. 4.** Effect of insulin and pioglitazone treatments on GLUT4 protein abundance. *Upper*, Increased GLUT4 protein levels on differentiation of 3T3-F442A cells. Cell culture, treatment conditions, protein extraction, and Western blot analyses were performed as described in Fig. 3 legend, except that 60  $\mu$ g/lane total protein were loaded for detection using the rabbit anti-GLUT4 primary antibody. Data are expressed as percent of control and represent mean  $\pm$  SEM for  $n = 10$  determinations. After background subtraction, the mean basal value was  $0.57 \pm 0.11$  arbitrary density units. Two factor ANOVA showed significant effects on GLUT4 by INS ( $P = 0.015$ ), PIO ( $P = 0.007$ ), and INS + PIO ( $P = 0.0003$ ). *Lower*, Representative immunoblot showing increased levels of GLUT4 protein in 7 day-treated (INS, PIO, I + P) compared to untreated control (CS) cells. GLUT4 protein appears as a stained band with apparent  $M_r$  of 46,000. In control cells (CS), a nonspecific band of apparent  $M_r$  60,000 cross-reacted with the secondary antibody.

ameliorate hyperglycemia in animal models of noninsulin-dependent diabetes mellitus (10, 11, 30). The purpose of our study was to further probe cellular action mechanisms underlying the antidiabetic effects of pioglitazone. Our prior findings indicated that the antidiabetic agent pioglitazone acted as a potent accelerator of adipocyte differentiation of 3T3-F442A cells (14). This was evidenced by our demonstration that treatment of fibroblast-like preadipocytes with pioglitazone led to expression of fat-specific genes along with acquisition of the morphological appearance of lipid-accumulating adipocytes with concomitant increases in triglyceride accumulation (14). In the present study, we showed that such pioglitazone-treated cells showed an increased capacity for glucose uptake, with associated increases in GLUT1 and GLUT4 proteins. We further measured increased levels of mRNA transcripts encoding these glucose transporters, and found that these increases corresponded with markedly enhanced stability of both GLUT1 and GLUT4 mRNA messages. Such increased expression of glucose transporters in adipocytes established the cells in a state active for glucose



**FIG. 5.** *Upper*, Enhanced GLUT1 mRNA stability associated with treatment of 3T3-F442A cells with insulin (INS), pioglitazone (PIO), or both (I + P). *Lower*, Enhanced GLUT4 mRNA stability associated with treatment of 3T3-F442A cells with I, P, or both. Confluent 3T3-F442A cells were differentiated with INS, PIO, I + P for 7 days as described in Materials and Methods. On day 7 of treatment, Act D (5  $\mu$ g/ml) was added to differentiated (INS, PIO, I + P) and undifferentiated (CS) control cells, and total RNA was extracted from cells at indicated time points (0, 1, 2, 4, 6, and 24 h). Abundance of mRNA was assessed by Northern blotting analysis as described earlier. Data are expressed as percent of mRNA remaining after Act D treatment relative to the levels before the treatment time 0. Each data point represents a mean value for  $n = 2$  determinations. Calculated mRNA half-lives are shown in Table 2.

uptake, thus ultimately facilitating glucose storage and metabolism as well.


Results of our present study showed that the differentiation of 3T3-F442A cells by treatment with insulin and pioglitazone was accompanied by strikingly increased capacity for basal glucose transport (60-fold) compared to that for fibroblast-like preadipocytes. Facilitated diffusion of glucose across the plasma membrane of adipocytes is known to be mediated by two glucose transporter proteins, i.e., GLUT1

TABLE 2. Calculated mRNA half-lives in undifferentiated and differentiated 3T3-F442A cells

Treatment	mRNA half-life (h)			
	CS	INS	PIO	INS + PIO
<b>Transporter</b>				
GLUT1	2.2	5.7	3.6	>24
GLUT4	1.2	14.3	10.3	>24

Data from the experiment involving Act D treatment (Fig. 5) were fitted to a single exponential decay curve by nonlinear least square regression analysis. The estimated first-order rate constant was used to calculate the mRNA half-life.

### GLUT1 mRNA Stability



### Hours after Actinomycin D Addition

FIG. 6. Autoradiographs of Northern blots probed for GLUT1 mRNA transcript abundance after D treatment. Experimental samples were prepared as described in Fig. 5. Data shown represent duplicate experimental points, except for the time 0 INS, where only a single sample is shown. Hours of film exposure to the radiolabeled blot were 40, 18, 24, and 8 for CS, INS, PIO, and INS + PIO, respectively. Some films required longer exposure intervals for detection of low level transcripts.

and GLUT4 (31). Multiple mechanisms exist by which hormones and other factors control the rate of cellular glucose uptake via these transporters. These include the rapid translocation of preexisting transporters from an intracellular pool to the plasma membrane, modulation of the intrinsic activity of preexisting plasma membrane glucose transporters, and stimulation of the synthesis of new transporters (32). We clearly observed increased transporter synthesis, since our results demonstrated increases in the expression of both GLUT1 and GLUT4 transporters on mRNA and protein

levels (5- to 10-fold maximal enhancement for each). These results are in agreement with previous studies in which GLUT1 and GLUT4 mRNA and protein levels were shown to increase during differentiation of 3T3 preadipose cells (27, 33). Our observed increase in glucose transporter activity appeared to be somewhat greater in proportion than the combined increases in the synthesis of the two transporter proteins. This observation indicated that another mechanism, such as increased intrinsic activity of transporters, may also contribute to the effect. Such regulation of intrinsic transporter activity has previously been reported (34, 35). Inhibition of 3T3-L1 adipocyte protein synthesis by actinomycin, for instance, appeared to stimulate glucose transport primarily by enhancing the intrinsic catalytic activity of cell surface GLUT1, and to a lesser extent GLUT4 proteins (34). Further, treatment of 3T3-L1 preadipocytes with tumor necrosis factor- $\alpha$  reportedly increased glucose transport and GLUT1 transporter intrinsic activity (35). Alternatively, it is possible that the apparent difference in glucose transport activity and glucose transporter protein levels may be a consequence of our presentation of data as fold-enhancement relative to low level controls. As such, we may have some differences in detection sensitivity rather than absolute differences in the magnitude of changes.

Increased mRNA abundance can be attributed to enhanced RNA transcription and/or increased message stability. It was previously established that increases in the steady state level of several mRNAs during differentiation were accompanied by activation of specific gene transcription (36-39). This was particularly shown for mRNAs whose abundance was increased markedly (20- to 100-fold) during differentiation, including the  $\alpha$ P2 and glycerolphosphate dehydrogenase genes (36). The same report showed no significant changes in the rates of transcription of mRNAs for which abundance was more moderately altered (2- to 4-fold) during differentiation, such as those encoding fructose-1,6-biphosphate,  $\beta$ -actin, and  $\beta$ -tubulin (36). In any case, most adipocyte mRNAs were far more abundant than would be predicted by their increased nuclear transcription rates. When increases in steady state mRNA levels cannot be attributed to changes in transcription, other levels of control such as mRNA stability likely contribute to the relative abundance of mRNAs during adipocyte differentiation. Since we observed moderate increases in GLUT1 and GLUT4 mRNA abundance (about 5-fold) with adipocyte differentiation, we compared mRNA half-lives in undifferentiated and differentiated cells using Act D (a transcription inhibitor) chase experiments. Differentiation of 3T3-F442A cells by insulin and/or pioglitazone dramatically increased the mRNA half-lives for GLUT1 and GLUT4 above their values in undifferentiated cells, *i.e.* from 1-2 h up to greater than 24 h. Such stabilization of these mRNAs with adipocyte differentiation correlated well with increases in the mRNA steady state levels. It is interesting to note that Actinomycin D itself has been reported in a few instances to have mRNA stabilizing effects (40-42). It would therefore be possible to extend our observations by conducting experiments using different transcription inhibitors such as 5,6-dichloro-1- $\beta$ -D-ribofuranosylbenzimidazole or thiolutin, or using a different method such as [ $^3$ H]uridine pulse to

verify message stability. However, our observed dramatic increase in the stability of transcripts encoding glucose transporters in adipocytes versus fibroblasts seems likely to remain, though there may be some differences in the absolute calculated half-lives.

Our findings represent the first study that directly associates increased steady state mRNA levels during adipocyte differentiation with increased mRNA stability. This process was, however, predicted earlier based on observed increases in mRNA transcript levels that could not be explained by increased gene transcription (36–38). Regulation of mRNA stability in such cells has, in fact, been reported for other conditions. Treatment of 3T3-F442A mature adipocytes with retinoic acid, for instance, specifically decreased the adipin mRNA level (43). For such studies, the rate of adipin gene transcription remained unchanged, whereas the half-life of adipin mRNA was greatly shortened in retinoic acid-treated adipocytes as compared with untreated cells (37.6–7.3 h). Another example is the induction of GLUT1, as well as other immediate-early growth-related protooncogenes, in 3T3-L1 fibroblasts by treatment with tumor necrosis factor- $\alpha$  (26, 35) and 8-bromo-cAMP (44). Whereas transcriptional activation of immediate-early genes correlated well with subsequent accumulation of their respective mRNAs, increased GLUT1 mRNA was due to an apparent increase in the stability of this message (45 min to several hours) without changes in its transcription. Another study showed that increased GLUT1 mRNA abundance by chronic exposure of L6 myocytes to insulin was due to increased transcription as well as prolonged half-life (2–5 h) (45).

In general, the stabilization/destabilization of mRNAs in response to biological and pharmacological stimuli has been recognized as an important posttranscriptional step for regulation of gene expression (46–49). Despite that, the mechanisms underlying such processes, including the signals that trigger mRNA degradation or stabilization, the structural elements of the RNA that are recognized by degradative enzymes or stabilization factors, as well as the enzymes or other *trans*-acting factors themselves, are largely unknown (46, 49–52). Interestingly, a recent report indicated that the 3'-untranslated region of GLUT1 mRNA contains a single copy of the destabilizing AUUUA motif in the context of an AU-rich region (26). The stability of GLUT1 mRNA was found to be partially controlled by its interaction with a sequence-specific mRNA binding protein, the adenosine-uridine binding factor which was speculated to mediate mRNA stabilization by blocking the AU-destabilizing motifs (26). We therefore propose that increasing mRNA abundance during differentiation by increasing message stability presents an interesting phenomenon awaiting further examination. Future efforts should be particularly directed toward identifying common mRNA sequences that may function as stabilizing elements in the differentiation-induced mRNAs as well as identifying their regulatory binding proteins.

#### Acknowledgments

The authors acknowledge the expert technical assistance of K. Lorenz and C. W. Edwards III (Hines, IL) and the statistical analysis assistance from Dr. Nancy Johnson (Hines, IL). We sincerely thank Dr. Graeme

Bell (Chicago, IL) for providing the DNA construct used for preparing rat GLUT1 Riboprobes and Dr. Morris Birnbaum (Boston, MA) for supplying rat GLUT4 cDNA. The 3T3-F442A cells were kindly provided by Dr. Jessica Schwartz (Ann Arbor, MI) with permission from Dr. Howard Green (Boston, MA).

#### References

- DiGirolamo M, Newby FD, Lovejoy J 1992 Lactate production in adipose tissue: a regulated function with extra-adipose implications. *FASEB J* 6:2405–2412
- Lonnroth P 1991 Regulation of insulin action at the cellular level. *J Int Med* 229:23–29
- Spiegelman BM 1988 Regulation of gene expression in the adipocyte: implications for obesity and proto-oncogene function. *Trends Genet* 4:203–207
- Olefsky JM, Garvey WT, Henry RR, Brillon D, Matthei S, Freidenberg GR 1988 Cellular mechanisms of insulin resistance in non-insulin dependent (type II) diabetes. *Am J Med* 85:86–104
- Moller DE, Flier JS 1991 Insulin resistance—mechanisms, syndromes, and implications. *N Engl J Med* 325:938–948
- DeFronzo RA, Bonadonna RC, Ferrannini E 1992 Pathogenesis of NIDDM: a balanced overview. *Diabetes Care* 15:318–353
- Gerich JE 1989 Oral hypoglycemic agents. *N Engl J Med* 321:1231–1245
- Melander A, Bitzen P, Faber O, Groop L 1989 Sulfonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. *Drugs* 37:58–72
- Hofmann CA, Colca JR 1992 New oral thiazolidinedione antidiabetic agents act as insulin-sensitizers. *Diabetes Care* 15:1075–1078
- Ikeda H, Taketomi S, Sugiyama Y, Sodha T, Meguro K, Fujita T 1990 Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. *Arzneim-Forsch/Drug Res* 40:156–160
- Hofmann C, Lorenz K, Colca JR 1991 Glucose transport deficiency in diabetic animals is corrected by treatment with the oral anti-hyperglycemic agent pioglitazone. *Endocrinology* 129:1915–1925
- Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH 1989 A potent *in vivo* effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. *Metabolism* 38:1089–1093
- Chang AY, Wyse BM, Gilchrist BJ 1983 Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and -/+ mice. *Diabetes* 32:839–845
- Sandouk T, Reda D, Hofmann C, The antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. *Am J Physiol*, in press
- Kletzien RF, Clarke SD, Ulrich RG 1992 Enhancement of adipocyte differentiation by an insulin-sensitizing agent. *Mol Pharmacol* 41:393–398
- Hiragun A, Sato M, Mitsui H 1988 Preadipocyte differentiation *in vitro*: identification of a highly active adipogenic agent. *J Cell Physiol* 134:124–130
- Schwartz J, Carter-Su C 1988 Effects of growth hormone on glucose metabolism and glucose transport in 3T3-F442A cells: dependence on cell differentiation. *Endocrinology* 122:2247–2256
- Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156–159
- Fournier RM, Miyashi J, Day RS, Paterson MC 1988 Northern blotting: efficient RNA staining and transfer. *FOCUS* 10:5–7
- Gould GW, Lienhard GE 1989 Expression of a functional glucose transporter in *Xenopus* oocytes. *Biochem* 28:9447–9452
- Birnbaum MJ 1989 Identification of a novel gene encoding an insulin-responsive glucose transporter protein. *Cell* 57:305–315
- Bonini J, Hofmann C 1991 A rapid, accurate, nonradioactive method for quantitating RNA on agarose gels. *Biotechnology* 11:708–709
- Kaestner KL, Flores-Riveros JR, McLennan JC, Janicot M, Lane MD 1991 Transcriptional repression of the mouse insulin-responsive glucose transporter (GLUT4) gene by cAMP. *Proc Natl Acad Sci USA* 88:10338–10342

- Sci USA 88:1933-1937
24. Dani C, Bertrand B, Bardon S, Doglio A, Amri EZ, Grimaldi P 1989 Regulation of gene expression by insulin in adipose cells: opposite effects on adipin and glycerolphosphate dehydrogenase genes. *Mol Cell Endocrinol* 63:199-208
  25. Cornelius P, Marlowe M, Lee MD, Pekala PH 1990 The growth factor-like effects of tumor necrosis factor-alpha. Stimulation of glucose transport activity and induction of glucose transporter and immediate early gene expression in 3T3-L1 preadipocytes. *J Biol Chem* 265:20506-20516
  26. Stephens JM, Carter BZ, Pekala PH, Malter JS 1992 Tumor necrosis factor-alpha induced glucose transporter (GLUT1) mRNA stabilization in 3T3-L1 preadipocytes. *J Biol Chem* 267:8336-8341
  27. Weiland M, Schurmann A, Schmidt WE, Joost H 1990 Development of the hormone-sensitive glucose transport activity in differentiating 3T3-L1 murine fibroblasts. *Biochem J* 270:331-336
  28. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. *Anal Biochem* 72:248-254
  29. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680-685
  30. Sugiyama Y, Shimura Y, Ikeda H 1990 Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. *Arzneim-Forsch/Drug Res* 40:436-440
  31. Kayano T, Burant CF, Fukumoto H, Gould GW, Fan Y, Eddy R, Byers MG, Shows TB, Seino S, Bell GI 1990 Human facilitative glucose transporters. *J Biol Chem* 265:13276-13282
  32. Pessin JE, Bell GI 1992 Mammalian facilitative glucose transporter family: structure and molecular regulation. *Annu Rev Physiol* 54:911-930
  33. Hainque B, Guerre-Millo M, Hainault I, Moustaid N, Wardzala LJ, Lavau M 1990 Long term regulation of glucose transporters by insulin in mature 3T3-F442A adipose cells. *J Biol Chem* 265:7982-7988
  34. Harrison SA, Clancy BM, Pessino A, Czech MP 1992 Activation of cell surface glucose transporters measured by photoaffinity labeling of insulin-sensitive 3T3-L1 adipocytes. *J Biol Chem* 267:3783-3788
  35. Cornelius P, Marlowe M, Douglas LM, Pekala PH 1990 The growth factor-like effects of tumor necrosis factor-alpha. *J Biol Chem* 265:20506-20516
  36. Bernlohr DA, Bolanowski MA, Kelly TJ, Lane MD 1985 Evidence for an increase in transcription of specific mRNAs during differentiation of 3T3-L1 preadipocytes. *J Biol Chem* 260:5563-5567
  37. Djian P, Phillips M, Green H 1985 The activation of specific gene transcription in the adipose conversion of 3T3 cells. *J Cell Physiol* 124:554-556
  38. Cook KS, Hunt CR, Spiegelman BM 1985 Developmentally regulated mRNAs in 3T3-adipocytes: analysis of transcriptional control. *J Cell Biol* 100:514-520
  39. Chapman AB, Knight DM, Ringold GM 1985 Glucocorticoid regulation of adipocyte differentiation: hormonal triggering of the developmental program and induction of a differentiation-dependent gene. *J Cell Biol* 101:1227-1235
  40. Knutsen HK, Tasken KA, Eskild W, Jahnsen T, Hansson V 1991 Adenosine 3',5'-monophosphate-dependent stabilization of messenger ribonucleic acids (mRNAs) for protein kinase-A (PKA) subunits in rat sertoli cells: rapid degradation of mRNAs for PKA subunits is dependent on ongoing RNA and protein synthesis. *Endocrinology* 129:2496-2502
  41. Pontecorvi A, Jamshed JR, Phyillaier M, Robbins J 1988 Selective degradation of mRNA: the role of short-lived proteins in differential destabilization of insulin-induced creatine phosphokinase and myosin heavy chain mRNAs during rat skeletal muscle L6 cell differentiation. *EMBO J* 7:1489-1495
  42. Iynedjian PB, Jotterand D, Nouspikel T, Asfari M, Pitot PR 1989 Transcriptional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system. *J Biol Chem* 264:21824-21829
  43. Antras J, Lasnier F, Pairault J 1991 Adipsin gene expression in 3T3-F442A adipocytes is posttranscriptionally down-regulated by retinoic acid. *J Biol Chem* 266:1157-1161
  44. Cornelius P, Marlowe M, Call K, Pekala PH 1991 Regulation of glucose transport as well as glucose transporter and immediate early gene expression in 3T3-L1 preadipocytes by 8-bromo-cAMP. *J Cell Physiol* 146:298-308
  45. Maher F, Harrison LC 1990 Stabilization of glucose transporter mRNA by insulin/IGF-1 and glucose deprivation. *Biochem Biophys Res Commun* 171:210-215
  46. Raghow R 1987 Regulation of messenger RNA turnover in eukaryotes. *Trends Biochem Sci* 12:358-360
  47. Ross J 1988 Messenger RNA turnover in eukaryotic cells. *Mol Biol Med* 5:1-4
  48. Stephens JM, Pekala PH 1991 Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. *J Biol Chem* 266:21839-21845
  49. Stephens JM, Pekala PH 1992 Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor. *J Biol Chem* 267:13580-13584
  50. Jackson RJ, Standart N 1993 Do the poly(A) tail and 3' untranslated region control mRNA translation? *Cell* 62:15-24
  51. Klausner RD, Horford JB 1989 Cis-trans models for post-transcriptional gene regulation. *Science* 246:870-872
  52. Brawerman G 1989 mRNA decay: finding the right targets. *Cell* 57:9-10

## L-Glutamic Acid $\gamma$ -Monohydroxamate

A POTENTIATOR OF VANADIUM-EVOKED GLUCOSE METABOLISM IN VITRO AND IN VIVO\*

(Received for publication, February 5, 1999, and in revised form, July 8, 1999)

Itzhak Goldwaser<sup>†‡§¶</sup>, Jinping Li<sup>†</sup>, Eytan Gershonov<sup>†§</sup>, Michal Armoni<sup>||</sup>, Eddy Karniel<sup>||</sup>,  
Mati Fridkin<sup>§\*\*</sup>, and Yoram Shechter<sup>† ‡‡</sup>

From the <sup>†</sup>Departments of Biological Chemistry and <sup>§</sup>Organic Chemistry, The Weizmann Institute of Science,  
Rehovot 76100, Israel and the <sup>||</sup>Institute of Endocrinology, Rambam Medical Center and the B. Rappaport Faculty of  
Medicine, Technion, Haifa 31096, Israel

We report that the vanadium ligand L-Glu( $\gamma$ )HXM potentiates the capacity of free vanadium ions to activate glucose uptake and glucose metabolism in rat adipocytes *in vitro* (by 4–5-fold) and to lower blood glucose levels in hyperglycemic rats *in vivo* (by 5–7-fold). A molar ratio of two L-Glu( $\gamma$ )HXM molecules to one vanadium ion was most effective. Unlike other vanadium ligands that potentiate the insulinomimetic actions of vanadium, L-Glu( $\gamma$ )HXM partially activated lipogenesis in rat adipocytes in the absence of exogenous vanadium. This effect was not manifested by D-Glu( $\gamma$ )HXM. At 10–20  $\mu$ M L-Glu( $\gamma$ )HXM, lipogenesis was activated 9–21%. This effect was approximately 9-fold higher ( $140 \pm 15\%$  of maximal insulin response) in adipocytes derived from rats that had been treated with vanadium for several days. Titration of vanadium(IV) with L-Glu( $\gamma$ )HXM led to a rapid decrease in the absorbance of vanadium(IV) at 765 nm, and <sup>51</sup>V NMR spectroscopy revealed that the chemical shift of vanadium(IV) at –490 ppm disappeared with the appearance of a signal characteristic to vanadium(V) (–530 ppm) upon adding one equivalent of L-Glu( $\gamma$ )HXM. In summary, L-Glu( $\gamma$ )HXM is highly active in potentiating vanadium-activated glucose metabolism *in vitro* and *in vivo* and facilitating glucose metabolism in rat adipocytes in the absence of exogenous vanadium probably through conversion of trace intracellular vanadium into an active insulinomimetic compound. We propose that the active species is either a 1:1 or 2:1 L-Glu( $\gamma$ )HXM vanadium complex in which the endogenous vanadium(IV) has been altered to vanadium(V). Finally we demonstrate that L-Glu( $\gamma$ )HXM- and L-Glu( $\gamma$ )HXM-vanadium-evoked lipogenesis is arrested by wortmannin and that activation of glucose uptake in rat adipocytes is because of enhanced translocation of GLUT4 from low density microsomes to the plasma membrane.

Intensive studies have been carried out during the last two decades on the insulinomimetic effects of vanadium (1–4). Va-

nadium salts mimic most of the effects of insulin on the main target tissues of the hormone *in vitro* and also induce normoglycemia and improve glucose homeostasis in insulin-deficient (5–7) and insulin-resistant diabetic rodents *in vivo* (5–8). On the basic research frontier, data continue to accumulate showing that vanadium salts manifest their insulin-like metabolic effects through alternative pathways not involving insulin receptor tyrosine kinase activation or phosphorylation of insulin receptor substrate 1 (9–19). The key events of this backup system appear to involve inhibition of protein-phosphotyrosine phosphatases and activation of nonreceptor protein-tyrosine kinases (20–23).

Vanadium salts are seriously considered as a possible treatment for diabetes, and several clinical studies have already been performed. In those studies, because of its toxicity, only low doses of vanadium (2 mg/kg/day) were used. Although ~20-fold lower than doses used in most animal studies, several beneficial effects were observed and documented (24–26). Any manipulation to elevate the insulinomimetic efficacy of vanadium without increasing its toxicity is of major clinical interest for the future care of diabetes (reviewed in Ref. 27).

Organically chelated vanadium compounds, such as vanadium-acetylacetone and vanadium-RL-252,<sup>1</sup> are more potent than free vanadium in facilitating insulin-like effects in rat adipocytes (28, 29). Similarly, chelated vanadium compounds such as bis(maltolato)oxovanadium and bis(picolinato)oxovanadium are more effective than free vanadium in reducing circulating glucose levels in hyperglycemic streptozocin-treated rats (30–33).

In the wake of these findings, we have continued our search for more effective vanadium binding agents. Of special interest to us were vanadium chelators that synergize with vanadium both *in vivo* (*i.e.* in streptozocin rats) and *in vitro* (*i.e.* in isolated rat adipocytes) and therefore enable us to gain insight into the basic mechanism(s) by which such compounds potentiate the insulinomimetic activity of vanadium. Specifically, we have studied hydroxamic acid derivatives. These compounds are involved in the microbial transport of iron and are therefore applied therapeutically in conditions of iron deficiency (34). They are also inhibitors of urease activity and have been used in the treatment of hepatic coma. Monoamino acid hydroxamates are simple, nontoxic derivatives of amino acids. D-Aspartic acid  $\beta$ -hydroxamate was shown to have antitumoral activity on murine leukemia L5178Y, both *in vitro* and *in vivo*, and is


\* This work was supported by grants from the Minerva Foundation, Munich, Germany, The Israel Academy of Science Foundation, the Israeli Ministry of Health, and The Lapid Pharmaceutical Company. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† Partial fulfillment of the requirements for the Ph.D. degree.

\*\* Lester Pearson Professor of Protein Chemistry.

‡ The incumbent of the C. H. Hollenberg Chair in Metabolic and Diabetes Research established by the friends and associates of Dr. C.H. Hollenberg of Toronto, Canada. To whom correspondence should be addressed. Tel.: 972-8-9343698; Fax: 972-8-9344118.

<sup>1</sup> The abbreviations used are: RL-252, [(CH<sub>2</sub>)<sub>2</sub>-C-(CH<sub>2</sub>O-(CH<sub>2</sub>)<sub>2</sub>-CO-NHCH(iBu)CONOHCH<sub>2</sub>)<sub>2</sub>]; L-Glu( $\gamma$ )HXM, L-glutamic acid  $\gamma$ -monohydroxamate; GLUT4, glucose transporter 4; PM, plasma membranes; LDM, low density microsomes; BSA, bovine serum albumin; VOCl<sub>2</sub>, vanadyl dichloride; NaVO<sub>3</sub>, sodium metavanadate.



**FIG. 1. Increase in the lipogenic capacity of vanadium(V) following the addition of L-glutamic acid(γ)monohydroxamate.** Freshly prepared rat adipocytes ( $3 \times 10^5$  cells/ml) suspended in KRB buffer, pH 7.4, containing 0.7% BSA were preincubated for 10 min with the indicated concentrations of  $\text{NaVO}_3$ , free  $\text{Glu}(\gamma)\text{HXM}$ , and a 1:1 complex of  $\text{L-Glu}(\gamma)\text{HXM-NaVO}_3$ . The cells were then supplemented with [ $\text{U-}^{14}\text{C}$ ]glucose, and lipogenesis was performed for 2 h at 37 °C. Radioactivity incorporated into extracted lipids was then determined. Maximal response (100%) is that obtained in the presence of 17 nM insulin.

active against Friend leukemia cells *in vitro* as well (35). L-Glu(γ)HXM is cytotoxic against L1210 cells in culture and remarkably antitumoral against L1210 leukemia and B16 melanoma *in vivo* (35, 36).

#### EXPERIMENTAL PROCEDURES

**Materials**—D-[ $\text{U-}^{14}\text{C}$ ]glucose and 2-deoxy-D-[G- $^3\text{H}$ ]glucose were purchased from NEN Life Science Products. Collagenase type I (134 units/mg) was obtained from Worthington. Porcine insulin was purchased from Eli Lilly Co. (Indianapolis, IN). Phloretin, 2-deoxyglucose, L-glutamic acid(γ)-monohydroxamate, L-aspartic acid(β)-monohydroxamate, glycine hydroxamate, L-isoleucine(α)-hydroxamate, and L-tyrosine(α)-hydroxamate were purchased from Sigma. RL-252 was prepared and characterized as described earlier (28).

Krebs-Ringer bicarbonate (KRB) buffer (pH 7.4) contained 110 mM NaCl, 25 mM  $\text{NaHCO}_3$ , 5 mM KCl, 1.2 mM  $\text{KH}_2\text{PO}_4$ , 1.3 mM  $\text{CaCl}_2$ , 1.3 mM  $\text{MgSO}_4$ . Krebs-Ringer bicarbonate HEPES (KRBH) buffer (pH 7.4) consisted of 117 mM NaCl, 10 mM  $\text{NaHCO}_3$ , 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgSO}_4$ , 4 mM  $\text{KH}_2\text{PO}_4$ , 30 mM HEPES. All other chemicals and reagents used in this study were of analytical grade.


**Streptozocin-treated Rats**—Diabetes was induced by a single intravenous injection of a freshly prepared solution of streptozocin (55 mg/kg body weight) in 0.1 M citrate buffer, pH 4.5 (9). The effect of the L-Glu(γ)HXM-vanadium complex on blood glucose level was determined 8 days after induction of diabetes by streptozocin.

**Cell Preparation and Bioassays**—Rat adipocytes were prepared from the fat pads of male Wistar rats (130–150 g) by collagenase digestion according to the method of Rodbell (37). Cell preparations showed more than 95% viability by Trypan blue exclusion at least 3 h after digestion. All bioassays were performed as described in figure legends. Glucose transport was carried out using 2-deoxy-D-[G- $^3\text{H}$ ]glucose uptake (38),

and lipogenesis (the incorporation of  $\text{U-}^{14}\text{C}$ -labeled glucose into lipids) was performed according to Moody *et al.* (39). Briefly, freshly prepared rat adipocytes were suspended in KRBH, 0.7% BSA buffer and divided into about 50 plastic vials. Each vial contained 0.5 ml of adipocyte suspension (about  $1.5 \times 10^5$  cells). These were incubated for 2 h at 37 °C under an atmosphere of 95%  $\text{O}_2$ , 5%  $\text{CO}_2$  with 0.16 mM [ $\text{U-}^{14}\text{C}$ ]glucose. Each assay contained vials with and without 17 nM insulin and the various test compounds. Lipogenesis was terminated by adding toluene-based scintillation fluid, and the extracted lipids were counted (39). Results are expressed as a percent of maximal insulin response. Only assays in which insulin activated lipogenesis 5–6-fold above basal (basal  $\sim 4000$  cpm/1.5  $\times 10^5$  cells/2 h,  $V_{\text{insulin}} = 20,000$ –24,000 cpm/1.5  $\times 10^5$  cells/2 h) were taken into consideration. Insulin activated lipogenesis in this assay at an  $ED_{50}$  value of  $33 \pm 3$  pM. A concentration of 0.3 nM insulin and above already facilitated maximal (100%) response (*i.e.* Ref. 16). All assays were performed in duplicate or triplicate.

**Western Immunoblot Analysis of GLUT4 in Subcellular Membranes Following Stimulation of Rat Adipocytes**—Adipocytes prepared from 6-week-old rats were incubated with and without insulin and with L-Glu(γ)HXM alone and complexed with vanadate as specified in the figure. Cells were then homogenized and fractionated to low density microsomal membrane (LDM) and plasma membrane (PM) fractions by differential ultracentrifugation according to Ref. 40. Membrane proteins were then solubilized in sample buffer for 30 min at 25 °C, resolved on 10% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose paper, and immunoblotted with anti-GLUT4 antisera (41). Visualization was performed by phosphoimaging. The relative intensity of bands corresponding to GLUT4 was quantitated using MacBas 1000.

**$^{51}\text{V}$  NMR Spectroscopy**—The  $^{51}\text{V}$  NMR spectra were recorded on a 200-MHz Bruker WPS4 (4.7T) spectrometer. Spectrum width of 16,000




**FIG. 2. Stimulation of lipogenesis at varying molar ratios of L-Glu(γ)HXM to vanadium(V).** Freshly prepared rat adipocytes ( $3 \times 10^5$  cells/ml) suspended in KRB buffer, pH 7.4, containing 0.7% BSA were preincubated for 10 min with the indicated concentrations of 1:1 to 3:1 molar stoichiometry of L-Glu(γ)HXM to  $\text{NaVO}_3$  or with free  $\text{NaVO}_3$ (V) and free L-Glu(γ)HXM. The cells were then supplemented with [ $^{\text{U}}\text{C}$ ]glucose, and lipogenesis was performed for 2 h at 37 °C. Radioactivity incorporated into extracted lipids was then determined. Maximal response (100%) is that obtained in the presence of 17 nM insulin.

$\text{H}_3$ , a 90° pulse angle, and an accumulation time of 0.28 were used. The chemical shifts are reported relative to the external reference standard  $\text{VOCl}_2$  (-490 ppm).

## RESULTS

**L-Glutamic Acid(γ)Monohydroxamate Potentiates Vanadium-evoked Lipogenesis in Rat Adipocytes**—In this set of experiments, rat adipocytes were incubated for 10–20 min with submaximal concentrations of vanadate (10–30 μM), L-Glu(γ)HXM (10–30 μM), or an equimolar combination of them. The capacity to activate lipogenesis relative to insulin was then determined. As shown in Fig. 1, the combination was highly synergistic. For example, at 10 μM vanadate or L-Glu(γ)HXM, lipogenesis was 17 ± 3 and 9 ± 2%, respectively, whereas the combination produced a marked increase of 93 ± 4% activation of maximal insulin response. At 20 μM, the extent of lipogenesis was 37 ± 3, 20 ± 3, and 121 ± 7%, and at 30 μM, it was 42 ± 4, 23 ± 4, and 143 ± 7% of maximal. Wortmannin (100 nM), an inhibitor of phosphatidylinositol 3-kinase, fully blocked the activating effects of vanadate, L-Glu(γ)HXM, and its combination with vanadate (Fig. 1, right columns). Thus L-Glu(γ)HXM potentiated vanadate-evoked lipogenesis about 3.5–5-fold; the higher concentrations reached a level that is about 140% of that achieved by saturating concentrations of insulin or vanadate. A finding of significant interest to us was the ability of L-Glu(γ)HXM to partially activate lipogenesis even in the absence of exogenous vanadium (Fig. 1). This finding is examined in great detail in connection with Fig. 6.

In Fig. 2, lipogenesis in rat adipocytes was evaluated at a fixed, low concentration of vanadate (5 μM) with increasing concentrations of L-Glu(γ)HXM. Lipogenesis was negligible at 5 μM vanadate or L-Glu(γ)HXM alone (4–6% of maximal insulin effect) but is augmented to 27.0 ± 3% when they were given in combination (at a molar stoichiometry of 1:1). At 2:1 and 3:1 L-Glu(γ)HXM·vanadium molar stoichiometry, lipogenesis expanded to 43 and 57%, respectively, of maximal response. Thus




**FIG. 3. Potentiation of hexose uptake by L-Glu(γ)HXM·vanadium (2:1).** Adipocytes ( $2 \times 10^6$  cells/ml) suspended in KRBH buffer containing 1% BSA were preincubated in the presence and absence of insulin (17 nM), sodium metavanadate (20 μM), L-Glu(γ)HXM (40 μM), and their combination (at 1:2 molar stoichiometry). Aliquots (70 μl) were transferred into tubes containing 2-deoxy-D-[6-<sup>3</sup>H]glucose (0.1 mM final concentration). Phloretin (0.1 mM) was added after 3 min for transport termination. This was followed by centrifugation of aliquots through a silicone layer.

a substantial synergistic effect is obtained at a 1:1 molar ratio and is increased further at a 2:1 molar stoichiometry and even higher, though much less pronounced, at a 3:1 molar ratio (Fig. 2).

**L-Glu(γ)HXM Potentiates Vanadate-evoked Glucose Uptake**—Fig. 3 shows activation of 2-deoxyglucose uptake by low concentrations of vanadate (20 μM), L-Glu(γ)HXM (40 μM), and by the 2:1 molar combination of them. 2-Deoxyglucose undergoes insulin- or vanadate-evoked influx into the cell via the same transporters as glucose and is phosphorylated *in situ* to 2-deoxyglucose 6-phosphate with no further metabolism (42, 43). Therefore, this measurement reflects an effect on glucose entry into the cell in a manner largely independent of the metabolism of the endogenous saccharide. Vanadate (20 μM) and L-Glu(γ)HXM (40 μM) affected 2-deoxyglucose uptake of 7 ± 0.7 and 31 ± 4% of maximal insulin effect, respectively. Together they caused 2-deoxyglucose uptake 117 ± 9% of maximal insulin response (Fig. 3).

**L-Glu(γ)HXM Alone and L-Glu(γ)HXM·Vanadate Lead to Translocation of GLUT4 from LDM to PM Fractions in Rat Adipocytes**—Incubation of rat adipocytes with L-Glu(γ)HXM and L-Glu(γ)HXM·vanadate led to a decrease in the content of GLUT4 in the LDM fraction and an increase in the PM fraction (Fig. 4). The decrease in GLUT4 content in the low density lipoprotein fraction amounted to 32 ± 3, 3 ± 1, and 68 ± 5% of maximal insulin response upon incubating the cells with L-Glu(γ)HXM (40 μM), vanadate (20 μM, not shown), and the combination, respectively (calculated from Fig. 4). Under similar experimental conditions, L-Glu(γ)HXM, vanadate, and the combination activated 2-deoxyglucose uptake to an extent of 31 ± 4, 7 ± 0.7, and 117 ± 9% of maximal insulin response (Fig. 3), suggesting a contributing effect of the complex to glucose influx in addition to its effect in recruiting GLUT4 transporters



**Fig. 4.** **L-Glu(γ)HXM alone or complexed with vanadate induces translocation of GLUT4 from LDM to PM fraction in rat adipocytes.** Rat adipocytes were incubated for 30 min at 37 °C in the presence and the absence of insulin (17 nM) and the indicated concentrations of L-Glu(γ)HXM or L-Glu(γ)HXM-vanadate. Cells were then homogenized and fractionated to PM and LDM by differential ultracentrifugation, and GLUT4 protein was identified by Western immunoblot analysis ("Experimental Procedures"). Immunoreactive GLUT4 proteins were visualized by phosphoimaging (*top panels*) and were quantitated using MacBAS 1000 software (*histograms, bottom panels*).

from the low density lipoprotein to the PM fraction.<sup>2</sup>

**L-Glu(γ)HXM-Vanadate Normalizes Blood Glucose Levels in Streptozocin-treated Diabetic Rats**—In the experiments summarized in Fig. 5, streptozocin-treated rats received intraperitoneally sodium metavanadate (0.05 mmol/kg body weight), L-Glu(γ)HXM (0.1 mmol/kg body weight), or a combination of the two compounds 8 days after the induction of diabetes. As shown in the figure, vanadate and L-Glu(γ)HXM, at these concentrations, had a rather minor effect in reducing the high circulating glucose levels characterizing these hyperglycemic rats. The combination, however, was highly efficient at normalizing blood glucose levels. Normoglycemia was evident 1 day after the first administration and remained so following two more administrations. The glucose levels then remained close

to normal for the next 3 days (Fig. 5).

**Activation of Lipogenesis in Rat Adipocytes by L-Glu(γ)HXM in the Absence of Exogenous Vanadium**—L-glutamic acid(γ)HXM also activated lipogenesis in the absence of added vanadium, and this effect was studied in detail (Fig. 6). The dose-response curve (Fig. 6A) indicates that activation is already evident at 5 μM L-Glu(γ)HXM and that higher concentrations reach a level of 40 ± 7% of maximal insulin response (median effective dose = 35 ± 4 μM). Other amino acid hydroxamates such as L-Tyr(α)HXM, Gly(α)HXM, and L-Ile(α)HXM also activated lipogenesis, but they were considerably less potent ( $ED_{50} = 250 \pm 30 \mu M$ , 40 ± 5% of maximal insulin effect). L-Aspartic acid β-monohydroxamate showed higher lipogenic activity compared with the α-amino acid hydroxamates and was slightly less potent than L-Glu(γ)HXM ( $ED_{50} = 45 \pm 7 \mu M$ , Fig. 6B). N-acetyl-L-Glu(γ)HXM and L-Glu(γ)HXM-α-methyl ester were virtually ineffective, indicating the need for a free α-amino and, to a somewhat lesser extent, a free

<sup>2</sup> I. Goldwaser, J. Li, E. Gershonov, M. Armoni, E. Karnieli, M. Fridkin, and Y. Shechter, manuscript in preparation.

$\alpha$ -carboxyl moiety for the activation of lipogenesis by L-Glu( $\gamma$ )HXM in the rat adipose cell (Fig. 6C). Stereospecificity appears crucial as well, because the D-isomer of Glu( $\gamma$ )HXM was ineffective. All these

findings indicate that activation of lipogenesis by L-Glu( $\gamma$ )HXM depends on a specific entry of this L-amino acid analog into the adipose cell. Further investigation has led us to suggest that L-Glu( $\gamma$ )HXM enters the adipose cell primarily through the non-Na<sup>+</sup>-dependent glutamine transport system.<sup>2</sup>

Several organic chelators, which potentiate the insulinomimetic activity of vanadium either *in vitro* or *in vivo*, have been documented. These include acetylacetone (29), maltol (30, 31), picolinate (32, 33), and RL-252 (28). In Fig. 6D, we have examined whether they are capable of activating lipogenesis in the absence of exogenous vanadium. Unlike L-Glu( $\gamma$ )HXM, none of these agents were able to activate lipogenesis in the rat adipose cell at concentrations of 100  $\mu$ M (Fig. 6D) or lower (not shown).

**Extensive Potentiation of L-Glu( $\gamma$ )HXM-evoked Lipogenesis in Rat Adipocytes in Vitro Following Enrichment with Vanadium in Vivo**—The findings presented in Figs. 1–4 have taught us that L-Glu( $\gamma$ )HXM potentiates the insulinomimetic potency of vanadium and that activation of lipogenesis by L-Glu( $\gamma$ )HXM alone never exceeds 40  $\pm$  7% of maximal insulin effect (Fig. 6). To examine whether L-Glu( $\gamma$ )HXM-evoked lipogenesis can be affected by the level of intracellular vanadium, a group of male Wistar rats received daily subcutaneous administrations of vanadate (0.1 mmol/kg/day) over a period of 5 days to raise the level of endogenous vanadium. Rats were then sacrificed 7 h after the last administration. Adipocytes were prepared, and the effect of L-Glu( $\gamma$ )HXM on lipogenesis was compared with that in nontreated freshly prepared adipocytes. As shown in Fig. 7, vanadium-enriched adipocytes became dramatically sensitive to L-Glu( $\gamma$ )HXM-evoked lipogenesis. This was valid both in terms of a leftward shift in the dose-response curve to L-Glu( $\gamma$ )HXM ( $ED_{50} = 6.4 \pm 0.3 \mu$ M versus  $ED_{50} = 35 \pm 4 \mu$ M in control adipocytes) and in terms of the degree of lipogenesis (145  $\pm$  15 versus 40  $\pm$  7% of maximal insulin response, *i.e.* Fig. 6). At 10  $\mu$ M, L-Glu( $\gamma$ )HXM already stimulated lipogenesis and amounted to 120% of maximal insulin effect in the vanadium-enriched adipose cells (as opposed to only 8.0  $\pm$  1.5% in control adipocytes) (Fig. 7).




FIG. 5. Effect of L-Glu( $\gamma$ )HXM-vanadate administration on blood glucose levels of streptozocin-treated rats. Male Wistar rats, 8 days after induction of diabetes (circulating glucose levels 310–340 mg/dalton), were divided into several groups. At the time points indicated by the arrows (intraperitoneal, at 11:00 a.m.), groups of diabetic rats received either vanadate (0.05 mmol/kg body weight ●), L-Glu( $\gamma$ )HXM (0.1 mmol/kg body weight □), L-Glu( $\gamma$ )HXM (0.1 mmol/kg) and vanadate (0.05 mmol/kg, ▲), or none (■). Circulating glucose levels were determined daily (at 8:00 a.m.). Each point in the figure represents the arithmetic mean of plasma glucose for 5 rats. The dashed line indicates the arithmetic mean of plasma glucose of control healthy male Wistar rats.






FIG. 6. Activation of lipogenesis by L-Glu( $\gamma$ )HXM in the absence of exogenous vanadium. Comparison to other amino acid( $\alpha$ )-hydroxamates and ineffectiveness of the D-isomer and of chemically modified L-Glu( $\gamma$ )HXM derivatives. Freshly prepared adipocytes ( $3 \times 10^5$  cells/ml) suspended in KRB buffer, pH 7.4, containing 0.7% BSA were preincubated for 10 min with the indicated concentrations of the various test compounds. The cells were then supplemented with [ $U$ - $^{14}$ C]glucose (final concentration 0.16 mM), and lipogenesis was performed for 2 h at 37 °C. Radioactivity incorporated into extracted lipids was then determined. Maximal response (100%) is that obtained in the presence of 17 nM insulin.

**FIG. 7. Activation of lipogenesis by L-Glu(γ)HXM.** Comparison between normal adipocytes and vanadium-enriched adipocytes. Male Wistar rats received daily subcutaneously injected NaVO<sub>3</sub> (0.1 mmol/kg/day) for 5 days (called enriched vanadium rats). The rats were then sacrificed (7 h after the last administration). Lipogenesis was performed comparing the freshly prepared rat adipocytes ( $3 \times 10^5$  cells/ml) from nonenriched vanadium rats with the enriched ones suspended in KRB buffer, pH 7.4, containing 0.7% BSA. The cells were preincubated for 10 min with the indicated concentrations of L-Glu(γ)HXM. The cells were then supplemented with [ $U\text{-}^{14}\text{C}$ ]glucose, and lipogenesis was performed for 2 h at 37 °C. Radioactivity incorporated into extracted lipids was then determined. Maximal response (100%) is that obtained in the presence of 17 nM insulin.




**FIG. 8.  $^{51}\text{V}$  NMR spectra of vanadium(V), vanadium(IV), and a mixture of vanadium(IV) with L-Glu(γ)monohydroxamate.** *A*,  $^{51}\text{V}$  NMR spectrum of sodium metavanadate (20 mM, pH 7.1); *B*,  $^{51}\text{V}$  NMR spectrum of vanadium dichloride(IV) (20 mM, pH 6.8); *C*,  $^{51}\text{V}$  NMR spectrum of a mixture (1:1 molar ratio) of  $\text{VOCl}_2$ (IV) and L-Glu(γ)HXM (20 mM, pH 7.0). Spectra were monitored with fresh solutions. In *C*, the spectrum was monitored 5 min after the addition of L-Glu(γ)HXM to  $\text{VOCl}_2$ .

**Spectroscopic Studies—**Previously we found in cell-free experiments that vanadium(IV), at neutral pH values, undergoes slow spontaneous oxidation to vanadium(V). This occurs similarly in the presence of 10 mM reduced glutathione, an ineffectual reductant of vanadium(V), at neutral pH values with a  $t_{1/2}$  value of  $1 \pm 0.1$  h at 25 °C (29). The results summarized in Fig. 8 show the  $V^{51}$  NMR spectra of vanadium dichloride(IV) at pH 7.0 prior to and after the addition of L-Glu(γ)HXM. Vanadium dichloride(IV) appeared as a single peak with a chemical shift of -490 ppm in its  $V^{51}$  spectrum, indicating one main species present at >95% purity. Upon the addition of L-Glu(γ)HXM (1

equivalent), the chemical shift of vanadium(IV) at -490 ppm disappeared within minutes and the principal chemical shift characterizing vanadium(V) at -530 ppm appeared (Fig. 8).

Vanadium(IV) (*i.e.* vanadyl sulphate or  $\text{VOCl}_2$ ) has a characteristic "blue" absorbance with  $\epsilon_{765\text{ nm}} = 14 \pm 0.3$ , whereas vanadium(V) does not absorb at all at this wavelength (29). The addition of 2–3 equivalents of L-Glu(γ)HXM to  $\text{VOCl}_2$ (IV) (50 mM at pH 7.5) led rapidly to a near total decrease in vanadium(IV) absorbance at 765 nm (Fig. 9). Fig. 8*B* depicts complex formation as a function of the pH in the range of pH 2–9. Decrease is minimal at pH 4.0, quite significant at pH 5.0,

**FIG. 9. Decrease in absorbance of vanadium(IV) at 765 nm upon addition of L-Glu( $\gamma$ )HXM.** Effect of pH: A, left column, absorbance of  $\text{VOCl}_2$  alone (50 mM in  $\text{H}_2\text{O}$ ); right column, absorbance of  $\text{VOCl}_2$  (50 mM) and L-Glu( $\gamma$ )HXM (150 mM) titrated with  $\text{NaHCO}_3$  to pH 7.4. B, samples of  $\text{VOCl}_2$  (50 mM) and L-Glu( $\gamma$ )HXM (100 mM) in  $\text{H}_2\text{O}$  were titrated either with HCl or with  $\text{NaHCO}_3$  before absorbance at 765 nm and were monitored to obtain the pH values indicated in the figure. L-Glu( $\gamma$ )HXM alone does not absorb at 765 nm. Vanadium dichloride alone, which tends to precipitate at neutral pH values, remains completely soluble at all pH values in the presence of two or more equivalents of L-Glu( $\gamma$ )HXM.



half-maximal at pH 5.7, and reaches a stable plateau at pH range 7–9 (Fig. 9B).

#### DISCUSSION

It has been consistently observed that chelated vanadium compounds are more potent than the free metaloxide in facilitating the metabolic actions of insulin. This was demonstrated *in vitro* with systems like rat adipocytes, as well as in diabetic rodents such as streptozocin-treated hyperglycemic rats (28–33, 44). Because of the variations in the experimental models used, the oxidation state of vanadium applied, and the different administration modes, the basis for the higher insulinomimetic potencies of complexed vanadium remained rather speculative. Because this topic has immediate therapeutic relevance, we looked for new vanadium chelators characterized by: (a) higher synergistic potencies than previously documented for vanadium chelators with respect to vanadium-evoked glucose uptake and glucose metabolism both *in vitro* and in diabetic rats *in vivo*, (b) low indices of toxicity, and (c) reasonable solubility in aqueous, neutral media after complexation with vanadium.

In this study, we have introduced the L-isomer of glutamic acid( $\gamma$ )monohydroxamate as it satisfactorily fulfilled the above criteria. It potentiated vanadium-activated hexose uptake, glucose metabolism, and recruitment of GLUT4 transporters from LDM to PM fractions (Figs. 1–4). *In vivo* it potentiated the efficacy of vanadium to lower blood glucose levels in streptozocin rats (Fig. 5). This amino acid analog has negligible toxicity in mammals.<sup>2</sup> Both L-Glu( $\gamma$ )HXM alone and its complexes with vanadium are fairly soluble in aqueous media at neutral pH values. An important finding was that L-Glu( $\gamma$ )HXM alone, in the absence of exogenous vanadium, showed a reasonable amount of insulinomimetic activity in that it activated glucose uptake and glucose metabolism in the rat adipose cell (Figs. 1–3). Further investigation revealed that this activating effect is unique to the L-isomer of Glu( $\gamma$ )HXM but is not facilitated by the D-isomer. Nonmodified  $\alpha$ -amino and  $\alpha$ -carboxyl moieties appear essential. This intrinsic activity is exclusive to L-Glu( $\gamma$ )HXM not being shared by any of the other vanadium chelators that potentiate the actions of vanadium *in vivo* or *in vitro* (Fig. 6, A–D, and Refs. 28–33). Our assumption that L-Glu( $\gamma$ )HXM permeates into the cell interior and transforms the “dormant” intracellular vanadium pool into an insulinomimetic-activated species gains credence from the dramatic sen-

sitization of vanadium-enriched adipocytes to L-Glu( $\gamma$ )HXM-evoked lipogenesis (Fig. 7).

It should be mentioned at this point that because of the extreme complexity of aqueous vanadium chemistry (reviewed in Refs. 46–49), the intracellular milieu of the mammalian cell is still “a black box” with respect to the state and the form of entered vanadium. With the endogenously present vanadium pool, experiments have shown that it exists mostly as vanadium(IV), though some researchers may wonder even about this experimental finding because vanadium in its IV oxidation state is only stable at acidic pH values ( $\text{pH} < 3.0$ ) and readily oxidizes to vanadium(V) at neutral pH even in the presence of high glutathione concentrations (28, 46). The intracellular vanadium pool, however, can be preserved in its IV oxidation form at neutral pH values if it is chelated by ascorbic acid (not shown) or to endogenous proteins (50, 51). At the low physiological level of intracellular vanadium, the cell should have the capacity to chelate all the endogenous vanadium.

Our experimental findings that L-Glu( $\gamma$ )HXM alone enhances glucose uptake and glucose metabolism (Figs. 1 and 2) together with the apparent rapid conversion of vanadium(IV) to vanadium(V) upon complexation (Figs. 8 and 9) strongly support the contention that vanadium(V) rather than vanadium(IV), and in a chelated form, is the active insulinomimetic species that facilitates the activation of glucose uptake and its metabolism in rat adipocytes. Although most of our previous cell-free experiments support this conclusion, we were not fully convinced prior to the completion of this study. This is because protein phosphotyrosine phosphatases (with *p*-nitrophenylphosphate as a substrate) are inhibited by both vanadium(IV) and vanadium(V), free or chelated, at nearly the same concentrations (see Ref. 52). On the other hand, adipose non-receptor protein-tyrosine kinases, whether cytosolic or membranal, are with one exception activated by vanadium(V) but not at all by vanadium(IV) (22, 23). We have only observed vanadium(IV)-evoked activation of nonreceptor protein-tyrosine kinases when membranal protein phosphotyrosine phosphatases were extracted with Triton X-100 and added to the cytosolic protein-tyrosine kinase fraction (29). These experimental conditions, however, are not likely to occur in the intact cell system. For example, broken plasma membrane fragments (or deoxycholate-treated membranal fragments) did not sup-

port activation of cytosolic protein-tyrosine kinases in the presence of vanadium(IV) (29).

In summary, L-Glu(γ)HXM appears superior to previously documented organic chelators of vanadium in potentiating its activation of glucose uptake and glucose metabolism *in vitro* and *in vivo*. Taken together with earlier studies, this may be attributed to one or more of the following: (a) increased efficiency of this specific combination to permeate into cells or tissues; (b) a favorable 5-coordinated, rather than octahedral topography of this complex in an aqueous, neutral environment (Ref. 50);<sup>2</sup> and/or (c) higher intracellular stability of the L-Glu(γ)HXM-vanadium complex. Finally, we have recently observed that vanadate does not inhibit alkaline phosphatase in the presence of L-Glu(γ)HXM.<sup>2</sup> This inhibitory effect of vanadate (53) is undesirable from our point of view as it may contribute to vanadium toxicity in mammals, but not to the efficacy of vanadium to manifest the metabolic actions of insulin (reviewed in Ref. 54). This and other basic and diabetological aspects raised here are being further investigated.

**Acknowledgments**—We thank Elana Friedman for typing the manuscript, Dr. Sandra Moshonov and Dov P. Grossman for editing it, and Dr. Sun Qian for technical assistance.

#### REFERENCES

- Shechter, Y., and Karlish, S. J. (1980) *Nature* **284**, 556–558
- Shechter, Y. (1990) *Diabetes* **39**, 1–5
- Shechter, Y., Li, J., Meyerovitch, J., Gefel, D., Bruck, R., Elberg, G., Miller, D. S., and Shisheva, A. (1995) *Mol. Cell. Biochem.* **153**, 39–47
- Brichard, S. M., and Henquin, J. C. (1995) *Trends Pharmacol. Sci.* **16**, 265–270
- Heyliger, C. E., Tahiliani, A. G., and McNeill, J. H. (1985) *Science* **227**, 1471–1476
- Meyerovitch, J., Farfel, Z., Sack, J., and Shechter, Y. (1987) *J. Biol. Chem.* **262**, 6658–6662
- Brichard, S. M., Okitolonda, W., and Henquin, J. C. (1988) *Endocrinology* **123**, 2048–2053
- Brichard, S. M., Bailey, C. J., and Henquin, J. C. (1990) *Diabetes* **39**, 1326–1332
- Meyerovitch, J., Rothenberg, P., Shechter, Y., Bonner-Weir, S., and Kahn, C. R. (1991) *J. Clin. Invest.* **87**, 1286–1294
- Brichard, S. M., Pottier, A. M., and Henquin, J. C. (1989) *Endocrinology* **125**, 2510–2516
- Brichard, S. M., Assimacopoulos-Jeannet, F., and Jeanrenaud, B. (1992) *Endocrinology* **131**, 311–317
- Mooney, R. A., Bordwell, K. L., Luhowsky, J. S., and Casnelli, J. E. (1989) *Endocrinology* **124**, 422–429
- Strout, H. V., Vicario, D. D., Superstein, R., and Slater, E. E. (1989) *Endocrinology* **124**, 1918–1924
- Venkatesan, N., Avidin, A., and Davidson, M. B. (1991) *Diabetes* **40**, 492–498
- Fantus, I. G., Kadota, S., Deragon, G., Foster, B., and Posner, B. I. (1989) *Biochemistry* **28**, 8864–8871
- Shisheva, A., and Shechter, Y. (1992) *Biochemistry* **31**, 8059–8063
- Green, A. (1986) *Biochem. J.* **238**, 663–669
- D'Onofrio, F., Le, M. Q. U., Chiasson, J.-L., and Srivastava, A. K. (1994) *FEBS Lett.* **340**, 269–275
- Dadney, S. K., Chiasson, J.-L., and Srivastava, A. K. (1995) *Mol. Cell. Biochem.* **153**, 69–78
- Shisheva, A., and Shechter, Y. (1991) *FEBS Lett.* **300**, 93–96
- Shisheva, A., and Shechter, Y. (1993) *J. Biol. Chem.* **268**, 6463–6469
- Elberg, G., Li, J., and Shechter, Y. (1994) *J. Biol. Chem.* **269**, 9521–9527
- Elberg, G., He, Z., Li, J., Sekar, N., and Shechter, Y. (1997) *Diabetes* **46**, 1684–1690
- Goldfine, A. B., Simonson, D. C., Folli, F., Patti, M. E., and Kahn, C. R. (1995) *J. Clin. Endocrinol. Metab.* **80**, 3311–3320
- Cohen, N., Halberstam, M., Shlimovich, P., Chang, C. J., Shamoon, H., and Rossetti, L. (1995) *J. Clin. Invest.* **95**, 2501–2509
- Halberstam, M., Cohen, N., Shlimovich, P., Rossetti, L., and Shamoon, H. (1996) *Diabetes* **45**, 659–666
- Sekar, N., Li, J., and Shechter, Y. (1996) *Crit. Rev. Biochem. Mol. Biol.* **31**, 339–359
- Shechter, Y., Shisheva, A., Lazar, R., Libman, J., and Shanzer, A. (1992) *Biochemistry* **31**, 2063–2068
- Li, J., Elberg, G., Crans, D. C., and Shechter, Y. (1996) *Biochemistry* **35**, 8314–8318
- McNeill, J. H., Yuen, V. G., Hoveyda, H. R., and Orvig, C. (1992) *J. Med. Chem.* **35**, 1489–1491
- McNeill, J. H., Yuen, V. G., Dai, S., and Orvig, C. (1995) *Mol. Cell. Biochem.* **153**, 175–180
- Sakurai, H. (1994) *Environ. Health Perspect.* **3**, 35–36
- Sakurai, H., Fujii, K., Watanabe, H., and Tamura, H. (1995) *Biochem. Biophys. Res. Commun.* **214**, 1095–1101
- Fishbein, W. N., Streeter, C. L., and Daly, J. E. (1973) *J. Pharmacol. Exp. Ther.* **186**, 173–178
- Vila, J., Thomasset, N., Navarro, C., and Dore, J. F. (1990) *Int. J. Cancer* **45**, 737–743
- Boehlein, S. K., Schuster, S. M., and Richards, N. G. (1996) *Biochemistry* **35**, 3031–3037
- Rodbell, M. (1964) *J. Biol. Chem.* **239**, 375–380
- Whitesell, R. R., and Gliemann, J. (1979) *J. Biol. Chem.* **254**, 5276–5283
- Moody, A. J., Stan, M. A., Stan, M., and Glieman, J. (1974) *Horm. Metab. Res.* **6**, 12–16
- Hissin, P. J., Foley, J., Wardzala, L. J., Karnieli, E., Simpson, I. A., and Salans, L. B. (1982) *J. Clin. Invest.* **70**, 780–790
- Armoni, M., Harel, C., Burvin, R., and Karnieli, E. (1995) *Endocrinology* **136**, 3292–3298
- Olson, A. L., and Pessin, J. E. (1996) *Annu. Rev. Nutr.* **16**, 235–256
- McLean, P., Brown, J., and Greenbaum, A. L. (1968) *Handbook of Biochemistry* (Dickens, F., Whelan, W. J., and Randle, P. J., eds) Academic Press, New York
- Watanabe, H., Nakai, M., Komazawa, K., and Sakurai, H. (1994) *J. Med. Chem.* **37**, 876–877
- Deleted in proof
- Macara, J. G. (1980) *Trends Biochem. Sci.* **5**, 92–94
- Crans, D. C. (1994) *Comm. Inorg. Chem.* **16**, 1–33
- Crans, D. C., Mahroof Tahir, M., and Keramidas, A. D. (1995) *Mol. Cell. Biochem.* **153**, 17–24
- Dekoch, R. J., West, D. J., Cannon, J. C., and Chasteen, N. D. (1974) *Biochemistry* **13**, 4347–4354
- Casteen, N. D. (1981) in *Biological Magnetic Resonance* (Berliner, L., and Reuben, J., eds) Vol. II, pp. 53–119, Plenum Press, New York
- Crans, D. C., Bunch, R. L., and Theisen, L. A. (1989) *J. Am. Chem. Soc.* **111**, 7597–7607
- Li, J., Elberg, G., Sekar, N., bin He, Z., and Shechter, Y. (1997) *Endocrinology* **138**, 2274–2279
- Lopez, V., Stevens, T., and Lindquist, R. N. (1976) *Arch. Biochem. Biophys.* **175**, 31–38
- Elberg, E., Li, J., and Shechter, Y. (1997) in *Vanadium in the Environment* (Nriagu, J. O., ed) pp. 277–296, John Wiley & Sons, Inc., New York

## Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat Adipocytes\*

WENDY M. MUELLER, FRANCINE M. GREGOIRE, KIMBER L. STANHOPE,  
CHARLES V. MOBBS, TOORU M. MIZUNO, CRAIG H. WARDEN,  
JUDITH S. STERN, AND PETER J. HAVEL

Department of Nutrition (W.M.M., K.L.S., J.S.S., P.J.H.), and Department of Pediatrics (F.M.G., C.H.W.),  
School of Medicine, University of California, Davis, California 95616; and Neurobiology of Aging  
Laboratories, Mount Sinai School of Medicine (C.V.M., T.M.M.), New York, New York 10021

### ABSTRACT

Circulating leptin secreted from adipocytes is correlated with fat mass and plasma insulin concentrations in humans and rodents. Plasma leptin, insulin, and glucose decrease during fasting and increase after refeeding; however, the underlying mechanisms regulating the changes of leptin secretion are not known. To investigate the role of insulin-stimulated glucose metabolism in the regulation of leptin secretion, we examined the effects of insulin and inhibitors of glucose transport and metabolism on leptin secretion from rat adipocytes in primary culture. Insulin (0.16–16 nM) increased leptin secretion over 96 h; however, the increase in leptin was more closely related to the amount of glucose taken up by the adipocytes ( $r = 0.64$ ;  $P < 0.0001$ ) than to the insulin concentration *per se* ( $r = 0.20$ ;  $P < 0.28$ ), suggesting a role for glucose transport and/or metabolism in regulating leptin secretion.

2-Deoxy-D-glucose (2-DG), a competitive inhibitor of glucose transport and phosphorylation, caused a concentration-dependent (2–50 mg/dl) inhibition of leptin release in the presence of 1.6 nM insulin. The inhibitory effect of 2-DG was reversed by high concentrations of

glucose. Two other inhibitors of glucose transport, phloretin (0.05–0.25 mM) and cytochalasin-B (0.5–50  $\mu$ M), also inhibited leptin secretion. Inhibition of leptin secretion by these agents was proportional to the inhibition of glucose uptake ( $r = 0.60$  to  $0.86$ ; all  $P < 0.01$ ). Two inhibitors of glycolysis, iodoacetate (0.005–1.0 mM) and sodium fluoride (0.1–5 mM), produced concentration-dependent inhibition of leptin secretion in the presence of 1.6 nM insulin. In addition, both 2-DG and sodium fluoride markedly decreased the leptin (*ob*) messenger RNA content of cultured adipocytes, but did not affect 18S ribosomal RNA content.

We conclude that glucose transport and metabolism are important factors in the regulation of leptin expression and secretion and that the effect of insulin to increase adipocyte glucose utilization is likely to contribute to insulin-stimulated leptin secretion. Thus, *in vivo*, decreased adipose glucose metabolism may be one mechanism by which fasting decreases circulating leptin, whereas increased adipose glucose metabolism would increase leptin after refeeding. (Endocrinology 139: 551–558, 1998)

THE ADIPOCYTE hormone, leptin is implicated in the regulation of food intake, energy expenditure, and body fat stores (1). Circulating leptin decreases after fasting or caloric restriction in both humans (2–4) and rodents (5–7), and increases a number of hours after refeeding (3, 6). In humans, there is a nocturnal rise of plasma leptin (8), which has been hypothesized to be due to a delayed effect of insulin released during earlier meals. Consistent with this hypothesis, insulin increases expression of the *ob* gene in rodents (9–11) and in adipocytes *in vitro* (12, 13) after a number of hours. In humans, plasma insulin and leptin concentrations decrease in parallel after weight loss, independently of changes of adiposity (14). Furthermore, plasma leptin is negatively correlated with insulin sensitivity independently of adiposity in subjects with impaired glucose tolerance (15).

Short term insulin administration does not affect plasma leptin concentrations in human subjects (16, 17), but increases in circulating leptin have been reported after 4–6 h of high dose insulin administration (18, 19). These studies by

necessity require the infusion of large amounts of glucose to prevent hypoglycemia. Similarly, prolonged hyperglycemia in response to extended glucose infusions increases plasma leptin after several hours in nonhuman primates (20) and human subjects (21); however, glucose administration also markedly increases endogenous insulin levels. Therefore, the role of insulin *per se* on the adipocyte *vs.* the effect of insulin to increase glucose flux into adipocytes was not addressed by these experiments.

Several lines of evidence have led us to hypothesize that glucose is an important regulator of leptin expression and secretion. First, increases in *ob* messenger RNA (mRNA) after glucose administration in mice are more closely related to plasma glucose concentrations than to plasma insulin concentrations (22). Second, infusion of small amounts of glucose to prevent the decline of glycemia during fasting in humans also prevents the decrease in plasma leptin (2). Third, the decrease in plasma leptin during marked caloric restriction in humans is better correlated with the decrease in plasma glucose than with changes in insulinemia (4). Fourth, we have found that low plasma leptin levels in streptozotocin diabetic rats are acutely increased by insulin administration in proportion to the degree of glucose lowering (23). Lastly, lowering plasma glucose concentrations in hyperglycemic insulin-dependent diabetic human subjects by

Received July 9, 1997.

Address all correspondence and requests for reprints to: Peter J. Havel, D.V.M., Ph.D., Department of Nutrition, University of California, Davis, California 95616. E-mail: pjhavel@ucdavis.edu.

\* This work was supported by NIH Grants DK-50129, DK-18899, DK-07355, DK-35747, CA-61654, and DK-50110 and the Juvenile Diabetes Foundation.

infusing insulin at rates that produced physiological insulinemia increases circulating leptin (24).

To investigate the mechanisms by which glucose influences leptin secretion, we adapted and modified an *in vitro* system for culturing rat adipocytes in which the adipocytes are anchored in a defined mixture of extracellular matrix components (25). This matrix, Matrigel, appears to simulate normal basement membrane attachment of cells and may allow cell to cell interactions between adipocytes. Cells cultured in this system are, therefore, in an environment closer to their normal physiological milieu than in systems where adipocytes are free floating in the culture medium. Adipocytes cultured on Matrigel have been shown to maintain many of their differentiated characteristics and, in contrast with free-floating adipocytes, show no sign of dedifferentiation after 6 days of culture (25, 26). With this system we have investigated the regulation of leptin secretion by glucose and insulin and the effects of inhibitors of adipocyte glucose transport and metabolism on leptin secretion. The leptin (*ob*) mRNA content of the adipocytes after culture with insulin and inhibitors was also examined.

## Materials and Methods

### Materials

DMEM and FBS were purchased from Life Technologies (Grand Island, NY). The media were supplemented with 6 ml each of MEM nonessential amino acids, penicillin/streptomycin (5000 U/ml/5000 µg/ml), and nystatin (10,000 U/ml; all from Life Technologies) per 500 ml DMEM. BSA fraction V, HEPES, collagenase (*Clostridium histolyticum*; type II, Sigma Chemical Co., St. Louis, MO; SA, 456 U/mg), insulin, D-glucose, sodium fluoride (NaF), phloretin, iodoacetate, and fructose were purchased from Sigma Chemical Co. Matrigel matrix was purchased from Becton Dickinson (Franklin Lakes, NJ). 2-Deoxy-D-glucose (2-DG) was obtained from U.S. Biochemical Corp. (Cleveland, OH). Six-well Falcon tissue culture plates were purchased from Fisher Scientific (Pittsburgh, PA). Nylon filters were purchased from Tetko (Kansas City, MO).

### Animals

Male Sprague-Dawley rats were obtained from Charles River (Wilmington, MA). Animals were housed in hanging wire cages in temperature controlled rooms (22–24°C) with a 12-h light-dark cycle and fed Purina chow diet (Ralston-Purina, St. Louis, MO) and given deionized water *ad libitum*. The study protocol was approved by the University of California-Davis animal care and use committee.

### Cell isolation / preparation

Adipocytes were prepared from epididymal fat pads of male Sprague-Dawley rats (300–600 g) anesthetized with halothane. Epididymal fat depots were resected under aseptic conditions, and adipocytes were isolated by collagenase digestion according to the Rodbell procedure (27) with minor modifications as described below. The fat pads were minced into pieces in Krebs-Ringer HEPES buffer (pH 7.4; containing 5 mM D-glucose, 2% BSA, 135 mM NaCl, 2.2 mM CaCl<sub>2</sub>·2H<sub>2</sub>O, 1.25 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.45 mM KH<sub>2</sub>PO<sub>4</sub>, 2.17 mM Na<sub>2</sub>HPO<sub>4</sub>, and 10 mM HEPES). Adipose tissue fragments were digested in the same buffer in the presence of type II collagenase (2.5 mg/2 ml buffer/g tissue) at 37°C with gentle shaking at 60 cycles/min for 45 min. The resulting cell suspension was diluted in 24 ml cold HEPES-phosphate buffer. Isolated adipocytes were separated from undigested tissue by filtration through a 400-µm nylon mesh and washed three times. For washing, cells were centrifuged at 500 rpm for 5 min. Each time the infranatant was discarded, and the adipocytes were resuspended in Krebs-Ringer HEPES buffer, with the final wash being in 0.5, or 10 mM glucose culture medium supplemented

with 1% or 5% FBS. The isolated adipocytes were then incubated for 30 min at 37°C before being plated in Matrigel-coated culture plates.

### Adipocyte culture

Matrigel was thawed on ice to a liquid and uniformly applied to the surface of the culture dish (300 µl Matrigel/35-mm well). After the incubation, 150 µl of the adipocyte suspension (2:1 ratio of packed cells to medium) were plated on the liquid matrix. The warmth of the cells and buffer caused the Matrigel to gel around the adipocytes, effectively anchoring them to the culture dish. After a 30-min incubation at 37°C, 2 ml warm culture medium supplemented with FBS were added. The cells were maintained in an incubator at 37°C in 6% CO<sub>2</sub> for 96 h.

The initial medium concentration of glucose for the cultures conducted in the insulin dose-response experiment was 10.0–10.5 mM (180–190 mg/dl) to ensure that the cells would not deplete the glucose supply during the 96-h incubation when higher concentrations of insulin were used. Only 1% FBS was used in the insulin dose-response study to minimize the small amount of insulin present in the serum, which at 1% was less than 0.1 µU/ml. In the fructose study, medium made with glucose-free DMEM and 1% fetal serum was used to minimize the amount of glucose available to the adipocytes (<0.1 mmol/liter). However, it was not possible to eliminate all glucose from culture preparation because the Matrigel matrix itself contains ~4.2 mmol/liter glucose. For the fructose experiment, the Matrigel was diluted 1:2 with glucose-free medium to approximately 1.5 mmol/liter glucose.

In the other experiments with inhibitors of glucose transport, 2-DG (28), phloretin (29), and cytochalasin B (30), or with inhibitors of glycolysis, iodoacetate (31), and NaF (32), the initial medium glucose concentration was (5.0–5.5 mM; 90–100 mg/dl) with 5% fetal serum. These agents were used at concentrations at or below those typically employed to inhibit glucose transport or glycolysis in adipocytes (28–32). Cytochalasin B was initially dissolved in ethanol and diluted to 0.5% ethanol in the well with the highest dose. Therefore, the medium in all wells in the cytochalasin B experiment was equalized to 0.5% ethanol. Aliquots of adipocytes from each animal were divided into wells with the responses to insulin, the various inhibitors, or fructose being compared with those of an appropriate control well containing adipocytes from the same animal. In a preliminary insulin dose-response study, we found that medium leptin concentrations in the presence of insulin were not increased over those in control medium (no insulin) until after 24 h of incubation. Therefore, for the remainder of the studies, 300-µl samples (15% of the medium volume) were collected at 24, 48, 72, and 96 h and replaced with 300 µl fresh medium containing the appropriate concentrations of glucose, insulin, and/or inhibitors. Cultures were observed daily with a phase contrast microscope. After 96 h, a subset of the culture plates was frozen until analyzed for leptin (*ob*) mRNA content by Northern blot.

### Assays

Leptin concentrations in the medium were determined with a sensitive and specific RIA for mouse leptin as previously described (7) (Linco Research, St. Charles, MO). Leptin concentrations in medium from cultured rat adipocytes measured with this assay are very similar to those obtained with a newly developed assay specific for rat leptin. With the rat-specific assay, measured leptin concentrations in culture medium were 86 ± 3% of the mouse values and were highly correlated between the two assays (*r* = 0.97; *P* < 0.0001; unpublished data). Therefore, measurements of rat leptin made with the mouse assay provide a reliable measurement of leptin concentrations. The intra- and interassay coefficients of variation for this assay are 4.0% and 11.2%, respectively (7). The antibody used in the assay does not cross-react with insulin, proinsulin, glucagon, pancreatic polypeptide or somatostatin. Glucose and lactate were measured with a YSI glucose analyzer (model 2300, Yellow Springs Instruments, Yellow Springs, OH).

### Northern blot procedure

The following procedures were performed on culture plates incubated with 5 mM glucose and 5% fetal serum alone (control), 1.6 nM insulin, and 1.6 nM insulin with 10 mg/dl 2-DG or 1 mM NaF for 48 and 96 h. Northern blot analysis was performed as previously described (33).

In brief, 1 ml RNazol B (Tel-Test, Friendswood, TX) was added directly to the wells containing the adipocytes and matrix. The solution was repetitively taken in and expelled from the pipette to maximize dissolution of the adipose tissue. UV absorbance and integrity gels were used to estimate RNA. To allow loading of equal mass of RNA in each well, after analysis of leptin mRNA using a single-stranded complementary DNA probe followed by quantification of bands on a phosphoimager as well as from film, the blots were reanalyzed using a probe complementary to mouse 18S ribosomal RNA. Leptin mRNA was then normalized with respect to the 18S ribosomal signal, according to the absolute signal. The 18S RNA results were virtually identical in all cases. In particular, experimental conditions did not influence the 18S ribosomal signal.

#### Calculations and data analysis

The uptake of glucose was assessed by measuring the concentration of glucose in the medium in each well before and after 96 h of incubation and calculating the decrease over 96 h. To examine the relationship between adipocyte carbon flux and leptin secretion in response to increased insulin-mediated glucose uptake, the amount of carbon released as lactate per amount of carbon taken up as glucose over 96 h was calculated as  $\Delta[\text{lactate}]/\Delta[\text{glucose}]$ , where  $\Delta$  is the change, and expressed as a percentage. The area under the curve for leptin concentrations in the medium between 0–96 h was calculated by the trapezoidal method. The means of two groups were compared by paired *t* test. The means of more than two groups were compared by ANOVA. To examine the relationships between the medium concentrations of insulin or inhibitors employed, the amount of glucose taken up by the adipocytes, and leptin secretion, simple and multiple linear regression analyses were performed with a statistics software package (StatView for Macintosh, Abacus Concepts, Inc., Berkeley, CA). Data are expressed as the mean  $\pm$  SEM.

#### Results

##### Responses to insulin (0.16–16.0 nM)

The effects of insulin on leptin secretion, and the relationship between glucose uptake by adipocytes cultured with different concentrations of insulin and leptin secretion were examined. Insulin produced a concentration-dependent increase in glucose uptake by the cultured adipocytes ( $r = 0.61$ ;  $P < 0.0002$  vs. insulin concentration), as assessed by the decrease in glucose in the medium (Fig. 1A). With no added insulin, the medium glucose concentration decreased from  $10.1 \pm 0.1$  to  $8.2 \pm 0.3$  mmol/liter ( $\Delta, -1.9 \pm 0.3$  mmol/liter;  $P < 0.0001$ ). The addition of 0.16, 1.6, and 16.0 nM insulin increased glucose uptake ( $\Delta[\text{glucose}], -2.7 \pm 0.4, -3.3 \pm 0.3$ , and  $-3.9 \pm 0.4$  mmol/liter, respectively; all  $P < 0.01$  vs. no insulin). Insulin also produced a concentration-dependent increase in lactate production ( $r = 0.70$ ;  $P < 0.0001$ ), which was well correlated with the decrease in glucose in the medium over 96 h ( $r = 0.61$ ;  $P < 0.0002$ ), suggesting that a significant portion of the glucose entering the adipocytes was metabolized only as far as lactate and released from the cells into the medium (34, 35).

Leptin secretion was increased over the control value by all three concentrations of insulin (Fig. 1B). The production of lactate was not related to the leptin response ( $r = 0.10$ ;  $P = 0.59$ ). The area under the leptin concentration curve (AUC) from 0–96 h was independently related to the decrease in glucose in the medium during the incubation (Fig. 1C), but not to the insulin concentration (Table 1). Similarly, with a multiple regression model, the AUC for leptin was related to the decrease in glucose, but not to the insulin concentration. In addition, the percentage of carbon released as lactate per amount of carbon taken up as glucose was calculated. Over-





FIG. 1. A, Glucose concentrations in medium from 0–96 h from isolated rat adipocytes in primary culture with insulin concentrations from 0–16 nM ( $n = 8/\text{treatment}$ ). B, Leptin concentrations from 0–96 h from isolated rat adipocytes in primary culture with insulin concentrations from 0–16 nM ( $n = 8/\text{treatment}$ ). C, Relationship between glucose uptake, as assessed by the decrease in glucose in the culture medium, and leptin secretion, expressed as the AUC from 0–96 h, during incubation of adipocytes with 0–16 nM insulin ( $n = 32$ ).  $r = 0.64$ ;  $p < 0.0001$ .

**TABLE 1.** Relationship between glucose uptake ( $\Delta$ Gluc), leptin secretion ( $\Delta$ Lept) and the concentration of insulin or inhibitors of glucose uptake and metabolism after 96-h incubation of adipocytes with insulin and insulin plus inhibitors (2-DG, phloretin, cytochalasin-B, iodoacetate, or sodium fluoride at varying concentrations; see *Materials and Methods*)

Insulin or inhibitor (n)	Simple Regression				Multiple regression	
	$\Delta$ Lept vs. $\Delta$ Gluc		$\Delta$ Lept vs. [inhibitor]		$\Delta$ Lept vs. $\Delta$ Gluc (P)	$\Delta$ Lept vs. [inhibitor] (P)
	r	P	r	P		
Insulin (32)	0.64	0.0001	0.20	0.28	0.0001	0.09
2-DG (38)	0.67	0.0001	0.51	0.001	0.001	0.29
Phloretin (38)	0.86	0.0001	0.78	0.0001	0.0012	0.75
Cytochalasin-B (19)	0.60	0.01	0.58	0.02	0.22	0.25
Iodoacetate (34)	0.83	0.0001	0.74	0.0001	0.0001	0.17
Sodium fluoride (28)	0.85	0.0001	0.60	0.001	0.0001	0.73




**FIG. 2.** Effects of inhibiting glucose transport and metabolism with 2-DG on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture for 96 h with 1.6 nM insulin and the effect of adding glucose (55 mM) at 48 h on the inhibition of leptin secretion produced by 10 mg/dl 2-DG.

all, in the insulin experiment between 10–68% of the amount of carbon taken up as glucose was released as lactate (mean,  $34 \pm 2\%$ ). There was no direct relationship between this parameter and the insulin concentration; however, it was inversely proportional to the amount of leptin secreted, as expressed by the 0–96 h leptin AUC ( $r = 0.64$ ;  $P < 0.0001$ ). By multiple regression analysis, the relationship between glucose conversion to lactate and leptin secretion was not significantly related to lactate production ( $P = 0.06$ ), but leptin secretion was equally related to both the change in glucose and the amount of glucose carbon released as lactate (both  $P < 0.001$ ).

#### Effects of 2-DG (2–50 mg/dl)

The effect of inhibiting glucose uptake and metabolism with 2-DG on leptin secretion and its relationship to adipocyte glucose uptake were examined. 2-DG at a concentration of 50 mg/dl completely inhibited glucose uptake ( $\Delta$ ,  $0.1 \pm 0.3$  mmol/liter) in the presence of 1.6 nM insulin ( $\Delta$ glucose,  $-4.0 \pm 0.6$  mmol/liter) and inhibited the leptin response (AUC 0–96 h) by  $69 \pm 4\%$  ( $P < 0.0001$ ) compared with insulin alone (Fig. 2A). At a lower concentration of 2-DG (10 mg/dl), glucose uptake was still markedly inhibited ( $\Delta$ ,  $-0.1 \pm 0.4$



**FIG. 3.** Effects of inhibiting glucose transport with phloretin on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture for 96 h with 1.6 nM insulin and the effect of adding glucose (55 mM) at 48 h on the inhibition of leptin secretion produced by 0.25 mM phloretin.

mmol/liter) and leptin secretion was inhibited by  $47 \pm 5\%$  ( $P < 0.0001$ ). The lowest concentration of 2-DG (2 mg/dl) produced less of an inhibition of glucose uptake ( $\Delta$ ,  $-1.5 \pm 0.9$  mmol/liter;  $P < 0.01$  vs. insulin alone). At this concentration, the leptin response was not significantly inhibited until the 96 h point ( $P < 0.02$  vs. insulin alone; Fig. 2A).

Overall, the change in leptin at 96 h was related to the concentration of 2-DG and was well correlated with the decrease in medium glucose (Table 1). By multiple regression, the leptin concentration in the medium at 96 h was significantly correlated with the change in glucose, but not to the 2-DG concentration (Table 1). The addition of glucose (55.5 mM) at 48 h reversed the inhibition of leptin secretion produced by 2-DG at 10 mg/dl by 96 h ( $P < 0.01$  vs. 2-DG; NS vs. insulin alone; Fig. 2).

#### Effects of phloretin (0.05–0.25 mM)

The effect of inhibiting glucose uptake with phloretin on leptin secretion was examined. Phloretin at a concentration of 0.25 mM completely inhibited leptin secretion (Fig. 3). The 0–96 h AUC for leptin was inhibited by  $91 \pm 2\%$  of insulin alone ( $P < 0.0001$ ). This higher concentration of phloretin (0.25 mM) also completely blocked glucose uptake in the

presence of 1.6 nM insulin ( $\Delta$ glucose,  $0.7 \pm 0.1$  mmol/liter). Overall, the leptin response was inversely related to the concentration of phloretin and was highly correlated with the decrease in glucose in the medium (Table 1). However, by multiple regression, the leptin response was correlated with the decrease in glucose, but not with the concentration of phloretin (Table 1). The addition of 55.5 mM glucose at 48 h did not reverse the inhibition of leptin secretion by phloretin (Fig. 3).

#### Effects of cytochalasin B

The effect of inhibiting glucose uptake with cytochalasin B on leptin secretion was examined. Cytochalasin B produced a concentration-dependent inhibition of glucose uptake and leptin secretion (Fig. 4). The leptin response was significantly correlated with glucose uptake by simple regression (Table 1), but was not significantly correlated with glucose uptake (as observed with the other inhibitors; Table 1) by multiple regression, perhaps due to the smaller number of replicates ( $n = 19$ ) in this experiment.

#### Effects of iodoacetate (0.005–1.0 mM)

The effect of inhibiting glycolysis with iodoacetate on leptin secretion was examined. Iodoacetate at 1.0, 0.1, and 0.01 mM markedly inhibited glucose uptake ( $\Delta$ glucose,  $-0.1 \pm 1.1$ ,  $0.5 \pm 0.2$ , and  $0.3 \pm 0.2$  mmol/liter, respectively) and leptin secretion. The 0–96 h AUC for leptin was inhibited by  $-95 \pm 2\%$ ,  $-91 \pm 2\%$ , and  $-87 \pm 3\%$ , respectively, compared with insulin alone; (all  $P < 0.0001$ ). The lowest concentration of iodoacetate (0.005 mM) produced less of an inhibition of glucose uptake ( $\Delta$ glucose,  $-1.8 \pm 0.8$  mmol/liter) and less of an inhibition of leptin secretion ( $-51.0 \pm 16\%$ ) than insulin alone ( $P < 0.02$ ; Fig. 5). By simple regression, the release of leptin was related to the concentration of iodoacetate and was highly correlated with the change in glucose in the medium (Table 1). However, by multiple regression, the leptin secreted at 96 h was related to the change in glucose, but not to the concentration of iodoacetate (Table 1).




FIG. 4. Effects of inhibiting glucose transport with cytochalasin B on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture for 96 h with 1.6 nM insulin.




FIG. 5. Effects of inhibiting glycolysis with iodoacetate on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture for 96 h with 1.6 nM insulin.




FIG. 6. Effects of inhibiting glycolysis with NaF on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture for 96 h with 1.6 nM insulin.

#### Effects of NaF (0.1–5.0 mM)

The effect of inhibiting glycolysis with NaF was examined. The two highest concentrations of NaF (5.0 and 1.0 mM) completely inhibited glucose uptake ( $\Delta$ glucose,  $0.2 \pm 0.1$  and  $0.0 \pm 0.3$  mmol/liter, respectively). The 0.5 mM concentration of NaF produced less of an inhibition of glucose uptake ( $\Delta$ ,  $-2.1 \pm 0.6$  mmol/liter), and the lowest concentration (0.1 mM) of NaF did not inhibit glucose uptake ( $\Delta$ glucose,  $-3.9 \pm 0.5$  mmol/liter) compared with the effect of insulin alone. The two highest concentrations of NaF (5.0 and 1.0 mM) markedly inhibited leptin secretion ( $-81 \pm 6\%$  vs. insulin alone;  $P < 0.0001$ ). The next concentration of NaF (0.5 mM) produced an intermediate inhibition of leptin secretion ( $-47 \pm 15\%$  of insulin alone;  $P < 0.05$ ). The 0.1-mM concentration of NaF did not inhibit leptin secretion ( $-4 \pm 15\%$  vs. insulin alone;  $P = NS$ ; Fig. 6).

Overall, the decline in medium glucose was significantly

correlated with the concentration of NaFl and highly correlated with the 96 h leptin concentration (Table 1). By multiple regression, the amount of leptin secreted at 96 h was strongly correlated with the change in glucose in the medium ( $P < 0.0001$ ), but not to the NaFl concentration (Table 1).

#### Effects of insulin, 2-DG, and NaFl on leptin (*ob*) mRNA and 18S ribosomal RNA

The effects of inhibiting glucose uptake and metabolism with 2-DG or NaFl on leptin gene expression and ribosomal 18S RNA were examined. As shown in Fig. 7A, leptin (*ob*)




FIG. 7. A, Effects of no insulin (control), 1.6 nM insulin, and 1.6 nM insulin plus 10 mg/dl 2-DG or 1.0 mM NaFl on leptin (*ob*) mRNA after 48 h of incubation, as assessed by Northern blots. The inset above each bar is representative of the signal obtained for each condition. B, Effects of control (no insulin), 1.6 nM insulin, and 1.6 nM insulin plus 10 mg/dl 2-DG or 1.0 mM NaFl on 18S ribosomal RNA after 48 h of incubation, as assessed by Northern blots. The inset above each bar is representative of the signal obtained for each condition.

mRNA was detectable in adipocytes incubated for 48 h either with 1.6 nM insulin or without insulin (control). However, the leptin mRNA signal was reduced to near undetectable levels when adipocytes were incubated with 1.6 nM insulin and either 2-DG (10 mg/ml) or 1.0 mM NaFl (Fig. 7A). The effect of 2-DG and NaFl was specific, because in the same samples there was no effect of these concentrations of 2-DG or NaFl on 18S ribosomal RNA (Fig. 7B) or on nonspecific RNA bands (with a different mol wt than leptin mRNA) that could be detected on the Northern blots after long exposures (data not shown). Leptin mRNA was significantly reduced by 2-DG or NaFl regardless of whether the signal was normalized for 18S ribosomal signal ( $P = 0.0174$ ). Qualitatively similar effects of 2-DG or NaFl were observed in cultures incubated for 96 h ( $P = 0.0228$ ; data not shown).

#### Effects of fructose (5 mM)

The addition of 5 mM fructose to medium of cultures in which the glucose concentration was minimized by diluting the Matrigel 1:2 and using glucose-free DMEM with 1% serum augmented leptin secretion after 48 h. The initial response in the control wells was probably due to the residual glucose (~1.5 mmol/L) in the diluted Matrigel. However, both the integrated AUC from 0–96 h ( $P < 0.02$ ) and the leptin concentration at 96 h ( $P < 0.01$ ) were increased by fructose (Fig. 8).

#### Discussion

In the present study we found that addition of physiological concentrations of insulin stimulates leptin secretion from isolated rat adipocytes in primary culture. In this *in vitro* system we did not see an acute effect of insulin on leptin secretion. This is in agreement with previous reports that have demonstrated that the expression of *ob* gene and leptin protein release are not acutely regulated by insulin *in vivo* and *in vitro* (17,36). The strong correlation between adipocyte glucose uptake measured by the decrease in glucose in the media during incubation with insulin and the amount of




FIG. 8. Effect of fructose (5 mM) on leptin concentrations from 0–96 h in medium from isolated rat adipocytes in primary culture with a low (~1.5 mmol/liter) initial glucose concentration ( $n = 6$ /treatment).

leptin secreted from isolated adipocytes is consistent with the hypothesis that the rate of glucose metabolism is a determinant of leptin secretion. In addition, the absolute insulin concentration was not related to the leptin response, independently of the effect of insulin to increase glucose uptake.

Blockade of glucose transport with 2-DG, phloretin, or cytochalasin B at concentrations at or below those typically used in adipocytes (29, 30) produced a dose-dependent decrease in leptin secretion in the presence of high physiological concentrations of insulin. The competitive inhibition produced by 2-DG could be reversed by the addition of a high concentration of glucose, suggesting that 2-DG did not inhibit leptin secretion via a nonspecific toxic effect on the adipocytes. As expected, the inhibition by phloretin was not reversed by glucose, as phloretin is not a competitive inhibitor and, therefore, produces an irreversible inhibition of glucose transport that is not readily overcome by high glucose concentrations. These experiments provide evidence that glucose uptake is required to increase leptin secretion from isolated adipocytes despite the presence of high physiological insulin concentrations.

Inhibition of glycolysis with either iodoacetate or NaF at low concentrations (31, 32) also produced concentration-dependent inhibition of leptin secretion in the presence of insulin. When glycolysis is inhibited, glycolytic intermediates accumulate, resulting in a secondary impairment of glucose uptake. As with primary blockade of glucose uptake, during inhibition of glucose metabolism by either glycolytic inhibitor, the amount of glucose taken up over 96 h of incubation was highly correlated with the amount of leptin secreted despite the presence of insulin. These results suggest that the stimulation of leptin secretion by insulin is unlikely to be due to a direct effect of insulin *per se*, but is secondary to the effect of insulin to stimulate glucose uptake and metabolism in adipocytes.

We also found that inhibition of glucose transport and metabolism with 2-DG or glycolysis with NaF markedly inhibited leptin (*ob*) gene expression, as assessed by Northern blot analysis of leptin mRNA. In the same cultures, 18S ribosomal RNA levels were unaffected by either 2-DG or NaF, suggesting that the decrease in leptin gene expression was not due to a nonspecific overall effect of these inhibitors to impair adipocyte RNA synthesis. In addition, we examined the amount of heparin-released lipoprotein lipase (LPL) from adipocytes cultured with the various inhibitors (data not presented). Although LPL was modestly decreased by the inhibitors (~25–50% of insulin-stimulated levels), the suppression of leptin secretion was significantly greater (80–90%), suggesting a relative specificity of blocking glucose uptake and metabolism on leptin secretion *vs.* that on another protein (LPL) produced by adipose tissue. Lastly, the effects of the blockers to inhibit leptin expression and secretion are unlikely to be due to a depletion of adipocyte energy stores, as it is known that adipocytes can generate energy (ATP) by oxidizing fatty acids via mitochondrial  $\beta$ -oxidation (37, 38).

Taken together, these data suggest a physiological role for glucose in the regulation of leptin expression and secretion by adipocytes. Accordingly, we hypothesize that during fasting, when circulating insulin and glucose concentrations are low and glucocorticoids are elevated, leptin secretion de-

clines secondary to decreased glucose transport into adipose tissue. Upon refeeding, increases in circulating insulin and glucose and the resulting increases in adipose glucose uptake and metabolism stimulate leptin secretion and restores circulating leptin concentrations to prefasting levels. This model, therefore, can explain the effects of fasting and refeeding on circulating leptin in humans (2–4) and rodents (5–7). In addition, the nocturnal increase in plasma leptin observed in humans could potentially arise as a delayed consequence of increased insulin-stimulated glucose metabolism following meals (8). The effect of glucose infusions to prevent the fall of plasma leptin during fasting in human subjects may be similarly mediated (2).

Thus, leptin secretion appears to reflect the amount of glucose transported and metabolized by adipose tissue. There is convincing evidence that suggests that a significant portion of glucose entering adipose tissue is metabolized to lactate and released (34, 35). This lactate may contribute to the pool of gluconeogenic precursors during fasting. Our results show that when a smaller proportion of glucose carbon taken up by adipocytes is released as lactate, more leptin is secreted. These data are consistent with the changes in leptin secretion observed during fasting and refeeding. In addition, fructose, in the presence of low glucose concentrations, stimulates leptin secretion, demonstrating that a non-glucose substrate can induce the adipocyte to secrete leptin and suggesting that stimulation of leptin secretion by glucose metabolism occurs downstream of phosphofructokinase.

In summary, blockade of glucose transport or inhibition of glycolysis inhibits leptin secretion from and gene expression in isolated cultured adipocytes. The secretion of leptin is directly proportional to the amount of glucose taken up by the adipocytes. These results suggest that leptin secretion is linked to glucose transport and metabolism and help to explain the known effects of feeding/fasting and long term glucose and insulin administration on circulating leptin concentrations.

### Acknowledgments

We acknowledge the expert technical assistance of Ms. Debbie Porter, and thank Drs. Richard Freedland, Michael Schwartz, and Barbara Kahn for their helpful advice and discussion of the results.

### References

- Caro JR, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV 1996 Leptin: the tale of an obesity gene. *Diabetes* 45:1455–1461
- Boden G, Chen X, Mozzoli M, Ryan I 1996 Effect of fasting on serum leptin in normal human subjects. *J Clin Endocrinol Metab* 81:3419–3423
- Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR, Kuijper JL 1997 Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. *J Clin Endocrinol Metab* 82:561–565
- Dubuc GR, Phinney SD, Stern JS, Havel PJ, Changes of serum leptin and endocrine and metabolic parameters after 7 days energy restriction in men and women. *Metabolism*, in press
- Ahima SR, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS 1996 Role of leptin in the neuroendocrine response to fasting. *Nature* 382:250–252
- Hardie LJ, Rayner DV, Holmes S, Trayhurn P 1996 Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (*fa/fa*) rats as measured by ELISA. *Biochem Biophys Res Commun* 223:660–665
- Ahren B, Mansson S, Gingerich RL, Havel PJ 1997 Regulation of plasma leptin in mice: influence of age, high-fat diet and fasting. *Am J Physiol* 273:R113–R120
- Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephens TW,

- Magosin S, Marco C, Caro JF 1996 Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. *J Clin Invest* 97:1344–1347
9. Becker DJ, Ongemba LN, Brichard V, Henquin J-C, Brichard SM 1995 Diet- and diabetes-induced changes of *ob* gene expression in rat adipose tissue. *FEBS Lett* 371:324–328
  10. Cusin R, Sainsbury A, Doyle P, Rohner-Jeanrenaud F, Jeanrenaud B 1995 The *ob* gene and insulin: a relationship leading to clues to the understanding of obesity. *Diabetes* 44:1467–1470
  11. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J 1995 Transient increase in obese gene expression after food intake or insulin administration. *Nature* 377:527–529
  12. Leroy P, Dessolin S, Villageois P, Moon BC, Friedman JM, Ailhaud G, Dani C 1996 Expression of *ob* gene in adipose cells. *J Biol Chem* 271:2365–2368
  13. Yoshida T, Hayashi M, Monkawa T, Saruta T 1996 Regulation of obese gene expression by hormonal factors in primary cultures of rat adipocytes. *Eur J Endocrinol* 135:619–625
  14. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS 1996 Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. *J Clin Endocrinol Metab* 81:4406–4413
  15. Larsson H, Elmstahl S, Ahren B 1996 Plasma leptin levels correlate to islet function independently of body fat in postmenopausal women. *Diabetes* 45:1580–1584
  16. Dagogo-Jack S, Fanelli C, Paramore D, Brothers J, Landt M 1996 Plasma leptin and insulin relationships in obese and nonobese human. *Diabetes* 45:695–698
  17. Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R, Mudaliar SR, Olefsky J, Caro JF 1996 Acute and chronic effect of insulin on leptin production in humans: studies *in vivo* and *in vitro*. *Diabetes* 45:699–701
  18. Havel PJ, Aoki TT, Grecu EO, Stern JS, Kasim-Karakas S 1996 Leptin/adiposity relationships in intensively treated IDDM and NIDDM and increased plasma leptin after 6 hours of high dose insulin infusion. *Obesity Res* 4:15S (Abstract)
  19. Utriainen R, Malmstrom R, Makimattila S, Yki-Jarvinen H 1996 Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. *Diabetes* 45:1364–1366
  20. Havel PJ 1997 Glucose infusion increases circulating leptin in proportion to adipose stores in rhesus monkeys. *J Endocrinol Diabetes [Suppl 3]* 105:37–38
  21. Sonnenberg GE, Krakower GR, Hoffmann RG, Maas DL, Hennes MMI, Kisseebah AH 1996 Plasma leptin concentrations: effects of extended fasting and stepwise increases in glucose infusions. *Obesity Res* 4:13S (Abstract)
  22. Mizuno T, Bergen H, Kleopoulos S, Bauman WA, Mobbs CV 1996 Effects of nutritional status and aging on leptin gene expression in mice: importance of glucose. *Horm Metab. Res* 28:679–684
  23. Havel PJ, Uriu-Hare JY, Stanhope KL, Stern JS, Keen CL 1997 Marked and rapid decrease of plasma leptin in insulin deficient diabetes: reversal by insulin. *Diabetologia [Suppl 1]* 40:A270 (Abstract)
  24. Havel PJ, Connors MH, Acerini CL, Crowne ED, Dunger DB 1997 Plasma leptin is increased proportionally to adiposity by physiologic insulinemia in insulin-dependent diabetes. *Diabetologia [Suppl 1]* 40:A268 (Abstract)
  25. Hazen SA, Rowe WA, Lynch CJ 1995 Monolayer cell culture of freshly isolated adipocytes using extracellular basement membrane components. *J Lipid Res* 36:868–878
  26. Hajduck EJ, Guerre-Millo M, Hainault IA, Guichard CM, Lavau MM 1992 Expression of glucose transporters (GLUT1 and GLUT4) in primary cultured rat adipocytes: differential evolution with time and chronic insulin effect. *J Cell Biochem* 49:251–258
  27. Rodbell M 1964 Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. *J Biol Chem* 239:375–380
  28. Brown J 1962 Effects of 2-deoxyglucose on carbohydrate metabolism: review of the literature and studies in the rat. *Metabolism* 11:1098–1112
  29. Wierlinga T, Van Putten JP, Krans HM 1981 Rapid phloretin-induced dephosphorylation of 2-deoxyglucose-6-phosphate in rat adipocytes. *Biochem Biophys Res Commun* 103:841–847
  30. Marette A, Bukowiecki LJ 1991 Noradrenaline stimulates glucose transport in rat brown adipocytes by activating thermogenesis. Evidence that fatty acid activation of mitochondrial respiration enhances glucose transport. *Biochem J* 277:119–124
  31. Nimmo GA, Nimmo HG 1984 Studies of rat adipose tissue glycerol phosphate acyltransferase. *Biochem J* 224:101–108
  32. Holland RI 1977 Effect of fluoride on glycerol production in rat adipocytes *in vitro*. *Acta Pharmacol Toxicol* 41:97–102.29
  33. Mizuno TM, Bergen H, Funabashi T, Kleopoulos SP, Zhong YG, Bauman WA, Mobbs CB 1996 Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. *Proc Natl Acad Sci USA* 93:3434–3438
  34. DiGirolamo M, Newby FD, Lovejoy J 1992 Lactate production in adipose tissue: a regulated function with extra-adipose implications. *FASEB J* 6:2405–2412
  35. Heckler BK, Carey GB 1997 Lactate production by swine adipocytes: effects of age, nutritional status, glucose concentration, and insulin. *Am J Physiol* 272:E957–E966
  36. Vidal H, Auboeuf D, De Vos P, Staels B, Riou JP, Auwerx J, Laville M 1996 The expression of *ob* gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. *J Clin Invest* 98:251–255
  37. Mayers PA 1993 Lipid transport and storage. In: Murray RK, Granner DK, Mayes PA, Rodwell VW (eds) *Harper's Biochemistry*. Appleton and Lange, Norwalk, pp 250–265
  38. Moore KH, Tsatsos P, Staudacher DM, Kiechle FL 1996 Counter modulation of adipocyte mitochondrial processes by insulin and S-oxalylglutathione. *Int J Biochem Cell Biol* 28:183–191

# Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat Adipocytes

Wendy M. Mueller,\* Kimber L. Stanhope,\* Francine Gregoire,† Joseph L. Evans,‡ and Peter J. Havel\*

## Abstract

MUELLER, WENDY M., KIMBER L. STANHOPE, FRANCINE GREGOIRE, JOSEPH L. EVANS, AND PETER J. HAVEL. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. *Obes Res.* 2000;8:530–539.

**Objective:** We have reported that glucose utilization regulates leptin expression and secretion from isolated rat adipocytes. In this study, we employed two antidiabetic agents that act to increase glucose uptake by peripheral tissues, metformin and vanadium, as pharmacological tools to examine the effects of altering glucose utilization on leptin secretion in primary cultures of rat adipocytes.

**Research Methods and Procedures:** Isolated adipocytes (100 µL of packed cells per well) were anchored in a defined matrix of basement membrane components (Matrigel) with media containing 5.5 mM glucose and incubated for 96 hours with metformin or vanadium. Leptin secretion, glucose utilization, and lactate production were assessed.

**Results:** Metformin (0.5 and 1.0 mM) increased glucose uptake in the presence of 0.16 nM insulin by 37 ± 10% ( $p < 0.005$ ) and 62 ± 8% ( $p < 0.0001$ ) over insulin alone, respectively. Metformin from 0.5 to 5.0 mM increased lactate production by 105 ± 43% ( $p < 0.025$ ) to 202 ± 52% ( $p < 0.0025$ ) and at 1.0 and 5.0 mM increased the proportional rate of glucose conversion to lactate by 78 ± 18% ( $p < 0.005$ ) and 166 ± 41% ( $p < 0.0025$ ), respectively. At concentrations less than 0.5 mM, metformin did not affect leptin secretion, but at 0.5 mM, the only concentration that significantly increased glucose utilization without increasing glucose conversion to lactate, leptin secretion was modestly stimulated (by 20 ± 9%;  $p < 0.05$ ). Concentrations from 1.0 to 25 mM inhibited leptin secretion by 25 ± 8%

( $p < 0.005$ ) to 89 ± 4% ( $p < 0.0001$ ). Across metformin doses, leptin secretion was inversely related to the percentage of glucose taken up and released as lactate ( $r = -0.74$ ;  $p < 0.0001$ ). Vanadium (5 to 20 µM) increased glucose uptake from 20 ± 7% ( $p < 0.01$ ) to 34 ± 13% ( $p < 0.02$ ) and increased lactate production at 5 µM by 17 ± 8% ( $p < 0.025$ ) and 10 µM by 61 ± 20% ( $p < 0.02$ ) but did not alter the conversion of glucose to lactate. Vanadium (5 to 50 µM) inhibited leptin secretion by 33 ± 6% ( $p < 0.0025$ ) to 61 ± 8% ( $p < 0.0001$ ).

**Discussion:** Both metformin and vanadium increase glucose uptake and inhibit leptin secretion from cultured adipocytes. The inhibition of leptin secretion by metformin is related to an increase in the metabolism of glucose to lactate. The inhibition by vanadium most likely involves direct effects on cellular phosphatases. We hypothesize that the effect of glucose utilization to stimulate leptin production involves the metabolism of glucose to a fate other than anaerobic lactate production, possibly oxidation or lipogenesis.

**Key words:** glucose uptake, lactate production, anaerobic metabolism

## Introduction

The adipocyte hormone, leptin, has a central role in the regulation of food intake, energy expenditure, and body fat stores (1,2). Circulating leptin concentrations are well correlated with adipose stores in humans (3–5) and animals (5–7). However, leptin production is also acutely regulated by nutritional status. For example, circulating leptin decreases after fasting (6,8–10) or energy restriction (11,12) and increases after refeeding or overfeeding (9,13). These changes of circulating leptin are disproportionate to the relatively small changes of body fat. Although the regulation of leptin expression and secretion is incompletely understood, changes of insulin secretion during fasting and refeeding precede changes of circulating leptin concentrations. There is a growing body of evidence that suggests a role for insulin and glucose in mediating changes of circulating leptin levels in vivo. For example, infusion of small amounts of glucose to prevent the reductions of insulin and

Submitted for publication October 18, 1999.

Accepted for publication in final form February 22, 2000.

Departments of \*Nutrition and †Pediatrics, School of Medicine, University of California, Davis, California and the ‡Medical Research Institute, Inc., San Bruno, California.

Address correspondence to Peter J. Havel, D.V.M., Ph.D., Department of Nutrition, University of California, Davis, One Shields Avenue, Davis, CA 95616. E-mail: pjhavel@ucdavis.edu

Copyright © 2000 NAASO

glucose during fasting in humans also prevents the decrease in plasma leptin (8). Although insulin administration does not acutely increase plasma leptin concentrations in human subjects (14,15) increases have been reported after 4 to 6 hours during insulin infusions producing supraphysiological (16,17) or physiological (18) increments of plasma insulin levels. Similarly, prolonged hyperglycemia and hyperinsulinemia in response to extended glucose infusions increases plasma leptin after several hours in nonhuman primates (7) and human subjects (19). Lastly, leptin concentrations increase 4 to 6 hours after high carbohydrate meals, which induce large plasma insulin and glucose responses in humans (20).

In vitro studies have shown that insulin increases leptin expression and secretion in isolated rodent (21–23) and human (15,24) adipocytes. It has not, however, been clear whether the effect of insulin to increase leptin production is a direct consequence of increased insulin signaling or might be indirectly mediated by insulin's actions on glucose metabolism. Several in vivo studies have provided support for the latter explanation. First, glucose administration induces increases of *ob* mRNA expression, which are more closely related to changes of plasma glucose than to plasma insulin concentrations (25,26).

In addition, the decrease in plasma leptin during marked caloric restriction in humans is better correlated with the decrease in plasma glucose than with changes in insulinemia (11,12). Furthermore, we have found that low plasma leptin levels in insulin-deficient streptozotocin diabetic rats are acutely increased by insulin administration in proportion to the degree of glucose lowering (27). Further support from in vitro experiments for a role for adipose glucose utilization in the regulation of leptin production is provided by our recent report that increased glucose metabolism is an important mediator of insulin-stimulated leptin expression and secretion. Blockade of glucose uptake or inhibition of glycolysis decreases *ob* gene expression and leptin secretion in isolated rat adipocytes (28). However, glucose uptake, by itself, only seems to be important in that glucose must first be taken up by the adipocytes before it can be metabolized. Rather than glucose uptake per se, the inverse relationship observed, between the proportional conversion of glucose to lactate and leptin secretion by isolated adipocytes (28), suggests that a regulatory step for glucose metabolism to mediate changes of leptin production involved the metabolism of glucose to a point beyond the anaerobic metabolism of glucose-derived pyruvate to lactate.

Metformin and vanadium are two antidiabetic agents, which are able to enhance glucose uptake and utilization by peripheral tissues (29,30). In the present study, we employed metformin and vanadium as pharmacological tools to examine the effects of altering adipocyte glucose utilization on leptin production in primary cultures of isolated adipocytes. Glucose utilization, lactate production, and lep-

tin secretion were measured over 96 hours in isolated rat adipocytes cultured in a basement membrane matrix that maintains adipocyte differentiation.

## Research Methods and Procedures

### Materials

Media (Dulbecco's modified Eagle's medium [DMEM]) and fetal bovine serum (FBS) were purchased from Life Technologies (Grand Island, NY). The media was supplemented with 6 mL each of minimal essential medium amino acids, penicillin/streptomycin (5000 U/mL/5000 µg/mL), and nystatin (10,000 U/mL; all from Life Technologies) per 500 mL of DMEM. Bovine serum albumin fraction V, 4-(2-hydroxyethyl)-1-piperazineethansulfonic acid (HEPES), collagenase (*Clostridium histolyticum*, type II; specific activity, 456 U/mg), insulin, and metformin were purchased from Sigma Chemical Co. (St. Louis, MO). Matrigel matrix was purchased from Becton Dickinson (Franklin Lakes, NJ). Bis(maltolato) oxovanadium(IV) (BMOV), an organified form of vanadium (31), was a gift from Drs. John McNeill and Violet Yuen, Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. Six-well Falcon plates were purchased from Fisher Scientific (Pittsburgh, PA). Nylon filters were purchased from Tetko (Kansas City, MO).

### Animals

Male Sprague-Dawley rats (3 to 6 months of age) were obtained from Charles River (Wilmington, MA). Animals were housed in hanging wire cages in temperature-controlled rooms (22 °C) with a 12-hour light-dark cycle and fed Purina chow diet (Ralston-Purina, St. Louise, MO) and given deionized water ad libitum. Animal use and care was in accordance with the National Institutes of Health Guide for the Use and Care of Laboratory Animals and conducted in facilities accredited by the American Association for Accreditation of Laboratory Animal Care. The study protocol was approved by the Administrative Animal Use and Care Committee at University of California, Davis.

### Methods

**Cell Isolation/Preparation.** Adipocytes were prepared from epididymal fat pads from male Sprague-Dawley rats weighing 300 to 600 g. Epididymal fat depots were resected from halothane-anesthetized rats under aseptic conditions, and adipocytes were isolated by collagenase digestion by the Rodbell method (32) with minor modifications as previously described (28). The isolated adipocytes were then incubated for 30 minutes at 37 °C before being plated and cultured on Matrigel-coated plates.

**Adipocyte Culture.** Adipocytes were maintained in culture anchored to a basement membrane matrix (Matrigel, Becton Dickinson). Although all in vitro systems have

inherent advantages and disadvantages, advantages of this system compared with cultures containing free-floating adipocytes are that the matrix simulates their normal basement membrane attachment and that the cells are maintained in close proximity to each other, allowing direct cell-to-cell contact. Together the cell contact and basement membrane attachment help to maintain differentiation, because adipocytes have a strong tendency to dedifferentiate in long term (>24-hour) culture. In addition, the matrix and the small amount of serum in the media both contain growth factors, which are also likely to help maintain cell differentiation. Furthermore, the adipocytes in this system are not exposed to toxic levels of oxygen at the interface of the media and the incubator atmosphere, as opposed to free-floating adipocytes which aggregate at the surface of the media. An advantage of the system over those containing minced adipose tissue is that all of the cells in the culture are equally exposed to the nutrients and the oxygen dissolved in the media. Thus, although clearly different from the *in vivo* situation, we believe that this system provides a more physiological environment than most systems for maintaining adipocytes in long term culture. In the case of the present studies, the goal was to examine the direct actions of metformin and vanadium on leptin production and adipocyte metabolism. Therefore, the advantage of employing *in vitro* experimentation for this purpose over *in vivo* models was that it was possible to control confounding variables, such as effects of these agents on food intake, which would indirectly influence leptin production via changes of insulin secretion (18,20). Unlike an *in vivo* system, in this study the environment surrounding the adipocytes within the individual wells of each culture plate was identical with the exception of the presence or absence and the concentration of metformin or vanadium, allowing assessment of the direct effects of the treatments.

In culturing each suspension, Matrigel was first thawed on ice to a liquid and uniformly applied to the surface of culture dishes (300  $\mu$ L of Matrigel/35-mm well). After the incubation period, 150  $\mu$ L of the adipocyte suspension (2:1 ratio of packed cells to media) were plated on the liquid Matrigel matrix. Adipocytes from each suspension were thoroughly mixed with a transfer pipette before plating to insure that a similar number of adipocytes with a similar size distribution were added to the control and experimental wells for each suspension. The warmth of the added cells and media caused the Matrigel to gel around the adipocytes, effectively anchoring them to the culture dish. After a 30-minute incubation at 37 °C, 2 mL of warm culture medium was added. The cells were maintained in an incubator at 37 °C for 96 hours with 6% CO<sub>2</sub>. Aliquots of adipocytes from each animal were divided into wells, with the

different concentrations of either metformin or vanadium (as detailed below). In each plate an appropriate control well contained adipocytes from the same animal. Adipocytes were incubated with media (DMEM) containing 5.5 mM (100 mg/dL) glucose plus 5% FBS at five concentrations of Metformin (0.1, 0.25, 0.5, 1.0, 5.0, and 25.0 mM). A low basal concentration of insulin (0.16 nM) was added to the incubations performed with metformin, because metformin is thought to act in part by increasing insulin signaling (33,34). Vanadium was added at four concentrations (5.0, 10.0, 20.0, and 50.0  $\mu$ M) in DMEM with 5.0 to 5.5 mM glucose and 1% FBS. Adipocytes were cultured with vanadium without added insulin, because vanadium action is considered to be largely independent of insulin (35,36). To examine the responses to insulin in the adipocytes obtained from each adipocyte suspension in the vanadium experiments, a separate well containing 1.6 nM insulin was included for each suspension. In all experiments, aliquots of media (300  $\mu$ L, 15% of the media volume) were collected from culture wells and replaced with fresh media containing the appropriate concentrations of metformin or vanadium at 24, 48, 72, and 96 hours.

**Assays.** Leptin concentrations in the medium were determined with a sensitive and specific radioimmunoassay for rat leptin (37) with reagents obtained from Linco Research, St. Charles, MO. Glucose and lactate were measured with a glucose analyzer (model 2300, YSI, Yellow Springs, OH).

**Data Analysis.** The uptake of glucose was assessed by measuring the concentration of glucose in the media in each well before and at 24, 48, 72, and 96 hours of incubation and calculating the decrease over 96 hours after correcting for the amount of glucose that was removed during each 24-hour media sampling and the amount added by the replacement of fresh media (15% of total volume). Lactate production was calculated as the increase of media lactate at 24, 48, 72, and 96 hours by correcting for the amount of lactate removed by sampling and added with media replacement. To examine the relationship between adipocyte carbon flux and leptin secretion in adipocytes cultured with metformin or vanadium, the amount of carbon released as lactate per amount of carbon taken up as glucose over 96 hours was calculated as lactate production/glucose utilization and expressed as a percentage (28). Cumulative leptin production was calculated as the change of media leptin concentrations at 24, 48, 72, and 96 hours with correction for the amount of leptin removed during sampling. The area under the curve for leptin production between 0 and 96 hours was calculated by the trapezoidal method. The experimental results from each adipocyte suspension prepared from a single animal were analyzed in relation to a control well from the same suspension. Given the

individual variation in leptin responses between animals and/or suspensions, it was not appropriate to compare means from control and treated adipocytes from different animals and/or suspensions. Therefore, the means for all the controls in the metformin ( $n = 18$ ) and vanadium ( $n = 14$ ) experiments contain a larger sample size ( $n$ ) of animals and/or suspensions than all except the 1.0 mM metformin dose, which was studied in every experiment. Thus, when the number of wells with a particular concentration of metformin or vanadium differed from the total number of control wells (e.g., 0.5 mM metformin;  $n = 9$ ), each result was compared only to that obtained in a corresponding control well from the same suspension in a pair-wise comparison. To examine the relationships between the medium concentrations of metformin or vanadium, glucose uptake, lactate production, and glucose conversion to lactate, and leptin secretion, simple and multiple linear regression analyses were performed with a statistics software package (StatView for Macintosh, Abacus Concepts, Inc., Berkeley, CA).

Because metformin exhibited toxic effects on adipocyte metabolism at concentrations greater than 5.0 mM, results from cultures incubated with metformin at concentrations greater than 5.0 mM were not included in these analyses. The relationship between lactate production from glucose and leptin secretion was also examined within the control groups alone. Data are expressed as means + SEM.

## Results

### *Effects of Metformin*

The effects of metformin on glucose uptake, lactate production, and leptin secretion were examined. Metformin at a concentration of 0.1 mM did not affect glucose uptake compared with the corresponding control suspensions containing insulin (0.16 nM) alone. At 0.25 mM, glucose uptake was increased ( $\% \Delta = +9 \pm 8\%$ ), but the effect was not statistically significant perhaps due to the smaller number of trials ( $n = 5$ ) performed at this concentration. Metformin stimulated glucose uptake at concentrations of 0.5 mM ( $+37 \pm 10\%$ ,  $p < 0.005$ ) and 1.0 mM ( $+62 \pm 8\%$ ,  $p < 0.0001$ ) compared with that in the corresponding control suspensions (Table 1, Figure 1). At 5.0 mM, glucose uptake was not significantly different from control. Higher concentrations of metformin ( $\geq 25.0$  mM) markedly inhibited glucose uptake most likely reflecting a toxic effect of metformin at these very high concentrations. Metformin had no significant effect on lactate production at concentrations lower than 0.5 mM but increased lactate production at concentrations of 0.5 mM ( $+105 \pm 43\%$ ,  $p < 0.025$ ), 1.0 mM ( $+186 \pm 31\%$ ,  $p < 0.0001$ ), and 5.0 mM ( $+202 \pm 52\%$ ,  $p < 0.0025$ ) vs. insulin alone (Table 1, Figure 1). At concentrations of 25.0 mM, lactate production was markedly inhibited ( $p < 0.0001$ ), because glucose utilization was

almost completely suppressed. Concentrations of metformin of 0.5 mM and below did not affect the proportional conversion of glucose to lactate (Table 1). However, glucose conversion to lactate was increased at a concentration of 1.0 mM, and this effect was marked at 5.0 mM with more than twice the amount of glucose released as lactate (Table 1). Although 1.0 mM metformin did increase mean glucose uptake over control rates, a significantly larger proportion of the glucose that was taken up was released as lactate. The concentration of 0.5 mM was the only level of metformin that induced a significant increase of glucose utilization without increasing the proportion of glucose carbon released as lactate (Table 1).

At concentrations of metformin lower than 0.5 mM, leptin secretion was unaffected. With metformin at 0.5 mM, the area under the curve (AUC) for leptin secretion over 96 hours was significantly greater ( $+20.5 \pm 9\%$ ,  $p < 0.05$ ) than control (Figure 2). Metformin inhibited leptin secretion at concentrations of 1.0 mM ( $-25 \pm 8\%$ ,  $p < 0.005$ ), 5.0 mM ( $-89 \pm 4\%$ ,  $p < 0.0001$ ), and by 90% at toxic concentrations of 25.0 mM ( $p < 0.0001$ ) (Figure 2).

Within the 18 control wells, leptin secretion was inversely related to the conversion of glucose to lactate ( $r = -0.61$ ;  $p < 0.01$ ). At metformin concentrations from 0 to 5.0 mM, leptin secretion was inversely proportional to the log of the metformin concentration ( $r = -0.53$ ;  $p < 0.0001$ ), to lactate production ( $r = -0.53$ ;  $p < 0.0001$ ), and to the proportional conversion of glucose to lactate across metformin doses ( $r = -0.74$ ;  $p < 0.0001$ ) (Figure 3) but was not related to glucose uptake ( $r = 0.13$ ;  $p = 0.27$ ) by simple regression. By multiple regression analysis, leptin secretion was inversely related to the conversion of glucose to lactate ( $p < 0.0001$ ) but not to the log of the metformin concentration ( $p = 0.91$ ), lactate production ( $p = 0.39$ ), or glucose uptake ( $p = 0.62$ ). Leptin secretion was only increased over control by metformin at 0.5 mM, which was also the only concentration that significantly increased glucose uptake without shunting a greater proportion of the glucose into lactate production (Table 1). A similar inverse relationship ( $r = -0.73$ ;  $p < 0.0025$ ) between leptin production and anaerobic glucose metabolism to lactate was observed in 32 control wells containing either no insulin or a low insulin concentration of 0.16 nM ( $\sim 20 \mu\text{U/mL}$ ) (Figure 4).

### *Effects of Vanadium*

The effects of vanadium on glucose uptake, lactate production, and leptin secretion were examined in adipocytes cultured with concentrations of vanadium of 0 to 50  $\mu\text{M}$ . Vanadium at 5.0  $\mu\text{M}$  ( $+20 \pm 7\%$ ,  $p < 0.01$ ), 10.0  $\mu\text{M}$  ( $+38 \pm 12\%$ ,  $p < 0.02$ ), and 20.0  $\mu\text{M}$  ( $+34 \pm 13\%$ ,  $p < 0.02$ ) increased glucose uptake, compared with rates of glucose uptake in the corresponding control suspensions (Table 2, Figure 5). The effect of vanadium at these con-


**Table 1.** Effects of metformin in the presence of 0.16 nM insulin on glucose uptake, lactate production, and the percentage of glucose carbon taken up that was released as lactate by isolated rat adipocytes over 96 hours in culture (mean  $\pm$  SEM)

[Metformin] (mM) + Insulin (0.16 nM)	Glucose uptake ( $\mu\text{mol}$ ) over 96 hours	Lactate production ( $\mu\text{mol}$ ) over 96 hours	Glucose to lactate (%)
Control ( $n = 18$ )	$7.5 \pm 0.7$	$5.7 \pm 0.5$	$40.9 \pm 3.6$
0.1 ( $n = 4$ )	$6.5 \pm 0.9$	$5.9 \pm 0.6$	$47.2 \pm 6.3$
0.25 ( $n = 5$ )	$11.0 \pm 1.4$	$8.6 \pm 1.3$	$40.2 \pm 5.9$
0.5 ( $n = 9$ )	$11.0 \pm 1.2^\dagger$	$9.5 \pm 1.2^\dagger$	$44.9 \pm 5.1$
1.0 ( $n = 18$ )	$11.6 \pm 0.7^\ddagger$	$14.4 \pm 0.9^\ddagger$	$63.8 \pm 3.4^*$
5.0 ( $n = 15$ )	$8.3 \pm 0.6$	$14.4 \pm 1.0^\ddagger$	$85.6 \pm 4.1^\ddagger$


\*  $p = 0.01$ ;  $\dagger p = 0.005$ ;  $\ddagger p = 0.0005$ ; vs. corresponding controls from the same adipocyte suspensions.

centrations was comparable to that of insulin at 1.6 nM, which increased glucose uptake by  $38 \pm 8\%$  ( $p < 0.0001$ )(Table 2, Figure 5). Vanadium at 50.0  $\mu\text{M}$  did not significantly affect glucose uptake ( $\% \Delta = -4 \pm 14\%$ ). Vanadium at 5.0  $\mu\text{M}$  increased lactate production by  $+17 \pm 8\%$  ( $p < 0.025$ ). Mean lactate production in the six wells that served as controls for the 10.0  $\mu\text{M}$  concentration of vanadium was lower than average; however, lactate production was increased in five of six corresponding experimental wells. Thus, vanadium at 10  $\mu\text{M}$  increased lactate production by  $61 \pm 20\%$  ( $p < 0.02$ ) despite absolute lactate production being similar to the mean of the total 14 control wells. At 20.0 and 50.0  $\mu\text{M}$ , lactate production was not significantly different from that of the control (Table 2).


Insulin at 1.6 nM increased leptin secretion over 96 hours by  $59 \pm 15\%$  ( $p < 0.005$ ) and the 0- to 96-hour AUC by  $38 \pm 8\%$  ( $p < 0.0001$ )(Figure 5). Leptin secretion was unaffected by vanadium at a concentration of 5  $\mu\text{M}$ . Higher concentrations of 10, 20, and 50  $\mu\text{M}$  consistently inhibited leptin secretion over 96 hours by  $-33 \pm 6\%$  ( $p < 0.0025$ ),  $-53 \pm 7\%$  ( $p < 0.0001$ ), and  $-61 \pm 8\%$  ( $p < 0.001$ ), respectively (Figure 6). Across vanadium concentrations, leptin secretion at 96 hours was positively correlated with glucose uptake ( $r = 0.35$ ;  $p < 0.02$ ) and inversely related to the log of the vanadium concentration ( $r = -0.44$ ;  $p < 0.0001$ ), to lactate production ( $r = -0.30$ ;  $p < 0.025$ ), and to the conversion of glucose to lactate ( $r = -0.58$ ;  $p <$



**Figure 1.** Glucose utilization (corrected for media sampling and replacement) over 96 hours by isolated rat adipocytes in primary culture with insulin at 0.16 nM and metformin at concentrations from 0 to 25.0 mM.




**Figure 2.** Leptin secretion (corrected for media sampling and replacement) over 96 hours by isolated rat adipocytes in primary culture with insulin at 0.16 nM and metformin at concentrations from 0 to 25.0 mM.



**Figure 3.** Relationship between the percentage of glucose taken up and released as lactate and leptin secretion over 96 hours by adipocytes in primary culture with insulin (INS) at 0.16 nM and metformin (MET) at concentrations from 0 to 5.0 mM. Leptin secretion, glucose utilization, and lactate production are corrected for media sampling and replacement.

0.0001) (data not shown). By multiple regression analysis, leptin secretion at 96 hours was more closely related to glucose conversion to lactate ( $p < 0.0001$ ) than to absolute lactate production ( $p < 0.02$ ) or the log of the vanadium concentration ( $p < 0.005$ ) and was not related to absolute



**Figure 4.** Relationship between the percentage of glucose taken up and released as lactate and leptin secretion over 96 hours by adipocytes in primary culture in 32 control wells containing no added insulin or insulin at a low concentration of 0.16 nM. Leptin secretion, glucose utilization, and lactate production are corrected for media sampling and replacement.

glucose uptake ( $p = 0.22$ ). Despite the relationship between leptin secretion and the conversion of glucose to lactate across vanadium concentrations, unlike with metformin, the percentage of glucose released as lactate was not altered by any concentration of vanadium (Table 2). In contrast, insulin at 1.6 nM, which significantly decreased the proportional conversion of glucose to lactate (i.e., anaerobic glucose metabolism) (Table 2), stimulated leptin secretion (Figure 6).

## Discussion

We have recently reported that insulin-mediated glucose metabolism is an important factor regulating leptin expression and secretion in isolated rat adipocytes (28). Some previous studies have shown that drugs in the thiazolidinedione class, which are used in the treatment of type 2 diabetes, can inhibit leptin production in vitro and in vivo (38,39). In the present study, we examined the effects of metformin and vanadium, two other antidiabetic drugs known to increase cellular glucose utilization, on leptin secretion, glucose uptake, and lactate production in isolated cultured rat adipocytes. Our goal was to use these compounds as tools to examine their effects for altering adipocyte glucose utilization on leptin secretion. Therefore, we used concentrations within a range that were found to produce significant increases of adipocyte glucose uptake. Particularly in the case of metformin, these concentrations (0.25 to 5.0 mM) were far above the range of plasma concentrations (0.005 to 0.02 mM) observed in patients treated with therapeutic doses of metformin (40). In fact, at therapeutic concentrations, metformin seems to act primarily to inhibit hepatic glucose production with limited, if any, effects on peripheral glucose uptake (41–43). At therapeutic concentrations, metformin generally has little direct effect on glucose utilization in vitro (44,45). At concentrations higher than those achieved in serum with therapeutic metformin administration, metformin stimulates glucose transport by rat (46,47) and human adipocytes (48), and in rat and human skeletal muscle (see reviews in 29,34,48,49). At the cellular level, high concentrations of metformin increase insulin receptor binding, along with tyrosine kinase activity, glucose transport, and glycogen synthesis (33,34).

In the present study, metformin concentrations ranging from 0.5 to 5.0 mM increased both glucose uptake and lactate production. In addition to increasing absolute lactate production, metformin at 1.0 and 5.0 mM increased the percentage of glucose carbon that was metabolized to lactate and released into the culture media by 80% to 170%. At high concentrations of metformin (= 25.0 mM), both glucose uptake and lactate production were markedly inhibited, most likely due to a toxic effect of very high levels of metformin on cellular metabolism. Metformin at 0.5 mM modestly increased leptin secretion by ~20%.

**Table 2.** Effects of insulin (1.6 nM) or vanadium on glucose uptake, lactate production, and the percentage of glucose carbon taken up that was released as lactate by isolated rat adipocytes over 96 hours in culture (mean  $\pm$  SEM)


[Vanadium] ( $\mu$ M); no insulin added	Glucose uptake ( $\mu$ mol) over 96 hours	Lactate production ( $\mu$ mol) over 96 hours	Glucose to lactate (%)
Control ( $n = 14$ )	6.8 $\pm$ 0.5	5.6 $\pm$ 0.6	42.4 $\pm$ 4.3
1.6 nM Ins ( $n = 14$ )	9.4 $\pm$ 0.9 $\ddagger$	5.7 $\pm$ 0.7	33.0 $\pm$ 3.5 $\ddagger$
5.0 ( $n = 12$ )	7.8 $\pm$ 1.1 $\ddagger$	5.7 $\pm$ 0.6*	40.5 $\pm$ 4.7
10.0 ( $n = 6$ )	8.2 $\pm$ 1.3 $\ddagger$	5.2 $\pm$ 0.8†	36.0 $\pm$ 6.5
20.0 ( $n = 12$ )	8.7 $\pm$ 1.2 $\ddagger$	6.3 $\pm$ 0.6	41.6 $\pm$ 5.0
50.0 ( $n = 13$ )	6.9 $\pm$ 1.02	4.9 $\pm$ 0.5	53.3 $\pm$ 9.4

\*  $p = 0.05$ ; †  $p = 0.02$ ; ‡  $p = 0.0025$ ; §  $p = 0.0005$ ; vs. corresponding control wells from the same adipocyte suspensions.


Importantly, this was the only concentration of metformin tested that increased glucose uptake without shunting a greater proportion of glucose into lactate production. In contrast, at concentrations of 1.0 mM and higher, leptin secretion was modestly to markedly suppressed.

A significant proportion of glucose taken up by adipose tissue is metabolized to lactate and released (50). At metformin concentrations  $\leq$  5.0 mM, leptin secretion was inversely related to the amount of glucose taken up by the adipocytes, converted to lactate, and released into the media. We have previously observed that the stimulation of leptin secretion by insulin is associated not only with increased glucose utilization, but with a decrease in the pro-

portional conversion of glucose to lactate (28), a finding that was also observed within the control groups in the present study (Figure 4). Thus, when lactate production is increased, less carbon derived from glucose is available to enter the tricarboxylic acid cycle either for oxidation or use in de novo lipogenesis. Together, these data suggest that it is not glucose uptake, per se, but its metabolism beyond pyruvate and lactate in the adipocyte that is involved in the action of glucose to stimulate leptin secretion. Thus, the anaerobic metabolism of glucose does not stimulate leptin production. The entry of glucose into the hexosamine biosynthetic pathway and the production of UDP-glucosamine have been suggested as a mechanism by which glucose utilization can



**Figure 5.** Glucose utilization (corrected for media sampling and replacement) over 96 hours by isolated rat adipocytes in primary culture with vanadium at concentrations from 0 to 50.0  $\mu$ M or with insulin at 1.6 nM.



**Figure 6.** Leptin secretion (corrected for media sampling and replacement) over 96 hours by isolated rat adipocytes in primary culture with vanadium at concentrations from 0 to 50.0  $\mu$ M or with insulin at 1.6 nM.

stimulate leptin production in adipose tissue (51). However, our results indicate that glucose can be metabolized to lactate, a point well beyond where glucose enters the hexosamine pathway, without stimulating leptin production. Therefore, if the hexosamine pathway were to be the sole mechanism by which glucose regulates leptin production, one would need to postulate that either anaerobic glucose metabolism and/or metformin itself, have an inhibitory effect on glucose entry into this pathway. The results of the present study suggest that it is more likely that the effect of glucose metabolism to stimulate leptin production involves glucose oxidation and/or the production of lipogenic precursors.

Metformin at 0.1 and 0.25 mM did not effect glucose metabolism or leptin secretion. Thus, metformin at therapeutic levels is unlikely to affect leptin production *in vivo*. Of the concentrations of metformin tested in this study, only 0.5 mM increased glucose uptake without shunting a larger proportion of the glucose into lactate. As previously discussed, this was the only concentration of metformin that had effects on glucose metabolism that did not inhibit leptin secretion, and, in fact, leptin secretion was modestly increased at 0.5 mM. Thus, only when glucose uptake *and* its metabolism beyond lactate were simultaneously increased, did we observe an increase, and not an inhibition, of leptin secretion. Therefore, it seems that only within a very narrow concentration range is metformin able to have a net effect to increase glucose uptake as well as its metabolism beyond lactate in isolated adipocytes. Accordingly, the effects of metformin to inhibit leptin secretion at most concentrations examined is likely to be a result of its effects to direct pyruvate metabolism into lactate and away from other potential pathways for pyruvate metabolism such as oxidation or lipogenesis.

The use of vanadium-containing compounds in the treatment of diabetes has been widely investigated in animals (52,53), and a few clinical trials have been conducted in human patients (54,55). A compound structurally similar to the form of organified vanadium used in this study (BMOV) has recently entered Phase 1 clinical trials. To our knowledge, the present study is the first report examining the effects of a vanadium compound on leptin production *in vivo* or *in vitro*.

Vanadium stimulated glucose uptake at concentrations up to 20  $\mu\text{M}$ , whereas glucose uptake was not affected by a concentration of 50  $\mu\text{M}$ . Lactate production was modestly increased at the lower concentrations of vanadium. We found that vanadium at a low concentration of 5.0  $\mu\text{M}$  did not affect leptin production, however, concentrations of 10.0  $\mu\text{M}$  and higher inhibited leptin secretion from isolated adipocytes by 30% to 60%. Although the amount of leptin secreted was inversely proportional to the percentage conversion of glucose to lactate across the concentrations of

vanadium tested, this relationship was significantly weaker than that observed across metformin concentrations.

Furthermore, the proportion of glucose taken up and released as lactate was unaffected by vanadium at any concentration. Thus, in contrast to what was observed with metformin, the ability of vanadium to inhibit leptin secretion seems to be independent of any effects on glucose metabolism or lactate production, most likely because it does not increase the proportion of glucose fluxing into anaerobic metabolism.

The observed effects of vanadium result from one or more of the multiple known biological actions of vanadium in cells. These include the inhibition of protein tyrosine phosphatases and the activation of cytosolic protein-tyrosine kinases, resulting in the alteration of cellular tyrosine phosphorylation content (30,56). Vanadium has also been shown to exert direct inhibitory effects on a number of other cellular enzymes, including acid, alkaline, and dual-function phosphatases, ATPases, glucose-6-phosphatase, and fructose-2,6-bisphosphatase (30,55). At high concentrations, vanadium might exert some toxic effects on the cells, an effect which could underlie the lack of effect of the highest concentration of vanadium to stimulate glucose uptake, as well as the inhibition of leptin production at the two highest concentrations examined. In particular, the effects of vanadium to inhibit the activity of one or more enzymes involved in cellular energy metabolism could both inhibit leptin production and, at high concentrations, impair the ability of the cell to utilize energy derived from glucose metabolism.

In vanadium-treated animals, plasma vanadium concentrations have been estimated to be in the 10 to 20  $\mu\text{M}$  range and in human clinical trials in the 1 to 5  $\mu\text{M}$  range (53). Although it is unlikely based on the present results that the concentration of vanadium achieved in humans would be sufficient to affect leptin production, previous human studies employed low doses of vanadyl sulfate or sodium metavanadate, which are molecular forms that exhibit poor bioavailability. The potential effects on leptin secretion of the more readily absorbed forms of vanadium, such as the organified vanadium compound (BMOV) used in the present study (31), should therefore be considered.

In summary, both metformin and vanadium inhibit leptin secretion from primary cultures of rat adipocyte at concentrations that significantly increase glucose utilization. The inhibition of leptin production by metformin, but not by vanadium, is related to an increased conversion of glucose to lactate (*i.e.*, anaerobic metabolism). This effect of metformin, coupled with our previous findings (28), suggests that the effect of glucose utilization to stimulate leptin production is not mediated by glucose uptake *per se* but involves the metabolism of glucose beyond pyruvate to a fate other than lactate, possibly oxidation or lipogenesis. Thus, metformin is a useful tool for examining the effects of

increasing anaerobic glucose metabolism. Further research, including examination of the potential roles of glucose oxidation and lipogenesis, needs to be conducted to determine the precise biochemical and molecular mechanisms by which glucose metabolism regulates leptin production.

### Acknowledgments

This work was supported in part by NIH Grants DK-50129 and DK-35747, the Juvenile Diabetes Foundation, the American Diabetes Association, and the United States Department of Agriculture. We thank Drs. John McNeill and Violet Yuen, in the Department of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, for generously providing the BMOV used in the study.

### References

1. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. *Nature*. 1998;395:763–770.
2. Havel PJ. Mechanisms regulating leptin production: implications for control of energy balance. *Am J Clin Nutr*. 1999; 70:305–306.
3. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med*. 1996;334:292–295.
4. Havel PJ, Kasim-Karakas S, Mueller WM, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. *J Clin Endocrinol Metab*. 1996;8:4406–13.
5. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodents measurement of plasma leptin and *ob* RNA in obese and weight-reduced subjects. *Nat Med*. 1995;1: 1155–61.
6. Ahren B, Mansson S, Gingerich RL, Havel PJ. Regulation of plasma leptin in mice: influence of age, high-fat diet and fasting. *Am J Physiol*. 1997;273:R113–R20.
7. Havel PJ. Glucose infusion increases circulating leptin in proportion to adipose stores in rhesus monkeys. *J Exp Endocrinol Diabetes*. 1997;105(Suppl 3):37–8.
8. Boden G, Chen X, Mozzoli M, Ryan I. Effect of fasting on serum leptin in normal human subjects. *J Clin Endocrinol Metab*. 1996;81:3419–23.
9. Kolaczynski JW, Considine RV, Ohannesian J, et al. Responses of leptin to short-term fasting and refeeding in humans: a link with ketogenesis but not ketones themselves. *Diabetes*. 1996;45:1511–15.
10. Weigle DS, Duell PB, Conner WE, et al. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels. *J Clin Endocrinol Metab*. 1997;82:561–5.
11. Dubuc GR, Phinney SD, Stern JS, Havel PJ. Changes of serum leptin and endocrine and metabolic parameters after 7 days energy restriction in men and women. *Metab Clin Exp*. 1998;47:429–34.
12. Keim NL, Stern JS, Havel PJ. Relationship between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women. *Am J Clin Nutr*. 1998;68: 794–801.
13. Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF. Response of leptin to short-term and prolonged overfeeding in humans. *J Clin Endocrinol Metab*. 1996;81: 4162–5.
14. Dagogo-Jack SC, Fanelli D, Paramore J, Brothers, Landt M. Plasma leptin and insulin relationships in obese and nonobese human. *Diabetes*. 1996;45:695–8.
15. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effect of insulin on leptin production in humans: studies *in vivo* and *in vitro*. *Diabetes*. 1996;45:699–701.
16. Havel PJ, Aoki TT, Grecu EO, Stern JS, Kasim-Karakas S. Leptin/adiposity relationships in intensively treated IDDM and NIDDM and increased plasma leptin after 6 hours of high dose insulin infusion. *Obes Res*. 1996;4:15S.
17. Utriainen R, Malmstrom R, Makimattila S, Yki-Jarvinen H. Supraphysiological hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. *Diabetes*. 1996;45:1364–6.
18. Saad MF, Khan A, Sharma A, et al. Physiological insulinemia acutely modulates plasma leptin. *Diabetes*. 1998;47: 544–9.
19. Grinspoon SK, Askari H, Landt ML, et al. Effects of fasting and glucose infusion on basal and overnight leptin concentrations in normal-weight women. *Am J Clin Nutr*. 1997;66: 1352–6.
20. Havel PJ, Townsend R, Chaump L, Teff K. High fat meals reduce 24 hour circulating leptin concentrations in women. *Diabetes*. 1999;48:334–41.
21. Gettys TW, Harkness PJ, Watson PM. The beta 3-adrenergic receptor inhibits insulin-stimulated leptin secretion from isolated rats adipocytes. *Endocrinology*. 1996;137:4054–7.
22. Leroy P, Dessolin S, Villageois P, et al. Expression of *ob* gene in adipose cells: regulation by insulin. *J Biol Chem*. 1996;271:2365–8.
23. Yoshida T, Hayashi M, Monkawa T, Saruta T. Regulation of obese mRNA expression by hormonal factors in primary cultures of rat adipocytes. *Eur J Endocrinol*. 1996;135: 619–25.
24. Wabitsch M, Jensen PB, Blum WF, et al. Insulin and cortisol promote leptin production in cultured human fat cells. *Diabetes*. 1996;45:1435–8.
25. Mizuno T, Bergen H, Kleopoulos S, Bauman WA, Mobbs CV. Effects of nutritional status and aging on leptin gene expression in mice: importance of glucose. *Horm Metab Res*. 1996;28:679–84.
26. Mizuno TM, Bergen H, Funabashi T, et al. Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. *Proc Natl Acad Sci USA*. 1996;93:3434–8.
27. Havel PJ, Uriu-Hare JY, Stanhope KL, Stern JS, Keen CL, Ahren B. Marked and rapid decrease of circulating leptin in streptozotocin diabetic rats: reversal by insulin. *Am J Physiol*. 1998;274:R1482–R91.
28. Mueller WM, Gregoire FM, Stanhope KL, et al. Evidence that glucose metabolism regulates leptin secretion from isolated adipocytes. *Endocrinology*. 1998;139:551–8.

29. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. *Diabetes Rev.* 1998;6:89–131.
30. Sekar N, Li J, Shechter Y. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research. *Crit Rev Biochem Mol Biol.* 1996;31:339–59.
31. McNeill JH, Yuen VG, Dai S, Orvig C. Increased potency of vanadium using organic ligands. *Mol Cell Biochem.* 1995;153:175–80.
32. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. *J Biol Chem.* 1964;239:375–80.
33. Fantus IG, Brosseau R. Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo. *J Clin Endocrinol Metab.* 1986;63:898–905.
34. Klip A, Leiter LA. Cellular mechanism of action of metformin. *Diabetes Care.* 1990;13:696–704.
35. Molero JC, Martinez C, Andres A, Satrustegui J, Carrascosa JM. Vanadate fully stimulates insulin receptor substrate-1 associated phosphatidyl inositol 3-kinase activity in adipocytes from young and old rats. *FEBS Lett.* 1998;425:298–304.
36. Nakai M, Watanabe H, Fujiwara C, et al. Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. *Biol Pharm Bull.* 1995;18:719–25.
37. Landt M, Gingerich RL, Havel PJ, et al. Radioimmunoassay of rat leptin: sexual dimorphism reversed from humans. *Clin Chem.* 1998;44:565–70.
38. Kallen CB, Lazar M. Antidiabetic thiazolidinediones inhibit leptin (*ob*) gene expression in 3T3-L1 adipocytes. *Proc Natl Acad Sci USA.* 1996;93:5793–6.
39. Nolan JJ, Olefsky JM, Nyce MR, Considine RV, Caro JF. Effect of troglitazone on leptin production in vitro and in human subjects. *Diabetes.* 1996;45:1276–8.
40. Scheen AJ. Clinical pharmacokinetics of metformin. *Clin Pharmacokinet.* 1996;30:359–71.
41. Shulman G. Cellular mechanisms of insulin resistance in humans. *Am J Cardiol.* 1999;84:3J–10J.
42. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. *N Engl J Med.* 1998;338:867–72.
43. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. *Diabetes.* 1987;36:632–40.
44. Pedersen O, Nielson OH, Bak J, et al. The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. *Diabetic Med.* 1989;6:249–56.
45. Fischer Y, Thomas J, Rosen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. *Endocrinology.* 1995;136:412–20.
46. Jacobs DB, Hayes GR, Truglia JA, Lockwood DH. Effects of metformin on insulin receptor tyrosine kinase activity in rat adipocytes. *Diabetologia.* 1986;29:798–801.
47. Di Paolo S. Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. *Acta Endocrinol.* 1992;126:117–23.
48. Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. *Diabetes.* 1993;42:1159–65.
49. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin dependent diabetes mellitus. *Drugs.* 1995;49:721–49.
50. DiGirolamo M, Newby FD, Lovejoy J. Lactate production in adipose tissue: a regulated function with extra-adipose implications. *FASEB J.* 1992;6:2405–12.
51. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. *Nature.* 1998;393:684–8.
52. Yuen VG, Orvig C, McNeill JH. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats. *Am J Physiol.* 1997;272:E30–E5.
53. Yuen VG, Orvig C, McNeill JH. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. *Can J Physiol Pharmacol.* 1995;73:55–64.
54. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. *J Clin Invest.* 1995;95:2501–9.
55. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. *J Clin Endocrinol Metab.* 1995;80:3311–20.
56. Tsiani E, Fantus IG. Vanadium compounds: biological actions and potential as pharmacological agents. *Trends Endocrinol Metab.* 1997;8:51–8.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**